

chain nodes :

7 22 23 24 25 30

ring nodes :

1 2 3 4 5 6 8 9 10 11 12 13 14 15 16 17 18 19

chain bonds :

1-18 3-22 5-7 6-30 7-10 24-25

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13 14-15 14-19 15-16
16-17 17-18 18-19

exact/norm bonds :

3-22 5-7 6-30 7-10 24-25

exact bonds :

1-18

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13 14-15 14-19 15-16
16-17 17-18 18-19

isolated ring systems :

containing 1 : 14 :

G1:H,Cl,Br,F,I,NH,NH2,N, [*1], [*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 22:CLASS 23:CLASS
24:CLASS 25:CLASS 30:CLASS



Generic attributes :

23:
Saturation : Saturated
25:
Saturation : Saturated

Element Count :

Node 23: Limited
C,C1-10

Node 25: Limited
C,C1-10



chain nodes :

8 9 10 11 12 16 18 19

ring nodes :

1 2 3 4 5 6

chain bonds :

3-18 8-9 9-10 11-12 18-19

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

3-18 8-9 9-10 11-12 18-19

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:H,Cl,Br,F,I,NH,NH2,N


G2:[*2],[*3]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:CLASS 9:CLASS 10:Atom 11:CLASS
12:Atom 16:CLASS 17:CLASS 18:CLASS 19:Atom

=>

Uploading C:\Program Files\Stnexp\Queries\10671070 (Q=N) (species).str



chain nodes :

88 90

ring nodes :

1	2	3	4	5	6	7	8	9	10	11	12	14	15	16	17	18	19	20	21	22	23	24
25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45		
46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66		
67	73	74	75	76	77	78	79	80	81	82	83	84										

chain bonds :

5-20 8-90 14-30 36-38 48-50 56-66 78-80 88-90

ring bonds :

1-2	1-6	2-3	3-4	4-5	5-6	7-8	7-12	8-9	9-10	10-11	11-12	14-15	14-19
15-16	16-17	17-18	18-19	20-21	20-25	21-22	22-23	23-24	24-25	26-27	26-31		
27-28	28-29	29-30	30-31	32-33	32-37	33-34	34-35	35-36	36-37	38-39	38-43		
39-40	40-41	41-42	42-43	44-45	44-49	45-46	46-47	47-48	48-49	50-51	50-55		
51-52	52-53	53-54	54-55	56-57	56-61	57-58	58-59	59-60	60-61	62-63	62-67		
63-64	64-65	65-66	66-67	73-74	73-78	74-75	75-76	76-77	77-78	79-80	79-84		
80-81	81-82	82-83	83-84										

exact/norm bonds :

8-90 88-90

exact bonds :

5-20 14-30 36-38 48-50 56-66 78-80

normalized bonds :

1-2	1-6	2-3	3-4	4-5	5-6	7-8	7-12	8-9	9-10	10-11	11-12	14-15	14-19
15-16	16-17	17-18	18-19	20-21	20-25	21-22	22-23	23-24	24-25	26-27	26-31		
27-28	28-29	29-30	30-31	32-33	32-37	33-34	34-35	35-36	36-37	38-39	38-43		
39-40	40-41	41-42	42-43	44-45	44-49	45-46	46-47	47-48	48-49	50-51	50-55		
51-52	52-53	53-54	54-55	56-57	56-61	57-58	58-59	59-60	60-61	62-63	62-67		
63-64	64-65	65-66	66-67	73-74	73-78	74-75	75-76	76-77	77-78	79-80	79-84		
80-81	81-82	82-83	83-84										

isolated ring systems :

containing 1 : 14 : 20 : 26 : 32 : 38 : 44 : 50 : 56 : 62 :

G1:[*1],[*2],[*3],[*4],[*5],[*6]

G2

Match level :

1:Atom	2:Atom	3:Atom	4:Atom	5:Atom	6:Atom	7:Atom	8:Atom	9:Atom	10:Atom
11:Atom	12:Atom	14:Atom	15:Atom	16:Atom	17:Atom	18:Atom	19:Atom	20:Atom	
21:Atom	22:Atom	23:Atom	24:Atom	25:Atom	26:Atom	27:Atom	28:Atom	29:Atom	
30:Atom	31:Atom	32:Atom	33:Atom	34:Atom	35:Atom	36:Atom	37:Atom	38:Atom	
39:Atom	40:Atom	41:Atom	42:Atom	43:Atom	44:Atom	45:Atom	46:Atom	47:Atom	
48:Atom	49:Atom	50:Atom	51:Atom	52:Atom	53:Atom	54:Atom	55:Atom	56:Atom	
57:Atom	58:Atom	59:Atom	60:Atom	61:Atom	62:Atom	63:Atom	64:Atom	65:Atom	
66:Atom	67:Atom	73:Atom	74:Atom	75:Atom	76:Atom	77:Atom	78:Atom	79:Atom	
80:Atom	81:Atom	82:Atom	83:Atom	84:Atom	88:CLASS	90:CLASS			

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 14:49:23 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1005 TO ITERATE

100.0% PROCESSED 1005 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.03

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**


PROJECTED ITERATIONS: 18199 TO 22001

PROJECTED ANSWERS: 3673 TO 5487

L2 50 SEA SSS SAM L1

=> =>

Uploading C:\Program Files\Stnexp\Queries\10671070 (species).str



chain nodes :

7

ring nodes :

1 2 3 4 5 6 8 9 10 11 12 13 14 15 16 17 18 19

chain bonds :

1-18 5-7 7-10

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13 14-15 14-19
15-16 16-17 17-18 18-19

exact/norm bonds :

5-7 7-10

exact bonds :

1-18

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13 14-15 14-19
15-16 16-17 17-18 18-19

isolated ring systems :

containing 1 : 14 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom

L3 STRUCTURE UPLOADED

=> d 13

L3 HAS NO ANSWERS

L3 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l3 sss sam

SAMPLE SEARCH INITIATED 14:51:55 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 314 TO ITERATE

100.0% PROCESSED 314 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**





PROJECTED ITERATIONS: 5217 TO 7343

PROJECTED ANSWERS: 1469 TO 2691

L4 50 SEA SSS SAM L3

=> =>

Uploading C:\Program Files\Stnexp\Queries\10671070 (species A).str



chain nodes :

7 22 23 24 25 30

ring nodes :

1 2 3 4 5 6 8 9 10 11 12 13 14 15 16 17 18 19

chain bonds :

1-18 3-22 5-7 6-30 7-10 24-25

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13 14-15 14-19
15-16 16-17 17-18 18-19

exact/norm bonds :

3-22 5-7 6-30 7-10 24-25

exact bonds :

1-18

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13 14-15 14-19
15-16 16-17 17-18 18-19

isolated ring systems :

containing 1 : 14 :

G1:H,Cl,Br,F,I,NH,NH₂,N,[*1],[*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
22:CLASS 23:CLASS 24:CLASS 25:CLASS 30:CLASS

Generic attributes :

23:

Saturation : Saturated

25:

Saturation : Saturated

Element Count :
Node 23: Limited
C,C1-10

Node 25: Limited
C,C1-10

L5 STRUCTURE UPLOADED

=> d 15

L5 HAS NO ANSWERS

L5 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 15 sss sam

SAMPLE SEARCH INITIATED 14:58:09 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 314 TO ITERATE

100.0% PROCESSED 314 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 5217 TO 7343

PROJECTED ANSWERS: 1031 TO 2089

L6 50 SEA SSS SAM L5

=> => s 15 sss ful

FULL SEARCH INITIATED 15:04:33 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 5857 TO ITERATE

100.0% PROCESSED 5857 ITERATIONS







1679 ANSWERS

SEARCH TIME: 00.00.02

L7 1679 SEA SSS FUL L5

=>

Uploading C:\Program Files\Stnexp\Queries\10671070 (species Sub).str



chain nodes :
 8 9 10 11 12 16 18 19
 ring nodes :
 1 2 3 4 5 6
 chain bonds :
 3-18 8-9 9-10 11-12 18-19
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6
 exact/norm bonds :
 3-18 8-9 9-10 11-12 18-19
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6

G1:H,Cl,Br,F,I,NH,NH2,N

G2:[*2],[*3]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:CLASS 9:CLASS 10:Atom 11:CLASS
 12:Atom 16:CLASS 17:CLASS 18:CLASS 19:Atom

L8 STRUCTURE UPLOADED

=> d 18

L8 HAS NO ANSWERS

L8 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l8 sub=l7 sss sam

SAMPLE SUBSET SEARCH INITIATED 15:09:33 FILE 'REGISTRY'

SAMPLE SUBSET SCREEN SEARCH COMPLETED - 78 TO ITERATE

100.0% PROCESSED 78 ITERATIONS

31 ANSWERS

SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):

ONLINE **COMPLETE**

PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):

1031 TO 2089

PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):

286 TO 954

L9 31 SEA SUB=L7 SSS SAM L8

=> => d his

(FILE 'HOME' ENTERED AT 14:48:32 ON 15 JUN 2006)

FILE 'REGISTRY' ENTERED AT 14:48:39 ON 15 JUN 2006

L1 STRUCTURE UPLOADED

L2 50 S L1 SSS SAM

L3 STRUCTURE UPLOADED

L4 50 S L3 SSS SAM

L5 STRUCTURE UPLOADED

L6 50 S L5 SSS SAM

L7 1679 S L5 SSS FUL

L8 STRUCTURE UPLOADED

L9 31 S L8 SSS SAM SUB=L7

L10 686 S L8 SSS FUL SUB=L7

L11 993 S L7 NOT L10

=> => s l11

L12 48 L11

=> d l12 1-48 bib,ab,hitstr

L12 ANSWER 1 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:301346 CAPLUS

DN 144:350708

TI Novel pyrimidine compounds, process for their preparation, pharmaceutical compositions, and their use as antiinflammatory, cytotoxic, rheumatic, immunosuppressive and cardiovascular agents for treatment of diseases

IN Kalleda, Srinivas; Padakanti, Srinivas; Kumar Swamy, Nalivela; Yeleswarapu, Koteswar Rao; Alexander, Christopher W.; Khanna, Ish Kumar; Iqbal, Javed; Pillarisetti, Sivaram; Pal, Manojit; Barange, Deepak

PA Reddy US Therapeutics, Inc., USA

SO PCT Int. Appl., 336 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006034473	A2	20060330	WO 2005-US34243	20050923
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006084644	A1	20060420	US 2005-234257	20050923
US 2006084645	A1	20060420	US 2005-234695	20050923
PRAI US 2004-612374P	P	20040923		

AB The invention provides heterocyclic compds., particularly substituted pyrimidines of formula I, methods and compns. for making and using these heterocyclic compds., and methods for treating a variety of diseases and disease states, including atherosclerosis, arthritis, restenosis, diabetic nephropathy, or dyslipidemia, or disease states mediated by the low expression of Perlecan. Compds. of formula I wherein R1, R2 and R4 are independently (un)substituted (hetero)aryl or (un)substituted heterocyclyl; and their pharmaceutically acceptable salts, prodrugs, diastereoisomeric mixts., enantiomers, tautomers, and racemic mixts. thereof are claimed in this invention. Example compound II was prepared by acylation of 4-methoxyacetophenone with di-Et carbonate; the resulting Et 4-methoxybenzoylacetate underwent cyclization with guanidine carbonate to give 2-amino-6-(4-methoxyphenyl)pyrimidin-4-ol, which was converted to 4-chloro-6-(methoxyphenyl)pyrimidin-2-ylamine, which underwent amination with 3-chloro-4-methoxyaniline to give compound II. The invention compds. were evaluated for their antiinflammatory, proliferative, cardiovascular, and immunosuppressive activity (no data).


IT 881193-01-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate and intermediate; preparation of pyrimidine compds. and their use as antiinflammatory, proliferative, rheumatic, immunosuppressive and cardiovascular agents for treatment of diseases)

RN 881193-01-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(3-chloro-4-methoxyphenyl)-6-phenyl- (9CI) (CA INDEX NAME)




IT 881193-11-9P 881194-28-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of pyrimidine compds. and their use as antiinflammatory, proliferative, rheumatic, immunosuppressive and cardiovascular agents for treatment of diseases)


RN 881193-11-9 CAPLUS

CN Benzoic acid, 2-[(2-amino-6-phenyl-4-pyrimidinyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 881194-28-1 CAPLUS

CN Cyclohexanol, 4-[[4-[(3-chloro-4-methoxyphenyl)amino]-6-phenyl-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



IT 881193-00-6P 881193-02-8P 881193-03-9P

881193-04-0P 881193-05-1P 881193-06-2P

881193-07-3P 881193-08-4P 881193-09-5P


881193-10-8P 881193-14-2P 881193-15-3P
 881193-16-4P 881193-17-5P 881193-18-6P
 881193-19-7P 881193-35-7P 881194-14-5P
 881194-21-4P 881194-23-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of pyrimidine compds. and their use as
 antiinflammatory, proliferative, rheumatic, immunosuppressive and
 cardiovascular agents for treatment of diseases)


RN 881193-00-6 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(3-chloro-4-methoxyphenyl)-6-(4-methoxyphenyl)-
 (9CI) (CA INDEX NAME)




RN 881193-02-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(3-chloro-4-methoxyphenyl)-6-(4-fluorophenyl)-
 (9CI) (CA INDEX NAME)




RN 881193-03-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(3-chloro-4-methoxyphenyl)-6-(4-ethoxyphenyl)-
 (9CI) (CA INDEX NAME)




RN 881193-04-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(3-chloro-4-methoxyphenyl)-6-(4-methylphenyl)-
 (9CI) (CA INDEX NAME)




RN 881193-05-1 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(3-chloro-4-methoxyphenyl)-6-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 881193-06-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(3-fluoro-4-methoxyphenyl)-6-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 881193-07-3 CAPLUS

CN Phenol, 4-[[2-amino-6-(4-methoxyphenyl)-4-pyrimidinyl]amino]-2-chloro- (9CI) (CA INDEX NAME)




RN 881193-08-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-1,3-benzodioxol-5-yl-6-phenyl- (9CI) (CA INDEX NAME)




RN 881193-09-5 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(4-chloro-3-methoxyphenyl)-6-phenyl- (9CI) (CA INDEX NAME)




RN 881193-10-8 CAPLUS
CN Phenol, 4-[(2-amino-6-phenyl-4-pyrimidinyl)amino]-2-chloro- (9CI) (CA INDEX NAME)




RN 881193-14-2 CAPLUS
CN 2,4-Pyrimidinediamine, N,N'-bis(3-chloro-4-methoxyphenyl)-6-phenyl- (9CI) (CA INDEX NAME)



RN 881193-15-3 CAPLUS
CN Acetamide, N-[4-[(3-chloro-4-methoxyphenyl)amino]-6-(4-ethoxyphenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 881193-16-4 CAPLUS
CN Acetamide, N-[4-[(3-chloro-4-methoxyphenyl)amino]-6-(4-methoxyphenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 881193-17-5 CAPLUS

CN Propanamide, N-[4-[(3-chloro-4-methoxyphenyl)amino]-6-(4-methoxyphenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 881193-18-6 CAPLUS

CN Glycine, N-[4-[(3-chloro-4-methoxyphenyl)amino]-6-phenyl-2-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 881193-19-7 CAPLUS

CN Acetamide, N-[4-[(3-chloro-4-methoxyphenyl)amino]-6-phenyl-2-pyrimidinyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)




RN 881193-35-7 CAPLUS

CN Acetic acid, [[4-[(3-chloro-4-methoxyphenyl)amino]-6-(4-methoxyphenyl)-2-pyrimidinyl]oxy]- (9CI) (CA INDEX NAME)




RN 881194-14-5 CAPLUS

CN 4-Pyrimidinamine, 6-phenyl-N-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 881194-21-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(3-chloro-4-methoxyphenyl)-6-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 881194-23-6 CAPLUS

CN Benzoic acid, 2-[(2-amino-6-phenyl-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)



L12 ANSWER 2 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:232088 CAPLUS

DN 144:312100

TI Preparation of substituted pyridines and pyrimidines as vanilloid receptor ligands

IN Norman, Mark H.; Pettus, Liping H.; Wang, Xianghong; Zhu, Jiawang

PA USA

SO U.S. Pat. Appl. Publ., 96 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006058308	A1	20060316	US 2005-226844	20050913
WO 2006031852	A1	20060323	WO 2005-US32660	20050913
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2004-609718P P 20040913

OS MARPAT 144:312100

AB Title compds. I [J = NH, O or S; X = N or CR2; Y = N or CR2, wherein at least one of X and Y = N; R1 = (un)saturated or partially saturated 5-7 membered

monocyclic or 6-11 membered bicyclic ring containing 0-4 heteroatoms, wherein the available carbon atoms are substituted by 0-2 oxo or thioxo groups, the ring may contain addnl. substituents; R2 = halo, (un)substituted alkyl, benzyl, etc.; R3 = CN, alkoxy, (un)substituted alkyl, etc.; R4 = 6-11 membered bicyclic ring containing 0-4 atoms selected from N, O and S, wherein the available carbon atoms are substituted by 0-2 oxo or thioxo groups, the ring may contain addnl. substituents], and their pharmaceutically acceptable salts, are prepared and disclosed as vanilloid receptor ligands. Thus, e.g., II was prepared by coupling of 4-tert-butylphenylboronic acid with 2,4,6-trichloropyrimidine followed by subsequent substitutions with 1,4-benzodioxane-6-amine and 4-methylpiperazine. Selected compds. of the invention exhibited IC50 values of less than 10 nM in the human VR1 capsaicin antagonist assay. I should prove useful in treating pain and inflammatory conditions.

IT 879596-30-2P 879596-36-8P 879596-43-7P

879596-49-3P 879596-55-1P 879602-68-3P


879605-03-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted pyridines and pyrimidines as vanilloid receptor ligands)


RN 879596-30-2 CAPLUS

CN Ethanol, 2-[[4-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-6-[4-(1,1-dimethylethyl)phenyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 879596-36-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(2,3-dihydro-1,4-benzodioxin-6-yl)-6-[4-(1,1-dimethylethyl)phenyl]-N2-[2-(1-pyrrolidiny)ethyl]- (9CI) (CA INDEX NAME)




RN 879596-43-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(2,3-dihydro-1,4-benzodioxin-6-yl)-6-[4-(1,1-dimethylethyl)phenyl]-N2-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 879596-49-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(2,3-dihydro-1,4-benzodioxin-6-yl)-N2-[2-(dimethylamino)ethyl]-6-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 879596-55-1 CAPLUS

CN 4-Pyrimidinamine, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-6-[4-(1,1-dimethylethyl)phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 879602-68-3 CAPLUS


CN 2-Naphthalenol, 8-[[2-[[[(1S)-1-(4-fluorophenyl)ethyl]amino]-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]-1,2,3,4-tetrahydro-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 879602-67-2

CMF C29 H26 F4 N4 O


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 879605-03-5 CAPLUS

CN 2-Naphthalenol, 8-[[2-[[[(1S)-1-(4-fluorophenyl)ethyl]amino]-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]-1,2,3,4-tetrahydro-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 879608-79-4P 879609-17-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of substituted pyridines and pyrimidines as vanilloid receptor ligands)

RN 879608-79-4 CAPLUS


CN 4-Pyrimidinamine, 2-chloro-N-(2,3-dihydro-1,4-benzodioxin-6-yl)-6-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 879609-17-3 CAPLUS

CN 2-Naphthalenol, 8-[[2-chloro-6-[4-(trifluoromethyl)phenyl]-4-

pyrimidinyl]amino]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



L12 ANSWER 3 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:49982 CAPLUS

DN 144:205343

TI Allosteric inhibitors of Bcr-abl-dependent cell proliferation

AU Adrian, Francisco J.; Ding, Qiang; Sim, Taebo; Velentza, Anastasia; Sloan, Christine; Liu, Yi; Zhang, Guobao; Hur, Wooyoung; Ding, Sheng; Manley, Paul; Mestan, Juergen; Fabbro, Dorian; Gray, Nathanael S.

CS Biological Chemistry Department, Genomics Institute of the Novartis Research Foundation, San Diego, CA, 92121, USA

SO Nature Chemical Biology (2006), 2(2), 95-102

CODEN: NCBABT; ISSN: 1552-4450

PB Nature Publishing Group

DT Journal

LA English

AB Chronic myelogenous leukemia (CML) is a myeloproliferative disorder characterized at the mol. level by the expression of Bcr-abl, a 210-kDa fusion protein with deregulated tyrosine kinase activity. Encouraged by the clin. validation of Bcr-abl as the target for the treatment of CML by imatinib, we sought to identify pharmacol. agents that could target this kinase by a distinct mechanism. We report the discovery of a new class of Bcr-abl inhibitors using an unbiased differential cytotoxicity screen of a combinatorial kinase-directed heterocycle library. Compds. in this class (exemplified by GNF-2) show exclusive antiproliferative activity toward Bcr-abl-transformed cells, with potencies similar to imatinib, while showing no inhibition of the kinase activity of full-length or catalytic domain of c-abl. We propose that this new class of compds. inhibits Bcr-abl kinase activity through an allosteric non-ATP competitive mechanism.

IT 778270-11-4, GNF 2 875557-38-3, GNF 3


875557-39-4, GNF 4

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(allosteric inhibitors of Bcr-abl-dependent cell proliferation)

RN 778270-11-4 CAPLUS


CN Benzamide, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 875557-38-3 CAPLUS

CN Benzamide, N-(17-amino-3,6,9,12,15-pentaoxaheptadec-1-yl)-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 875557-39-4 CAPLUS

CN Benzamide, N-(17-amino-3,6,9,12,15-pentaoxaheptadec-1-yl)-3-[6-[methyl[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L12 ANSWER 4 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:38998 CAPLUS
 DN 144:292704
 TI A Highly Regioselective Amination of 6-Aryl-2,4-dichloropyrimidine
 AU Peng, Zhi-Hui; Journet, Michel; Humphrey, Guy
 CS Department of Process Research, Merck & Co., Inc., Rahway, NJ, 07065, USA
 SO Organic Letters (2006), 8(3), 395-398
 CODEN: ORLEF7; ISSN: 1523-7060
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 144:292704
 AB A highly regioselective amination of 6-aryl-2,4-dichloropyrimidines with aliphatic secondary amines and aromatic amines which strongly favors the formation of the C4-substituted product has been developed. The reactions with aliphatic amines are carried out using LiHMDS as the base and are catalyzed by Pd, while the aromatic amines require no catalyst.
 IT **878199-73-6P 878199-75-8P 878199-79-2P**
878199-83-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (regioselective amination of 6-aryl-2,4-dichloropyrimidines)
 RN 878199-73-6 CAPLUS
 CN 4-Pyrimidinamine, 2-chloro-6-(4-fluorophenyl)-N-phenyl- (9CI) (CA INDEX NAME)



RN 878199-75-8 CAPLUS
 CN 4-Pyrimidinamine, 2-chloro-6-(4-fluorophenyl)-N-methyl-N-phenyl- (9CI)
 (CA INDEX NAME)




RN 878199-79-2 CAPLUS
 CN 4-Pyrimidinamine, 2-chloro-N-methyl-N,6-diphenyl- (9CI) (CA INDEX NAME)



RN 878199-83-8 CAPLUS

CN 4-Pyrimidinamine, 2-chloro-6-(4-methoxyphenyl)-N-methyl-N-phenyl- (9CI)
(CA INDEX NAME)



RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:1168931 CAPLUS
 DN 143:440430
 TI Pyrimidin-4-yl-1H-indazol-5-yl-amines as CHK-1 kinase inhibitors, their preparation, pharmaceutical compositions, and use in therapy
 IN Birault, Veronique; Woodland, Christopher Andrew
 PA Biofocus Discovery Ltd., UK
 SO PCT Int. Appl., 34 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005103036	A1	20051103	WO 2005-GB1566	20050422
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI GB 2004-9080	A	20040423		

OS MARPAT 143:440430

AB The invention relates to compds. of formula I, which are useful in the inhibition of protein kinases, in particular serine/threonine kinases, more particularly CHK-1 kinase. In compds. I, R1 is H, OH, halo, trifluoromethyl, trifluoromethoxy, amino, cyano, carboxy, (un)substituted alkyl, (un)substituted alkoxy, (un)substituted aryloxy, etc.; and R2 is (un)substituted aryl or (un)substituted heteroaryl; including pharmaceutically acceptable salts, hydrates, solvates, geometrical isomers, tautomers, optical isomers, or prodrugs thereof. The invention also relates to the preparation of I, pharmaceutical compns. comprising compound I and a pharmaceutically acceptable diluent or carrier, as well as to the use of the compns. in the prevention and/or treatment of a wide variety of diseases including cancer, and disease states associated with angiogenesis and/or cellular proliferation. Substitution of 4,6-dichloropyrimidine with 1H-indazol-5-ylamine gave secondary amine II, which underwent Suzuki coupling with 4-(aminomethyl)phenylboronic acid resulting in the formation of indazolyl(pyrimidinyl)amine III. Several compds. of the invention express an IC50 towards CHK-1 kinase of <10 µM and three compds., e.g., III, express <1 µM. The compds. of the invention also show selectivity for CHK-1 kinase with compound I (R1 = H; R2 = 4-(Me2NCH2)C6H4) expressing a 50-fold selectivity for CHK-1 over CDK-1 kinase.

IT **868545-65-7P**, [6-(5-(Dimethylaminomethyl)-2-methoxyphenyl)pyrimidin-4-yl](1H-indazol-5-yl)amine **868545-66-8P**, N-[3-[6-(1H-Indazol-5-ylamino)pyrimidin-4-yl]phenyl]methanesulfonamide **868545-67-9P**, N'-[6-(4-((Dimethylamino)methyl)phenyl)pyrimidin-4-yl]-1H-indazole-3,5-diamine **868545-69-1P**, 3-[6-(1H-Indazol-5-ylamino)pyrimidin-4-yl]benzamide **868545-70-4P**, [6-(4-((Dimethylamino)methyl)phenyl)pyrimidin-4-yl](1-methyl-1H-indazol-5-yl)amine **868545-71-5P**, [4-[6-(1H-Indazol-5-ylamino)pyrimidin-4-


yl]phenyl] (4-methylpiperazin-1-yl)methanone **868545-72-6P**,
 [3-[6-(1H-Indazol-5-ylamino)pyrimidin-4-yl]phenyl]methanol
868545-74-8P, [4-[6-(1H-Indazol-5-ylamino)pyrimidin-4-yl]phenyl]methanol **868545-76-0P**, 3-[6-(1H-Indazol-5-ylamino)pyrimidin-4-yl]-phenol **868545-77-1P**,
 [6-(3-((Dimethylamino)methyl)phenyl)pyrimidin-4-yl] (1H-indazol-5-yl)amine
868545-78-2P, [6-(4-Dimethylaminomethyl-3-fluorophenyl)pyrimidin-4-yl] (1H-indazol-5-yl)amine **868545-79-3P**, N-(3-(Dimethylamino)propyl)-4-[6-((1H-indazol-5-yl)amino)pyrimidin-4-yl]benzamide **868545-80-6P**, N-(2-(Dimethylamino)ethyl)-4-[6-((1H-indazol-5-yl)amino)pyrimidin-4-yl]benzamide **868545-81-7P**,
 [6-(4-((Dimethylamino)methyl)phenyl)pyrimidin-4-yl] (1H-indazol-5-yl)amine
868545-82-8P, [6-(4-Aminomethylphenyl)pyrimidin-4-yl] (1H-indazol-5-yl)amine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidinylindazolylamines as CHK-1 kinase inhibitors and therapeutic agents for treatment of cancer, angiogenesis- and cellular proliferation-associated disorders)


RN 868545-65-7 CAPLUS

CN 1H-Indazol-5-amine, N-[6-[5-[(dimethylamino)methyl]-2-methoxyphenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 868545-66-8 CAPLUS

CN Methanesulfonamide, N-[3-[6-(1H-indazol-5-ylamino)-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 868545-67-9 CAPLUS

CN 1H-Indazole-3,5-diamine, N5-[6-[4-[(dimethylamino)methyl]phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 868545-69-1 CAPLUS

CN Benzamide, 3-[6-(1H-indazol-5-ylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 868545-70-4 CAPLUS

CN 1H-Indazol-5-amine, N-[6-[4-[(dimethylamino)methyl]phenyl]-4-pyrimidinyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 868545-71-5 CAPLUS

CN Piperazine, 1-[4-[6-(1H-indazol-5-ylamino)-4-pyrimidinyl]benzoyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 868545-72-6 CAPLUS


CN Benzenemethanol, 3-[6-(1H-indazol-5-ylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 868545-74-8 CAPLUS
CN Benzenemethanol, 4-[6-(1H-indazol-5-ylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 868545-76-0 CAPLUS
CN Phenol, 3-[6-(1H-indazol-5-ylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 868545-77-1 CAPLUS
CN 1H-Indazol-5-amine, N-[6-[3-[(dimethylamino)methyl]phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 868545-78-2 CAPLUS
CN 1H-Indazol-5-amine, N-[6-[4-[(dimethylamino)methyl]-3-fluorophenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 868545-79-3 CAPLUS

CN Benzamide, N-[3-(dimethylamino)propyl]-4-[6-(1H-indazol-5-ylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 868545-80-6 CAPLUS

CN Benzamide, N-[2-(dimethylamino)ethyl]-4-[6-(1H-indazol-5-ylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 868545-81-7 CAPLUS

CN 1H-Indazol-5-amine, N-[6-[4-[(dimethylamino)methyl]phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 868545-82-8 CAPLUS

CN 1H-Indazol-5-amine, N-[6-[4-(aminomethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:1024910 CAPLUS
 DN 143:381701
 TI Diamino-C,N-diarylpyridine positional isomers as inhibitors of
 lysophosphatidic acid acyltransferase- β
 AU Hong, Feng; Hollenback, David; Singer, Jack W.; Klein, Peter
 CS Cell Therapeutics, Inc., Seattle, WA, 98119, USA
 SO Bioorganic & Medicinal Chemistry Letters (2005), 15(21), 4703-4707
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier B.V.
 DT Journal
 LA English
 AB 2,6-Diamino-4,N-diarylpyridines were identified as potent, isoform
 selective inhibitors of the enzymic activity of lysophosphatidic acid
 acyltransferase- β (LPAAT- β).
 IT **710334-85-3 710336-16-6**
 RL: PAC (Pharmacological activity); BIOL (Biological study)
 (diamino-C,N-diarylpyridine isomers preparation and inhibition of
 LPAAT- β)
 RN 710334-85-3 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methoxyphenyl)-N4-(4-chlorophenyl)-
 (9CI) (CA INDEX NAME)



RN 710336-16-6 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-(4-chlorophenyl)-
 (9CI) (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 7 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:1004351 CAPLUS
 DN 143:306328
 TI Preparation of 4-pyrimidinamines as neuroprotectants.
 IN Benjamin, Elfrida R.; Brown, Frank K.; Zivin, Robert Allan; McMillan, Michael Kurt; Zhong, Zhong; Reitz, Allen B.; Ross, Tina Morgan
 PA USA
 SO U.S. Pat. Appl. Publ., 45 pp., Cont.-in-part of U.S. Ser. No. 922,874, abandoned.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005203092	A1	20050915	US 2004-987562	20041112
	US 2003008883	A1	20030109	US 2001-922874	20010806
	US 2003212079	A1	20031113	US 2003-396158	20030325
	US 2004006094	A1	20040108	US 2003-395971	20030325
PRAI	US 2000-223791P	P	20000808		
	US 2001-922874	B2	20010806		

OS MARPAT 143:306328


AB This invention provides novel neuroprotective 4-pyrimidineamine derivs. (I, variables defined below) and neuroprotective pharmaceutical compns. comprising 4-pyrimidinamines. This invention also provides methods of using these compns. to prevent ischemic cell death, particularly neuronal cell death, and reduce the likelihood of neuronal cell death in a subject due to a traumatic event. Thus, a mixture of N-(2-aminoethyl)-N'-(6-biphenyl-3-ylpyrimidin-4-yl)-N-ethylbenzene-1,4-diamine (preparation given), N-benzoylalanine, diisopropylethylamine, HBTU, and DMF was stirred overnight at room temperature to give N-[1-[[2-[4-(6-biphenyl-3-ylpyrimidin-4-ylamino)phenyl]ethylamino]ethylcarbamoyl]ethyl]benzamide. Tested compds. in a differentiated P19 cell assay using 3 mM glutamate showed neuroprotectant activity with IC50 = 0.07 μ M to >1 μ M. For I the variables are: R20 = disubstituted amino; R21 = H, alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl and aralkylcarbonyl, wherein the aryl portion is optionally substituted; p = 0-3; q = 0-3; R22 and R23 = halogen, alkyl, alkoxy, amino, alkylamino, dialkylamino, nitro, cyano, carboxy, alkoxy carbonyl, aryloxy carbonyl, aminocarbonyl, alkylaminocarbonyl and dialkylaminocarbonyl.

IT 397850-40-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of 4-pyrimidinamines as neuroprotectants)

RN 397850-40-7 CAPLUS

CN 1,4-Benzenediamine, N-(2-aminoethyl)-N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl- (9CI) (CA INDEX NAME)




IT 397851-04-6

RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use);
 BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
 (preparation of 4-pyrimidinamines as neuroprotectants)

RN 397851-04-6 CAPLUS

CN Ethanol, 2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]- (9CI) (CA INDEX NAME)



IT 397850-34-9P 397850-35-0P 397850-36-1P

397850-37-2P 397850-38-3P 397850-39-4P

397850-41-8P 397850-42-9P 397850-43-0P

397850-44-1P 397850-45-2P 397850-46-3P

397850-47-4P 397850-48-5P 397850-49-6P

397850-50-9P 397850-51-0P 397850-52-1P

397850-53-2P 397850-54-3P 397850-55-4P

397850-56-5P 397850-57-6P 397850-58-7P

397850-59-8P 397850-60-1P 397850-61-2P

397850-62-3P 397850-63-4P 397850-64-5P

397850-65-6P 397850-66-7P 397850-67-8P

397850-68-9P 397850-69-0P 397850-70-3P

397850-71-4P 397850-72-5P 397850-73-6P

397850-74-7P 397850-75-8P 397850-76-9P

397850-77-0P 397850-78-1P 397850-79-2P

397850-80-5P 397850-81-6P 397850-82-7P

397850-83-8P 397850-84-9P 397850-85-0P

397850-86-1P 397850-87-2P 397850-88-3P

397850-89-4P 397850-90-7P 397850-91-8P

397850-92-9P 397850-93-0P 397850-94-1P

397850-95-2P 397850-96-3P 397850-97-4P

397850-98-5P 397850-99-6P 397851-00-2P


397851-01-3P 397851-02-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of 4-pyrimidinamines as neuroprotectants)

RN 397850-34-9 CAPLUS

CN Benzamide, N-[2-[[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 397850-35-0 CAPLUS


CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]hexahydro-2-oxo-,
(3aS,4S,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B





RN 397850-36-1 CAPLUS

CN Hexadecanamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-37-2 CAPLUS

CN Butanamide, N-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[4-[ethyl[2-[(1-oxobutyl)amino]ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 397850-38-3 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[(cyclohexylmethyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-39-4 CAPLUS

CN Alanine, N-benzoyl-, 2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl ester (9CI) (CA INDEX NAME)




RN 397850-41-8 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-(dimethylamino)ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-42-9 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(3-methoxypropyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-43-0 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[(3-chlorophenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-44-1 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[(2,4-dimethoxyphenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-45-2 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[(2-ethoxyphenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-46-3 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-(propylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 397850-47-4 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[(2,5-difluorophenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-48-5 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-
[[[(1R,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-
methylethyl)-1-phenanthrenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 397850-49-6 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(2-phenylethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-50-9 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[3,4-dimethoxyphenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-51-0 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[3-(diethylamino)propyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-52-1 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[(4-bromo-2-pyridinyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-53-2 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[2-(dimethylamino)ethyl](phenylmethyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-54-3 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[butyl(phenylmethyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-55-4 CAPLUS

CN 1,4-Benzenediamine, N-[2-([1,1'-biphenyl]-4-ylamino)ethyl]-N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-56-5 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(2-furanylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-57-6 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[3-iodophenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-58-7 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(2,2,2-trifluoroethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-59-8 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[3,4-difluorophenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-60-1 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-(2-thienyl)ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-61-2 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[(3,5-dimethyl-2-pyridinyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-62-3 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(2-phenylethyl)(phenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-63-4 CAPLUS

CN Acetamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]-2-ethoxy-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 397850-64-5 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-methoxyphenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-65-6 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[4-bromophenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 397850-66-7 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[[3,5-bis(trifluoromethyl)phenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 397850-67-8 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-(3-methoxyphenyl)ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OMe

RN 397850-68-9 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[(3,4,5-trimethoxyphenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 397850-69-0 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-(4-methoxyphenyl)ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OMe


RN 397850-70-3 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-(1H-imidazol-4-yl)ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-71-4 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-(trifluoromethyl)phenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-72-5 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(phenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-73-6 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[3-methoxyphenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-74-7 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[3-methylphenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-75-8 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[(3,5-dimethoxyphenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-76-9 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[(2-bromophenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 397850-77-0 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[2-(4-bromophenyl)ethyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B

— Br

RN 397850-78-1 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[4-fluorophenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-79-2 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-
[(1-naphthalenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 397850-80-5 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-
[(2-phenoxyethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-81-6 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[4-(trifluoromethyl)phenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-82-7 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-(butylamino)ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-83-8 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-bis(phenylmethyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-84-9 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-(3-pyridinylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 397850-85-0 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[(2-methylphenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-86-1 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[(2-fluorophenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-87-2 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[(3,4-dimethoxyphenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-88-3 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[ethyl(phenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-89-4 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 397850-90-7 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 397850-91-8 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-(1H-imidazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 397850-92-9 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-(3,4-dihydro-2(1H)-isoquinolinyl)ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-93-0 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-(hexahydro-1H-azepin-1-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 397850-94-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 397850-95-2 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanoic acid, hexahydro-2-oxo-, 2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl ester, (3aS,4S,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A






RN 397850-96-3 CAPLUS

CN Ethanol, 2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]-, benzoate (ester) (9CI) (CA INDEX NAME)




RN 397850-97-4 CAPLUS

CN Benzeneacetamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]-α-chloro- (9CI) (CA INDEX NAME)



RN 397850-98-5 CAPLUS


CN 3-Pyridinecarboxamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]-6-nitro- (9CI) (CA INDEX NAME)



RN 397850-99-6 CAPLUS


CN [1,1'-Biphenyl]-4-carboxamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-

pyrimidinyl)amino]phenyl]ethylamino]ethyl]- (9CI) (CA INDEX NAME)




RN 397851-00-2 CAPLUS

CN Benzamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl)-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]-4-butoxy- (9CI) (CA INDEX NAME)




RN 397851-01-3 CAPLUS

CN Benzamide, N-(6-[1,1'-biphenyl]-3-yl)-4-pyrimidinyl)-N-[4-[ethyl[2-[[4-(trifluoromethyl)benzoyl]amino]ethyl]amino]phenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 397851-02-4 CAPLUS

CN Benzamide, N-(6-[1,1'-biphenyl]-3-yl)-4-pyrimidinyl)-N-[4-[ethyl[2-[[3-fluorobenzoyl]amino]ethyl]amino]phenyl]-3-fluoro- (9CI) (CA INDEX NAME)




IT 397851-06-8 397851-07-9 397851-08-0
 397851-10-4 397851-14-8 397851-15-9
 397851-16-0 397851-17-1 397851-18-2
 397851-19-3 397851-20-6 397851-21-7
 397851-22-8 397851-24-0 397851-25-1
 397851-26-2 397851-27-3 397851-34-2
 397851-35-3 397851-37-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (preparation of 4-pyrimidinamines as neuroprotectants)


RN 397851-06-8 CAPLUS

CN 1,4-Benzenediamine, N,N-dimethyl-N'-[6-[4-(phenylmethoxy)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 397851-07-9 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 397851-08-0 CAPLUS

CN 1,4-Benzenediamine, N'-[6-[3,5-bis(trifluoromethyl)phenyl]-4-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 397851-10-4 CAPLUS

CN Ethanol, 2-[ethyl[4-[[6-[4-(trifluoromethoxy)phenyl]-4-pyrimidinyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 397851-14-8 CAPLUS

CN Ethanol, 2-[[4-[(6-[1,1'-biphenyl]-4-yl)-4-pyrimidinyl]amino]phenyl]ethylamino]- (9CI) (CA INDEX NAME)




RN 397851-15-9 CAPLUS

CN Ethanol, 2-[[4-[[6-[3,5-bis(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]phenyl]ethylamino]- (9CI) (CA INDEX NAME)




RN 397851-16-0 CAPLUS

CN Ethanol, 2-[ethyl[4-[[6-(3-nitrophenyl)-4-pyrimidinyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 397851-17-1 CAPLUS

CN Ethanol, 2-[ethyl[4-[[6-[4-(methylthio)phenyl]-4-pyrimidinyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 397851-18-2 CAPLUS

CN Ethanol, 2-[ethyl[4-[[6-(2-phenoxyphenyl)-4-pyrimidinyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 397851-19-3 CAPLUS

CN Benzonitrile, 4-[6-[[4-(dimethylamino)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 397851-20-6 CAPLUS

CN 1,4-Benzenediamine, N,N-dimethyl-N'-[6-(2-phenoxyphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 397851-21-7 CAPLUS

CN Benzonitrile, 4-[6-[[4-[ethyl(2-hydroxyethyl)amino]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 397851-22-8 CAPLUS

CN Phenol, 4-[6-[[4-(4-phenyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]-
(9CI) (CA INDEX NAME)




RN 397851-24-0 CAPLUS

CN 1,4-Benzenediamine, N,N-dimethyl-N'-[6-[2-(phenylmethoxy)phenyl]-4-
pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 397851-25-1 CAPLUS

CN Carbamic acid, [[4-[6-[[4-[ethyl(2-hydroxyethyl)amino]phenyl]amino]-4-
pyrimidinyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX
NAME)




RN 397851-26-2 CAPLUS

CN Ethanol, 2-[[4-[[6-[3-(dimethylamino)phenyl]-4-
pyrimidinyl]amino]phenyl]ethylamino]- (9CI) (CA INDEX NAME)




RN 397851-27-3 CAPLUS

CN 1,4-Benzenediamine, N'-[6-[4-(dimethylamino)phenyl]-4-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 397851-34-2 CAPLUS

CN 9H-Carbazol-3-amine, N-[6-(3,4-dimethoxyphenyl)-4-pyrimidinyl]-9-ethyl- (9CI) (CA INDEX NAME)




RN 397851-35-3 CAPLUS

CN 9H-Carbazol-3-amine, 9-ethyl-N-[6-(3,4,5-trimethoxyphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 397851-37-5 CAPLUS

CN 9H-Carbazol-3-amine, 9-ethyl-N-[6-[4-(4-methyl-1-piperazinyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




IT **397851-03-5P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 4-pyrimidinamines as neuroprotectants)

RN 397851-03-5 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-(2-chloroethyl)-N-ethyl- (9CI) (CA INDEX NAME)



L12 ANSWER 8 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:696886 CAPLUS

DN 143:194017

TI Preparation of heteroaryl-substituted pyrimidinylaminophenylbenzenesulfonamides as kinase inhibitors

IN Barsig, Johannes; Baudler, Monika; Bundschuh, Daniela; Gantner, Florian; Graedler, Ulrich; Heit, Isabelle; Martin, Thomas; Schaefer, Michaela; Schlemminger, Imre; Stadlwieser, Josef; Ulrich, Wolf-Ruediger

PA Altana Pharma A.-G., Germany

SO PCT Int. Appl., 115 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005070900	A1	20050804	WO 2005-EP50206	20050119
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI EP 2004-1310

A

20040122

OS MARPAT 143:194017

AB Title compds. I [R1-2 = (un)substituted Ph, naphthyl, etc.] are prepared For instance, 2,6-difluoro-N-[4-[[6-(4-fluorophenyl)pyrimidin-4-yl]amino]phenyl]benzenesulfonamide is prepared from N-[6-(4-fluorophenyl)pyrimidin-4-yl]benzene-1,4-diamine (preparation given) and 2,6-difluorobenzenesulfonyl chloride. Included in the biol. results are inhibition of protein kinases like p90 ribosomal S6 kinase (Rsk) family, Src family kinases and protein kinase C isoforms; in the Rsk kinase assay selected example compds. have IC50 < 1 µM. I are useful in the treatment of, e.g., acute or chronic rejection of organ or tissue all- or xenografts.


IT **861846-69-7P**, N-[6-(4-Fluorophenyl)pyrimidin-4-yl]benzene-1,4-diamine **861851-05-0P**, [4-[[6-(4-Fluorophenyl)pyrimidin-4-yl]amino]phenyl]carbamic acid tert-butyl ester

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of heteroaryl-substituted pyrimidinylaminophenylbenzenesulfonamides as kinase inhibitors)


RN 861846-69-7 CAPLUS

CN 1,4-Benzenediamine, N-[6-(4-fluorophenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 861851-05-0 CAPLUS

CN Carbamic acid, [4-[[6-(4-fluorophenyl)-4-pyrimidinyl]amino]phenyl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 9 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:585317 CAPLUS
DN 143:399001
TI Induction of Apoptosis Using Inhibitors of Lysophosphatidic Acid
Acyltransferase-{szligbeta} and Anti-CD20 Monoclonal Antibodies for
Treatment of Human Non-Hodgkin's Lymphomas
AU Pagel, John M.; Laugen, Christian; Bonham, Lynn; Hackman, Robert C.;
Hockenbery, David M.; Bhatt, Rama; Hollenback, David; Carew, Heather;
Singer, Jack W.; Press, Oliver W.
CS Fred Hutchinson Cancer Research Center, Univ. Washington, Seattle, WA, USA
SO Clinical Cancer Research (2005), 11(13), 4857-4866
CODEN: CCREF4; ISSN: 1078-0432
PB American Association for Cancer Research
DT Journal
LA English
AB PURPOSE: Lysophosphatidic acid acyltransferase- β (LPAAT- β) is a
transmembrane enzyme critical for the biosynthesis of phosphoglycerides whose
product, phosphatidic acid, plays a key role in raf and AKT/mTor-mediated
signal transduction. Exptl. Design: LPAAT- β may be a novel target
for anticancer therapy, and, thus, we examined the effects of a series of
inhibitors of LPAAT- β on multiple human non-Hodgkin's lymphoma cell
lines in vitro and in vivo. RESULTS: We showed that five LPAAT- β
inhibitors at doses of 500 nmol/L routinely inhibited growth in a panel of
human lymphoma cell lines in vitro by >90%, as measured by [3H]thymidine
incorporation. Apoptotic effects of the LPAAT- β inhibitors were
evaluated either alone or in combination with the anti-CD20 antibody,
Rituximab. The LPAAT- β inhibitors induced caspase-mediated apoptosis
at 50 to 100 nmol/L in up to 90% of non-Hodgkin's lymphoma cells. The
combination of Rituximab and an LPAAT- β inhibitor resulted in a
2-fold increase in apoptosis compared with either agent alone. To assess
the combination of Rituximab and a LPAAT- β inhibitor in vivo, groups
of athymic mice bearing s.c. human Ramos lymphoma xenografts were treated
with the LPAAT- β inhibitor CT-32228 i.p. (75 mg/kg) daily for 5 d/wk
x 4 wk (total 20 doses), Rituximab i.p. (10 mg/kg) weekly x 4 wk (4 doses
total), or CT-32228 plus Rituximab combined. Treatment with either
CT-32228 or Rituximab alone showed an approx. 50% xenograft growth delay;
however, complete responses were only observed when the two agents were
delivered together. CONCLUSIONS: These data suggest that Rituximab,
combined with a LPAAT- β inhibitor, may provide enhanced therapeutic
effects through apoptotic mechanisms.
IT 710334-99-9, CT 32521
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(CT-32521 in combination with rituximab induced caspase-mediated
apoptosis and inhibited tumor growth than alone in human and mouse
model of non-Hodgkin's lymphoma)
RN 710334-99-9 CAPLUS
CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methylphenyl)-N4-[4-
(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




IT 710335-06-1, CT 32615

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(CT-32615 in combination with rituximab induced caspase-mediated
apoptosis and inhibited tumor growth than alone in human and mouse
model of non-Hodgkin's lymphoma)


RN 710335-06-1 CAPLUS

CN Benzenemethanol, 4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-
pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 10 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:367661 CAPLUS
 DN 143:618
 TI Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)- β inhibitors
 AU Hideshima, Teru; Chauhan, Dharminder; Ishitsuka, Kenji; Yasui, Hiroshi; Raje, Noopur; Kumar, Shaji; Podar, Klaus; Mitsiades, Constantine; Hideshima, Hiromasa; Bonham, Lynn; Munshi, Nikhil C.; Richardson, Paul G.; Singer, Jack W.; Anderson, Kenneth C.
 CS Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, 02115, USA
 SO Oncogene (2005), 24(19), 3121-3129
 CODEN: ONCNES; ISSN: 0950-9232
 PB Nature Publishing Group
 DT Journal
 LA English
 AB PS-341 (bortezomib, Velcade) is a promising novel agent for treatment of advanced multiple myeloma (MM); however, 65% of patients with relapsed refractory disease in a phase II study do not respond to PS-341. We have previously shown that lysophosphatidic acid acyltransferase (LPAAT)- β inhibitor CT-32615 triggers caspase-dependent apoptosis, and can overcome resistance to conventional therapeutics (i.e., dexamethasone, doxorubicin, melphalan) in MM cells. In this study, we therefore determined whether CT-32615 could also overcome resistance to PS-341. We first characterized mol. mechanisms of resistance to PS-341 in DHL-4 cells. DHL-4 cells express low levels of caspase-3 and caspase-8; furthermore, no cleavage in caspase-8, caspase-9, caspase-3, poly ADP-ribose polymerase (PARP), or DNA fragmentation factor 45 was triggered by PS-341 treatment. We have previously shown that PS-341 treatment triggers phosphorylation of c-Jun NH₂-terminal kinase (JNK), which subsequently induces caspase-dependent apoptosis; conversely, JNK inhibition blocks PS-341-induced apoptosis. We here show that phosphorylation of SEK-1, JNK, and c-Jun are not induced by PS-341 treatment, suggesting that PS-341 does not trigger a stress response in DHL-4 cells. Importantly, CT-32615 inhibits growth of DHL-4 cells in a time- and dose-dependent fashion: a transient G2/M cell cycle arrest induced by CT-32615 is mediated via down-regulation of cdc25c and cdc2. CT-32615 triggered swelling and lysis of DHL-4 cells, without caspase/PARP cleavage or TUNEL-positivity, suggesting a necrotic response. Our studies therefore demonstrate that LPAAT- β inhibitor CT-32615 triggers necrosis, even in PS-341-resistant DHL-4 cells, providing the framework for its evaluation to overcome clin. PS-341 resistance and improve patient outcome.
 IT **710335-06-1, CT 32615**
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (mol. characterization of PS-341 (bortezomib) resistance and treatment using lysophosphatidic acid acyltransferase (LPAAT)- β inhibitors)
 RN 710335-06-1 CAPLUS
 CN Benzenemethanol, 4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 11 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:324144 CAPLUS

DN 142:392431

TI Pyrimidinylarylamines and pyrimidinylaryl benzamides as protein kinase inhibitors and their preparation

IN Chopiuk, Greg; Furet, Pascal; Gray, Nathanael Schiander; Imbach, Patricia; Liu, Yi; Schoepfer, Joseph; Steensma, Ruo

PA IRM LLC, Bermuda

SO PCT Int. Appl., 39 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005033086	A1	20050414	WO 2004-US32473	20040930
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004278413	A1	20050414	AU 2004-278413	20040930
CA 2539339	AA	20050414	CA 2004-2539339	20040930
US 2005171105	A1	20050804	US 2004-956412	20040930
PRAI US 2003-507592P	P	20030930		
WO 2004-US32473	W	20040930		

OS MARPAT 142:392431

AB The invention relates to a group of pyrimidinylarylamines and pyrimidinylaryl benzamides I which are protein kinase inhibitors. In compds. I, n is 0-3; Z is CH or N; R1 is H or NR4R5; wherein R4 is selected from H and C1-6 alkyl and R5 is selected from optionally substituted aryl, heteroaryl, cycloalkyl and heterocycloalkyl; R2 is selected from H and C1-6 alkyl; and R3 is selected from halo, cyano, C1-6 alkyl, arylamino, arylcarbonylamino, etc.; rings A and B can have up to 4 CH groups replaced by N. The invention also relates to the preparation of I, pharmaceutical compns. containing a therapeutically effective amount of I in combination with a pharmaceutically acceptable excipient, as well as to the use of the compns. to prevent, inhibit, or ameliorate the pathol. and/or symptomol. of diseases involving abnormal activation of protein kinases. Substitution of 4,6-dichloropyrimidine with 3-(dimethylamino)aniline followed by coupling with 2-aminophenylboronic acid gave II, which reacted with 3-nitrophenylboronic acid to give III. Hydrogenation of III followed by coupling with 4-(4-methylpiperazin-1-ylmethyl)benzoic acid then gave benzamide IV. Compds. of formula I inhibit protein kinases preferably showing IC50 values of 0.1 nM to 10 μ M for wild type BCR-Abl and b-Raf, with IV having an IC50 of 0.667 μ M for b-Raf. IV, at a concentration of 10 μ M, exhibits 56-96 % inhibition of the following kinases: Abl, c-RAF, CHK2, FGFR3, p70S6K, PDGFR α , and PKC α .

IT **850087-62-6P**, N-[3-[[2-[6-(3-Dimethylaminophenylamino)pyrimidin-4-yl]phenyl]amino]phenyl]-4-(4-methylpiperazin-1-ylmethyl)benzamide
850087-67-1P, N-[3-[[2-[6-(4-Trifluoromethylphenylamino)pyrimidin-

4-yl]phenyl]amino]phenyl]benzamide **850087-68-2P**,
 4-(4-Methylpiperazin-1-ylmethyl)-N-[3-[[2-[6-(4-trifluoromethylphenylamino)pyrimidin-4-yl]phenyl]amino]phenyl]benzamide
850087-69-3P, N-[3-[[2-[6-(3-Dimethylaminophenylamino)pyrimidin-4-yl]phenyl]amino]phenyl]-4-hydroxymethylbenzamide **850087-70-6P**,
 N-[3-[[2-[6-(3-Dimethylaminophenylamino)pyrimidin-4-yl]phenyl]amino]phenyl]-3-(morpholine-4-sulfonyl)benzamide
850087-71-7P, N-[3-[[2-[6-(3-Dimethylaminophenylamino)pyrimidin-4-yl]phenyl]amino]phenyl]-4-(3-methyl-5-oxo-4,5-dihydropyrazol-1-yl)benzamide **850087-72-8P**, N-[3-[[2-[6-(3-Dimethylaminophenylamino)pyrimidin-4-yl]phenyl]amino]phenyl]-3-(4-methylpiperazin-1-ylsulfonyl)benzamide **850087-73-9P**,
 4-[Bis(2-hydroxyethyl)sulfamoyl]-N-[3-[[2-[6-(3-dimethylaminophenylamino)pyrimidin-4-yl]phenyl]amino]phenyl]benzamide
850087-75-1P, N-Cyclopropyl-3-[[2-[6-(4-trifluoromethylphenylamino)pyrimidin-4-yl]phenyl]amino]benzamide
850087-76-2P, [6-[2-(3-Fluorophenylamino)phenyl]pyrimidin-4-yl](4-trifluoromethylphenyl)amine **850087-77-3P**,
 [6-[2-(2-Fluorophenylamino)phenyl]pyrimidin-4-yl](4-trifluoromethylphenyl)amine **850087-78-4P**, [6-[2-(4-Fluorophenylamino)phenyl]pyrimidin-4-yl](4-trifluoromethylphenyl)amine
850087-79-5P, [6-[2-(2-Chlorophenylamino)phenyl]pyrimidin-4-yl](4-trifluoromethylphenyl)amine **850087-80-8P**, [6-[2-(3-Chlorophenylamino)phenyl]pyrimidin-4-yl](4-trifluoromethylphenyl)amine
850087-81-9P, [6-[2-(4-Chlorophenylamino)phenyl]pyrimidin-4-yl](4-trifluoromethylphenyl)amine **850087-82-0P**, [6-(2-o-Tolylaminophenyl)pyrimidin-4-yl](4-trifluoromethylphenyl)amine
850087-83-1P, [6-(2-m-Tolylaminophenyl)pyrimidin-4-yl](4-trifluoromethylphenyl)amine **850087-84-2P**, [6-(2-p-Tolylaminophenyl)pyrimidin-4-yl](4-trifluoromethylphenyl)amine
850087-85-3P, 3-[[2-[6-(4-Trifluoromethylphenylamino)pyrimidin-4-yl]phenyl]amino]benzaldehyde **850087-86-4P**, 4-[[2-[6-(4-Trifluoromethylphenylamino)pyrimidin-4-yl]phenyl]amino]benzaldehyde
850087-87-5P, (4-Trifluoromethylphenyl)[6-[2-(2-trifluoromethylphenylamino)phenyl]pyrimidin-4-yl]amine
850087-88-6P, (4-Trifluoromethylphenyl)[6-[2-(4-trifluoromethylphenylamino)phenyl]pyrimidin-4-yl]amine
850087-89-7P, N,N-Dimethyl-N'-[2-[6-(4-trifluoromethylphenylamino)pyrimidin-4-yl]phenyl]benzene-1,4-diamine
850087-90-0P, Phenyl[6-(2-phenylaminophenyl)pyrimidin-4-yl]amine
850087-91-1P, [6-[2-(2,6-Dichlorophenylamino)phenyl]pyrimidin-4-yl](3,4,5-trimethoxyphenyl)amine **850087-92-2P**,
 [6-[2-(2,6-Dichlorophenylamino)phenyl]pyrimidin-4-yl][4-(4-methylpiperazin-1-yl)phenyl]amine


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidine-containing arylamines and aryl benzamides as protein kinase inhibitors)

RN 850087-62-6 CAPLUS

CN Benzamide, N-[3-[[2-[6-[[3-(dimethylamino)phenyl]amino]-4-pyrimidinyl]phenyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

Me

RN 850087-67-1 CAPLUS


CN Benzamide, N-[3-[[2-[6-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]phenyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 850087-68-2 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[3-[[2-[6-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]phenyl]amino]phenyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B

Me

RN 850087-69-3 CAPLUS
 CN Benzamide, N-[3-[[2-[6-[[3-(dimethylamino)phenyl]amino]-4-pyrimidinyl]phenyl]amino]phenyl]-4-(hydroxymethyl)- (9CI) (CA INDEX NAME)




RN 850087-70-6 CAPLUS
 CN Benzamide, N-[3-[[2-[6-[[3-(dimethylamino)phenyl]amino]-4-pyrimidinyl]phenyl]amino]phenyl]-3-(4-morpholinesulfonyl)- (9CI) (CA INDEX NAME)



RN 850087-71-7 CAPLUS
 CN Benzamide, 4-(4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)-N-[3-[[2-[6-[[3-


(dimethylamino)phenyl]amino]-4-pyrimidinyl]phenyl]amino]phenyl]- (9CI)
(CA INDEX NAME)



RN 850087-72-8 CAPLUS

CN Benzamide, N-[3-[[2-[6-[[3-(dimethylamino)phenyl]amino]-4-pyrimidinyl]phenyl]amino]phenyl]-3-[(4-methyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— Me

RN 850087-73-9 CAPLUS

CN Benzamide, 4-[[bis(2-hydroxyethyl)amino]sulfonyl]-N-[3-[[2-[6-[[3-(dimethylamino)phenyl]amino]-4-pyrimidinyl]phenyl]amino]phenyl]- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CH₂—OH


RN 850087-75-1 CAPLUS

CN Benzamide, N-cyclopropyl-3-[[2-[6-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 850087-76-2 CAPLUS

CN 4-Pyrimidinamine, 6-[2-[(3-fluorophenyl)amino]phenyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 850087-77-3 CAPLUS

CN 4-Pyrimidinamine, 6-[2-[(2-fluorophenyl)amino]phenyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 850087-78-4 CAPLUS

CN 4-Pyrimidinamine, 6-[2-[(4-fluorophenyl)amino]phenyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 850087-79-5 CAPLUS

CN 4-Pyrimidinamine, 6-[2-[(2-chlorophenyl)amino]phenyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 850087-80-8 CAPLUS

CN 4-Pyrimidinamine, 6-[2-[(3-chlorophenyl)amino]phenyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 850087-81-9 CAPLUS

CN 4-Pyrimidinamine, 6-[2-[(4-chlorophenyl)amino]phenyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 850087-82-0 CAPLUS

CN 4-Pyrimidinamine, 6-[2-[(2-methylphenyl)amino]phenyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 850087-83-1 CAPLUS

CN 4-Pyrimidinamine, 6-[2-[(3-methylphenyl)amino]phenyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 850087-84-2 CAPLUS

CN 4-Pyrimidinamine, 6-[2-[(4-methylphenyl)amino]phenyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 850087-85-3 CAPLUS

CN Benzaldehyde, 3-[[2-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 850087-86-4 CAPLUS

CN Benzaldehyde, 4-[[2-[6-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 850087-87-5 CAPLUS

CN 4-Pyrimidinamine, N-[4-(trifluoromethyl)phenyl]-6-[2-[[2-(trifluoromethyl)phenyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 850087-88-6 CAPLUS

CN 4-Pyrimidinamine, N-[4-(trifluoromethyl)phenyl]-6-[2-[[4-(trifluoromethyl)phenyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 850087-89-7 CAPLUS

CN 1,4-Benzenediamine, N,N-dimethyl-N'-[2-[6-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 850087-90-0 CAPLUS

CN 4-Pyrimidinamine, N-phenyl-6-[2-(phenylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 850087-91-1 CAPLUS

CN 4-Pyrimidinamine, 6-[2-[(2,6-dichlorophenyl)amino]phenyl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 850087-92-2 CAPLUS

CN 4-Pyrimidinamine, 6-[2-[(2,6-dichlorophenyl)amino]phenyl]-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




IT 850087-64-8P 850087-65-9P 850087-66-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyrimidine-containing arylamines and aryl benzamides as protein kinase inhibitors)


RN 850087-64-8 CAPLUS

CN 1,3-Benzenediamine, N'-[6-(2-aminophenyl)-4-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 850087-65-9 CAPLUS

CN 1,3-Benzenediamine, N,N-dimethyl-N'-[6-[2-[(3-nitrophenyl)amino]phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850087-66-0 CAPLUS

CN 1,3-Benzenediamine, N'-[6-[2-[(3-aminophenyl)amino]phenyl]-4-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 14 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:878265 CAPLUS
 DN 141:366255
 TI Preparation of substituted pyrimidinamines and triazinamines as protein kinase inhibitors
 IN Ding, Qiang; Sim, Tae-Bo; Zhang, Guobao; Adrian, Francisco; Gray, Nathanael S.; Schultz, Peter G.
 PA IRM LLC, Bermuda
 SO PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004089286	A2	20041021	WO 2004-US10083	20040402
	WO 2004089286	A3	20050421		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2005014753	A1	20050120	US 2004-817328	20040401
	AU 2004227943	A1	20041021	AU 2004-227943	20040402
	CA 2521184	AA	20041021	CA 2004-2521184	20040402
	EP 1613595	A2	20060111	EP 2004-758738	20040402
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
	BR 2004009173	A	20060411	BR 2004-9173	20040402
PRAI	US 2003-460838P	P	20030404		
	US 2004-817328	A	20040401		
	WO 2004-US10083	W	20040402		
OS	MARPAT 141:366255				
AB	The title compds. [I; X1, X2 = N, CR4 (wherein R4 = H, alkyl); L = a bond, O, NR5 (R5 = H, alkyl); R1 = X3NR6R7, X3OR7, X3R7 (X3 = a bond, alkylene; R6 = H, alkyl; R7 = aryl, heteroaryl); R2 = H, halo, NH2, etc.; R3 = (heterocycloalkyl)alkyl, heteroarylalkyl, arylalkyl, etc.], useful for treating or preventing diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of PDGF-R, c-Kit and Bcr-abl, were prepared E.g., a multi-step synthesis of II, starting from 4,6-dichloropyrimidine and p-trifluoromethoxyaniline, was given. The compds. I preferably show an IC50 in the range of 1x10-10 to 1x10-5M for Bcr-abl (specific data for one of the exemplified compds. I are given). The pharmaceutical composition comprising the compound I is claimed.				
IT	714962-06-8P 778269-75-3P 778269-83-3P 778270-03-4P 778270-11-4P 778270-17-0P 778270-68-1P 778271-72-0P 778271-79-7P 778273-82-8P 778273-90-8P 778274-04-7P 778274-14-9P 778274-20-7P 778274-28-5P 778274-34-3P 778274-38-7P 778274-42-3P 778274-49-0P 778274-58-1P 778274-65-0P				


778274-74-1P 778274-81-0P 778274-89-8P
 778274-97-8P 778275-02-8P 778275-08-4P
 778275-15-3P 778275-21-1P 778275-31-3P
 778275-36-8P 778275-45-9P 778275-58-4P
 778275-64-2P 778275-72-2P 778275-78-8P
 778275-86-8P 778275-92-6P 778276-06-5P
 778276-12-3P 778276-24-7P 778276-30-5P
 778276-36-1P 778276-42-9P 778276-48-5P
 778276-89-4P 778276-94-1P 778276-99-6P
 778277-15-9P 778277-22-8P 778277-24-0P
 778277-31-9P 778277-37-5P 778277-54-6P
 778277-62-6P 778277-67-1P 778279-08-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted pyrimidinamines and triazinamines as protein kinase inhibitors for treating tumors)


RN 714962-06-8 CAPLUS

CN Benzenesulfonamide, 4-methoxy-N-[3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 778269-75-3 CAPLUS

CN Benzamide, N,N-dimethyl-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 778269-83-3 CAPLUS

CN Benzamide, N-[2-(4-morpholinyl)ethyl]-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 778270-03-4 CAPLUS


CN 4-Pyrimidinamine, 6-[3-(methylsulfonyl)phenyl]-N-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 778270-11-4 CAPLUS


CN Benzenesulfonamide, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)

RN 778270-17-0 CAPLUS

CN 4-Pyrimidinamine, 6-(3-aminophenyl)-N-[4-(trifluoromethoxy)phenyl]- (9CI)
(CA INDEX NAME)


RN 778270-68-1 CAPLUS

CN Benzenesulfonamide, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 778271-72-0 CAPLUS

CN 4-Pyrimidinamine, 6-(3-methoxyphenyl)-N-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 778271-79-7 CAPLUS

CN Benzenemethanol, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-
(9CI) (CA INDEX NAME)




RN 778273-82-8 CAPLUS

CN Ethanone, 1-[3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 778273-90-8 CAPLUS

CN Acetamide, N-[3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 778274-04-7 CAPLUS

CN Benzamide, N-(1-methylethyl)-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 778274-14-9 CAPLUS

CN Benzamide, N-4-morpholinyl-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 778274-20-7 CAPLUS

CN Benzamide, N-[2-(dimethylamino)ethyl]-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 778274-28-5 CAPLUS

CN Benzamide, N-(2-furanylmethyl)-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 778274-34-3 CAPLUS

CN Morpholine, 4-[3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 778274-38-7 CAPLUS


CN Piperazine, 1-ethyl-4-[3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 778274-42-3 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]benzoyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 778274-49-0 CAPLUS

CN Benzamide, N-[(tetrahydro-2-furanyl)methyl]-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 778274-58-1 CAPLUS

CN Benzamide, N-(3-pyridinylmethyl)-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 778274-65-0 CAPLUS

CN 3-Piperidinecarboxamide, N,N-diethyl-1-[3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 778274-74-1 CAPLUS

CN Benzamide, N-[4-(dimethylamino)phenyl]-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 778274-81-0 CAPLUS


CN Benzamide, 4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)



RN 778274-89-8 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]benzoyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 778274-97-8 CAPLUS

CN Benzamide, N-(2-hydroxyethyl)-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 778275-02-8 CAPLUS

CN Benzamide, N-[2-(dimethylamino)ethyl]-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 778275-08-4 CAPLUS


CN Benzamide, N-[3-(aminocarbonyl)phenyl]-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 778275-15-3 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]benzoyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 778275-21-1 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]benzoyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 778275-31-3 CAPLUS

CN Morpholine, 4-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 778275-36-8 CAPLUS

CN Benzamide, N-4-morpholinyl-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 778275-45-9 CAPLUS

CN Benzamide, N-[3-(1H-imidazol-1-yl)propyl]-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 778275-58-4 CAPLUS

CN Benzamide, 2-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 778275-64-2 CAPLUS

CN Morpholine, 4-[3-amino-5-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 778275-72-2 CAPLUS

CN 4-Pyrimidinamine, 6-(2-aminophenyl)-N-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 778275-78-8 CAPLUS

CN Benzamide, 4-[5-methyl-6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 778275-86-8 CAPLUS

CN Morpholine, 4-[4-methyl-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 778275-92-6 CAPLUS

CN Benzamide, N-(2-hydroxyethyl)-4-methyl-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 778276-06-5 CAPLUS

CN Morpholine, 4-[3-amino-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 778276-12-3 CAPLUS

CN Benzamide, 3-amino-N-(2-hydroxyethyl)-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 778276-24-7 CAPLUS

CN Benzenesulfonamide, 4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 778276-30-5 CAPLUS

CN Morpholine, 4-[[3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 778276-36-1 CAPLUS

CN Morpholine, 4-[[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 778276-42-9 CAPLUS

CN Benzamide, N-(2,6-dichlorophenyl)-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 778276-48-5 CAPLUS


CN 3-Piperidinecarboxamide, 1-[3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 778276-89-4 CAPLUS


CN Benzamide, 3-[6-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)

RN 778276-94-1 CAPLUS

CN Benzamide, 4-[6-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)


RN 778276-99-6 CAPLUS

CN Benzamide, N-[2-(4-morpholinyl)ethyl]-4-[6-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 778277-15-9 CAPLUS

CN Benzamide, N-(2-hydroxyethyl)-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 778277-22-8 CAPLUS

CN Benzamide, N-(4-pyridinylmethyl)-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 778277-24-0 CAPLUS

CN Benzamide, N-[3-(1H-imidazol-1-yl)propyl]-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 778277-31-9 CAPLUS

CN 1-Piperazineethanol, 4-[3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 778277-37-5 CAPLUS


CN Benzamide, N-methyl-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 778277-54-6 CAPLUS


CN Benzamide, 3-amino-N-methyl-5-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-

pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 778277-62-6 CAPLUS

CN Benzamide, 2-fluoro-N-(2-hydroxyethyl)-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 778277-67-1 CAPLUS

CN Benzamide, 2-cyano-N-methyl-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 778279-08-6 CAPLUS

CN Benzamide, N-[2-(4-morpholinyl)ethyl]-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




IT 778278-85-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of substituted pyrimidinamines and triazinamines as protein kinase inhibitors for treating tumors)

RN 778278-85-6 CAPLUS

CN Benzoic acid, 4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



L12 ANSWER 15 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:857162 CAPLUS

DN 141:350185

TI Preparation of pyrimidine derivatives with lysophosphatidic acid acyltransferase β (LPAAT- β) inhibitory activityIN Bhatt, Rama; Gong, Baoqing; Hong, Feng; Jenkins, Scott A.; Klein, J. Peter; Kohm, Cory T.; Tulinsky, John

PA Cell Therapeutics, Inc., USA

SO U.S. Pat. Appl. Publ., 80 pp., which
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004204386	A1	20041014	US 2003-671070	20030924
PRAI	US 2002-419694P	P	20021017		
	US 2003-460776P	P	20030404		

OS MARPAT 141:350185


AB The title compds. I [X, Y, Z = N, CH, or CR with the proviso that two of X, Y and Z are N; R = alkyl, alkoxy, Cl, Br, (substituted)amino; Q = NR', R'N-(CH₂)_n, (CH₂)_n-NR', O, O-(CH₂)_n, (CH₂)_n-O, S, S-(CH₂)_n, or (CH₂)_n-S; n = 1-10; R' = H or alkyl; R1 = H, OH, alkyl, alkoxy, Cl, F, Br, etc.; R2, R7 = H, OH, alkyl, alkoxy, Cl, F, Br, I, etc.; R3 = H, alkyl, alkoxy, Cl, CCl₃, (substituted)amino; R4, R5, R6 = H, OH, alkyl, alkenyl, alkynyl, alkoxy, etc. or R4, R5 or R5, R6 are taken together with benzene ring to form a heterocycle] are prepared as lysophosphatidic acid acyltransferase β (LPAAT- β) inhibitors for the treatment of diseases related to cell proliferation, such as cancer. For example, reaction of 6-chloro-N4-(4-methylphenyl)-pyrimidine-2,4-diamine (preparation given) with 5-chloro-2-methoxy-Ph boronic acid yielded compound II. The latter exhibits an IC₅₀ = 0.12 μ M in the LPAAT- β assay.

IT 710335-06-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrimidine derivs. with lysophosphatidic acid acyltransferase β (LPAAT- β) inhibitory activity)

RN 710335-06-1 CAPLUS

CN Benzenemethanol, 4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



IT 710334-85-3P 710334-87-5P 710334-94-4P
710334-96-6P 710334-97-7P 710334-99-9P
710335-00-5P 710335-01-6P 710335-03-8P
710335-05-0P 710335-07-2P 710335-08-3P
710335-10-7P 710335-12-9P 710335-25-4P


710336-16-6P 774606-08-5P 774606-09-6P
774606-10-9P 774606-11-0P 774606-12-1P
774606-13-2P 774606-14-3P 774606-15-4P
774606-16-5P 774606-17-6P 774606-18-7P
774606-19-8P 774606-20-1P 774606-21-2P
774606-22-3P 774606-23-4P 774606-24-5P
774606-25-6P 774606-26-7P 774606-28-9P
774606-29-0P 774606-30-3P 774606-31-4P
774606-32-5P 774606-33-6P 774606-34-7P
774606-35-8P 774606-36-9P 774606-37-0P
774606-38-1P 774606-39-2P 774606-40-5P
774606-41-6P 774606-42-7P 774606-43-8P
774606-44-9P 774606-45-0P 774606-46-1P
774606-47-2P 774606-48-3P 774606-49-4P
774606-50-7P 774606-52-9P 774606-53-0P
774606-54-1P 774606-55-2P 774606-56-3P
774606-57-4P 774606-58-5P 774606-61-0P
774606-62-1P 774606-63-2P 774606-64-3P
774606-65-4P 774606-66-5P 774606-67-6P
774606-68-7P 774606-69-8P 774606-70-1P
774606-71-2P 774606-72-3P 774606-73-4P
774606-74-5P 774606-75-6P 774606-76-7P
774606-77-8P 774606-78-9P 774606-79-0P
774606-80-3P 774606-81-4P 774606-82-5P
774606-83-6P 774606-84-7P 774606-85-8P
774606-86-9P 774606-87-0P 774606-88-1P
774606-89-2P 774606-90-5P 774606-91-6P
774606-92-7P 774606-93-8P 774606-94-9P
774606-95-0P 774606-96-1P 774606-97-2P
774606-98-3P 774606-99-4P 774607-00-0P
774607-01-1P 774607-02-2P 774607-03-3P
774607-04-4P 774607-05-5P 774607-06-6P
774607-07-7P 774607-08-8P 774607-09-9P
774607-10-2P 774607-11-3P 774607-12-4P
774607-15-7P 774607-16-8P 774607-17-9P
774607-18-0P 774607-19-1P 774607-20-4P
774607-21-5P 774607-22-6P 774607-23-7P
774607-24-8P 774607-25-9P 774607-26-0P
774607-27-1P 774607-28-2P 774607-29-3P
774607-31-7P 774607-32-8P 774607-33-9P
774607-34-0P 774607-35-1P 774607-36-2P
774607-37-3P 774607-38-4P 774607-39-5P
774607-40-8P 774607-41-9P 774607-42-0P
774607-43-1P 774607-44-2P 774607-45-3P
774607-46-4P 774607-47-5P 774607-48-6P
774607-49-7P 774607-50-0P 774607-51-1P
774607-52-2P 774607-53-3P 774607-54-4P
774607-55-5P 774607-56-6P 774607-57-7P
774607-58-8P 774607-59-9P 774607-60-2P
774607-61-3P 774607-62-4P 774607-63-5P
774607-64-6P 774607-65-7P 774607-66-8P
774607-67-9P 774607-68-0P 774607-69-1P
774607-70-4P 774607-71-5P 774607-72-6P
774607-73-7P 774607-74-8P 774607-75-9P
774607-76-0P 774607-77-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of pyrimidine derivs. with lysophosphatidic acid
acyltransferase β (LPAAT- β) inhibitory activity)


RN 710334-85-3 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methoxyphenyl)-N4-(4-chlorophenyl)-
(9CI) (CA INDEX NAME)




RN 710334-87-5 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methoxyphenyl)-N4-1H-indazol-6-yl-
(9CI) (CA INDEX NAME)




RN 710334-94-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(4-chlorophenyl)-6-(2,5-dichlorophenyl)- (9CI)
(CA INDEX NAME)




RN 710334-96-6 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methylphenyl)-N4-(4-chlorophenyl)-
(9CI) (CA INDEX NAME)




RN 710334-97-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(4-bromophenyl)-6-(5-chloro-2-methylphenyl)-
(9CI) (CA INDEX NAME)




RN 710334-99-9 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methylphenyl)-N4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 710335-00-5 CAPLUS


CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-methylphenyl)-N4-(4-chlorophenyl)-
(9CI) (CA INDEX NAME)




RN 710335-01-6 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-methylphenyl)-N4-(4-bromophenyl)-

(9CI) (CA INDEX NAME)




RN 710335-03-8 CAPLUS

CN Phenol, 2-[2-amino-6-[(4-chlorophenyl)amino]-4-pyrimidinyl]-4-bromo- (9CI)
(CA INDEX NAME)


RN 710335-05-0 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-(2-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 710335-07-2 CAPLUS

CN Benzeneethanol, 4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 710335-08-3 CAPLUS

CN Benzenepropanol, 4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 710335-10-7 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 710335-12-9 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-1H-indazol-6-yl- (9CI) (CA INDEX NAME)




RN 710335-25-4 CAPLUS

CN Ethanone, 1-[4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 710336-16-6 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-(4-chlorophenyl)-
(9CI) (CA INDEX NAME)




RN 774606-08-5 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methoxyphenyl)-N4-(4-methylphenyl)-
(9CI) (CA INDEX NAME)



RN 774606-09-6 CAPLUS


CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methoxyphenyl)-N4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 774606-10-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(4-bromophenyl)-6-(5-chloro-2-methoxyphenyl)-,


monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774606-11-0 CAPLUS

CN Phenol, 4-[[2-amino-6-(5-chloro-2-methoxyphenyl)-4-pyrimidinyl]amino]-
(9CI) (CA INDEX NAME)




RN 774606-12-1 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methoxyphenyl)-N4-(4-methoxyphenyl)-
(9CI) (CA INDEX NAME)




RN 774606-13-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-6-benzothiazolyl-6-(5-chloro-2-methoxyphenyl)-
(9CI) (CA INDEX NAME)




RN 774606-14-3 CAPLUS

CN Benzoic acid, 4-[[2-amino-6-(5-chloro-2-methoxyphenyl)-4-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 774606-15-4 CAPLUS

CN Benzenemethanol, 4-[[2-amino-6-(5-chloro-2-methoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 774606-16-5 CAPLUS


CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methoxyphenyl)-N4-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 774606-17-6 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(4-aminophenyl)-6-(5-chloro-2-methoxyphenyl)-

(9CI) (CA INDEX NAME)




RN 774606-18-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-1,3-benzodioxol-5-yl-6-(5-chloro-2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 774606-19-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(4-bromophenyl)-6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)




RN 774606-20-1 CAPLUS


CN 2,4-Pyrimidinediamine, 6-(2,5-dichlorophenyl)-N4-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 774606-21-2 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(2,5-dichlorophenyl)-N4-(4-methoxyphenyl)- (9CI)
 (CA INDEX NAME)




RN 774606-22-3 CAPLUS
 CN Phenol, 4-[[2-amino-6-(2,5-dichlorophenyl)-4-pyrimidinyl]amino]- (9CI)
 (CA INDEX NAME)



RN 774606-23-4 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(2,5-dichlorophenyl)-N4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 774606-24-5 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(2,5-dichlorophenyl)-N4-1H-indazol-6-yl- (9CI)
 (CA INDEX NAME)




RN 774606-25-6 CAPLUS

CN Benzoic acid, 4-[[2-amino-6-(2,5-dichlorophenyl)-4-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 774606-26-7 CAPLUS

CN Benzenemethanol, 4-[[2-amino-6-(2,5-dichlorophenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 774606-28-9 CAPLUS


CN 2,4-Pyrimidinediamine, N4-1,3-benzodioxol-5-yl-6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)




RN 774606-29-0 CAPLUS

CN Benzonitrile, 4-[[2-amino-6-(2,5-dichlorophenyl)-4-pyrimidinyl]amino]-


(9CI) (CA INDEX NAME)




RN 774606-30-3 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(2,5-dichlorophenyl)-N4-(4-nitrophenyl)- (9CI)
(CA INDEX NAME)


RN 774606-31-4 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methylphenyl)-N4-(4-methylphenyl)-
(9CI) (CA INDEX NAME)


RN 774606-32-5 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methylphenyl)-N4-(4-methoxyphenyl)-
(9CI) (CA INDEX NAME)

RN 774606-33-6 CAPLUS


CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methylphenyl)-N4-1H-indazol-6-yl-
(9CI) (CA INDEX NAME)

RN 774606-34-7 CAPLUS

CN Benzonitrile, 4-[[2-amino-6-(5-chloro-2-methylphenyl)-4-pyrimidinyl]amino]-
(9CI) (CA INDEX NAME)


RN 774606-35-8 CAPLUS

CN Benzenemethanol, 4-[[2-amino-6-(5-chloro-2-methylphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774606-36-9 CAPLUS

CN 4-Pyrimidinamine, N-(4-bromophenyl)-6-(5-chloro-2-methoxyphenyl)-2-methyl-
(9CI) (CA INDEX NAME)




RN 774606-37-0 CAPLUS

CN 1H-Indazol-6-amine, N-[6-(5-chloro-2-methoxyphenyl)-2-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 774606-38-1 CAPLUS

CN 4-Pyrimidinamine, N-(4-bromophenyl)-6-(5-chloro-2-methylphenyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 774606-39-2 CAPLUS


CN 4-Pyrimidinamine, 6-(5-chloro-2-methylphenyl)-N-(4-chlorophenyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 774606-40-5 CAPLUS


CN 1H-Indazol-6-amine, N-[6-(5-chloro-2-methylphenyl)-2-methyl-4-pyrimidinyl]-

(9CI) (CA INDEX NAME)




RN 774606-41-6 CAPLUS

CN Benzonitrile, 4-[[2-amino-6-(5-chloro-2-methoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774606-42-7 CAPLUS

CN Benzeneethanol, 4-[[2-amino-6-(2,5-dichlorophenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774606-43-8 CAPLUS

CN Benzeneethanol, 4-[[2-amino-6-(5-chloro-2-methylphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774606-44-9 CAPLUS

CN Benzeneethanol, 4-[[2-amino-6-(5-chloro-2-methoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774606-45-0 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methoxyphenyl)-N4-1H-indazol-6-yl-5-methyl- (9CI) (CA INDEX NAME)




RN 774606-46-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-6-(5-chloro-2-methoxyphenyl)-N4-1H-indazol-6-yl- (9CI) (CA INDEX NAME)




RN 774606-47-2 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 774606-48-3 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 774606-49-4 CAPLUS

CN Benzonitrile, 4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 774606-50-7 CAPLUS


CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 774606-52-9 CAPLUS


CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-ethoxyphenyl)-N4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 774606-53-0 CAPLUS

CN Benzoic acid, 4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 774606-54-1 CAPLUS

CN Benzenemethanol, 4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774606-55-2 CAPLUS

CN Butanedioic acid, mono[[4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]phenyl]methyl] ester (9CI) (CA INDEX NAME)



RN 774606-56-3 CAPLUS


CN Glycine, [4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]phenyl]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774606-57-4 CAPLUS

CN Benzenemethanol, 4-[[6-(5-chloro-2-ethoxyphenyl)-2-(methylamino)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774606-58-5 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-[4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)




RN 774606-61-0 CAPLUS

CN Butanedioic acid, mono[2-[4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]phenyl]ethyl] ester (9CI) (CA INDEX NAME)




RN 774606-62-1 CAPLUS

CN Benzeneethanol, 4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 774606-63-2 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(4-chlorophenyl)-6-(5-methoxy-2-methylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774606-64-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(4-chlorophenyl)-6-(2,5-dimethylphenyl)- (9CI)
(CA INDEX NAME)



RN 774606-65-4 CAPLUS


CN Benzeneethanol, 4-[[2-amino-6-(2,5-dimethylphenyl)-4-pyrimidinyl]amino]-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774606-66-5 CAPLUS

CN Benzamide, 5-[[2-amino-6-(5-bromo-2-methylphenyl)-4-pyrimidinyl]amino]-2-
chloro-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774606-67-6 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(5-fluoro-2-methylphenyl)-N4-[4-(trifluoromethyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774606-68-7 CAPLUS
 CN Benzamide, 5-[[2-amino-6-(5-chloro-2-methylphenyl)-4-pyrimidinyl]amino]-2-bromo-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774606-69-8 CAPLUS


CN Benzamide, 5-[[2-amino-6-(5-bromo-2-methylphenyl)-4-pyrimidinyl]amino]-2-bromo-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774606-70-1 CAPLUS


CN 1H-Isoindole-1,3(2H)-dione, 5-[[2-amino-6-(5-chloro-2-methylphenyl)-4-pyrimidinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774606-71-2 CAPLUS


CN Butanoic acid, 4-[[4-(5-chloro-2-methylphenyl)-6-[[4-(trifluoromethyl)phenyl]amino]-2-pyrimidinyl]amino]-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774606-72-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(4-azidophenyl)-6-(5-bromo-2-methylphenyl)-
(9CI) (CA INDEX NAME)




RN 774606-73-4 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-methylphenyl)-N4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 774606-74-5 CAPLUS


CN 2-Oxazolepropanoic acid, 5-[4-[[2-amino-6-(5-chloro-2-methylphenyl)-4-pyrimidinyl]amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774606-75-6 CAPLUS

CN Benzonitrile, 4-[[2-amino-6-(5-bromo-2-methylphenyl)-4-pyrimidinyl]amino]-
(9CI) (CA INDEX NAME)




RN 774606-76-7 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-methylphenyl)-N4-[4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)




RN 774606-77-8 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-methylphenyl)-N4-(4-nitrophenyl)-
(9CI) (CA INDEX NAME)




RN 774606-78-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(4-chlorophenyl)-6-[5-chloro-2-(2,2,2-trifluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 774606-79-0 CAPLUS

CN Ethanol, 2-[4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 774606-80-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(4-bromophenyl)-6-[5-bromo-2-(2,2,2-trifluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 774606-81-4 CAPLUS

CN Benzenebutanol, 4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)






RN 774606-82-5 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 774606-83-6 CAPLUS

CN Benzenebutanoic acid, 4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-




RN 774606-87-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(4-bromophenyl)-6-(2,3,5-trichlorophenyl)- (9CI)
(CA INDEX NAME)


RN 774606-88-1 CAPLUS

CN Benzeneethanol, 4-[[2-amino-6-(5-bromo-2-methylphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774606-89-2 CAPLUS

CN Benzenepropanol, 4-[[2-amino-6-(5-bromo-2-methylphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774606-90-5 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(2,3,5-trichlorophenyl)-N4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 774606-91-6 CAPLUS

CN Benzenemethanol, 4-[[2-amino-6-(5-chloro-2-methylphenyl)-4-pyrimidinyl]amino]-α-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 774606-92-7 CAPLUS

CN Ethanone, 1-[4-[[2-amino-6-(5-chloro-2-methylphenyl)-4-pyrimidinyl]amino]phenyl]-2,2,2-trifluoro-, oxime (9CI) (CA INDEX NAME)




RN 774606-93-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(4-chlorophenyl)-6-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 774606-94-9 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(4-chlorophenyl)-6-phenyl-, monohydrochloride
(9CI) (CA INDEX NAME)



● HCl

RN 774606-95-0 CAPLUS


CN 2,4-Pyrimidinediamine, 6-(3-chlorophenyl)-N4-[4-(trifluoromethyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774606-96-1 CAPLUS


CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methylphenyl)-N4-(4-nitrophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774606-97-2 CAPLUS


CN Benzenepropanol, 4-[[2-amino-6-(5-chloro-2-methylphenyl)-4-pyrimidinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774606-98-3 CAPLUS


CN Benzenebutanol, 4-[[2-amino-6-(5-chloro-2-methylphenyl)-4-pyrimidinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774606-99-4 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methylphenyl)-N4-[3-(methylthio)phenyl]- (9CI) (CA INDEX NAME)



RN 774607-00-0 CAPLUS


CN 2,4-Pyrimidinediamine, 6-(3,5-dichlorophenyl)-N4-[4-(trifluoromethyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774607-01-1 CAPLUS

CN Benzenemethanol, 5-[[2-amino-6-(5-chloro-2-methylphenyl)-4-pyrimidinyl]amino]-2-chloro- (9CI) (CA INDEX NAME)




RN 774607-02-2 CAPLUS

CN Benzoic acid, 3-[[2-amino-6-(5-chloro-2-methylphenyl)-4-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 774607-03-3 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methylphenyl)-N4-(3-ethylphenyl)- (9CI) (CA INDEX NAME)




RN 774607-04-4 CAPLUS

CN 1,3-Propanediol, 2-[4-[[2-amino-6-(5-chloro-2-methylphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 774607-05-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(4-chlorophenyl)-6-(2,3-dichlorophenyl)- (9CI) (CA INDEX NAME)




RN 774607-06-6 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(3-bromophenyl)-N4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 774607-07-7 CAPLUS

CN Benzeneethanol, 4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]-α,α-dimethyl- (9CI) (CA INDEX NAME)




RN 774607-08-8 CAPLUS

CN Ethanone, 1-[4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 774607-09-9 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-(4-chlorophenyl)-N4-methyl- (9CI) (CA INDEX NAME)




RN 774607-10-2 CAPLUS

CN Ethanone, 1-[4-[[2-amino-6-(5-chloro-2-methylphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 774607-11-3 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 774607-12-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-1H-benzotriazol-5-yl-6-(5-chloro-2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 774607-15-7 CAPLUS

CN Benzenemethanol, 4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]- α -(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 774607-16-8 CAPLUS

CN Ethanone, 1-[4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]phenyl]-2,2,2-trifluoro-, oxime (9CI) (CA INDEX NAME)




RN 774607-17-9 CAPLUS

CN Ethanone, 1-[4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]phenyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)



RN 774607-18-0 CAPLUS


CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-ethoxyphenyl)-N4-(3,4-dimethylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774607-19-1 CAPLUS


CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-ethoxyphenyl)-N4-(4-nitrophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774607-20-4 CAPLUS

CN Benzenemethanol, 4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]-α-methyl- (9CI) (CA INDEX NAME)




RN 774607-21-5 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-propoxyphenyl)-N4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 774607-22-6 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[5-bromo-2-(1-methylethoxy)phenyl]-N4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 774607-23-7 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-ethoxyphenyl)-N4-[4-(1-methoxyethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 774607-24-8 CAPLUS


CN Benzamide, 3-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774607-25-9 CAPLUS

CN Ethanone, 1-[4-[[2-amino-6-(3-chlorophenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 774607-26-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(4-azidophenyl)-6-(2-ethoxy-5-iodophenyl)- (9CI) (CA INDEX NAME)



RN 774607-27-1 CAPLUS


CN Benzeneethanol, 4-[[2-amino-6-[5-bromo-2-(1-methylethoxy)phenyl]-4-pyrimidinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774607-28-2 CAPLUS


CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-methoxyphenyl)-N4-(4-chlorophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774607-29-3 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[5-bromo-2-(2-methoxyethoxy)phenyl]-N4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 774607-31-7 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[5-bromo-2-(hexyloxy)phenyl]-N4-(4-chlorophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774607-32-8 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-[5-bromo-2-(phenylmethoxy)phenyl]-N4-(4-chlorophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774607-33-9 CAPLUS
 CN Ethanone, 1-[4-[[2-amino-6-(2,3,5-trichlorophenyl)-4-pyrimidinyl]amino]phenyl]-, oxime (9CI) (CA INDEX NAME)




RN 774607-34-0 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-butoxyphenyl)-N4-(4-chlorophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774607-35-1 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[5-bromo-2-[2-(4-morpholinyl)ethoxy]phenyl]-N4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 774607-36-2 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-methoxyphenyl)-N4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 774607-37-3 CAPLUS


CN Benzeneethanol, 4-[[2-amino-6-(5-bromo-2-methoxyphenyl)-4-pyrimidinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774607-38-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(4-chlorophenyl)-6-(2-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 774607-39-5 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[5-bromo-2-(phenylmethoxy)phenyl]-N4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 774607-40-8 CAPLUS


CN Ethanone, 1-[4-[[2-amino-6-(2,5-dichlorophenyl)-4-pyrimidinyl]amino]phenyl]-, oxime (9CI) (CA INDEX NAME)



RN 774607-41-9 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-(4-chlorophenyl)-6-[5-chloro-2-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 774607-42-0 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-[5-bromo-2-[3-(dimethylamino)propoxy]phenyl]-N4-(4-chlorophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774607-43-1 CAPLUS
 CN Benzeneethanol, 4-[[2-amino-6-[5-chloro-2-(phenylmethoxy)phenyl]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774607-44-2 CAPLUS
 CN Boronic acid, [4-[[2-amino-6-(5-bromo-2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774607-45-3 CAPLUS


CN Benzonitrile, 4-[[2-amino-6-(5-bromo-2-methoxyphenyl)-4-pyrimidinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774607-46-4 CAPLUS


CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-methoxyphenyl)-N4-(4-nitrophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774607-47-5 CAPLUS


CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-methoxyphenyl)-N4-(4-bromophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774607-48-6 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(4-bromophenyl)-6-(5-chloro-2-ethylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774607-49-7 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethylphenyl)-N4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 774607-50-0 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[5-bromo-2-[(4-chlorophenyl)methoxy]phenyl]-N4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 774607-51-1 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[5-bromo-2-(2-phenylethoxy)phenyl]-N4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 774607-52-2 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethylphenyl)-N4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 774607-53-3 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[5-chloro-2-(cyclohexylmethoxy)phenyl]-N4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 774607-54-4 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethylphenyl)-N4-(4-nitrophenyl)-
(9CI) (CA INDEX NAME)



RN 774607-55-5 CAPLUS


CN Benzoic acid, 3-[[2-amino-6-(2,5-dichlorophenyl)-4-pyrimidinyl]amino]-,
ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774607-56-6 CAPLUS

CN Benzoic acid, 3-[[2-amino-6-(5-bromo-2-methoxyphenyl)-4-pyrimidinyl]amino]-,
ethyl ester (9CI) (CA INDEX NAME)




RN 774607-57-7 CAPLUS

CN 4-Pyrimidinamine, N-(4-bromophenyl)-6-(5-chloro-2-methylphenyl)- (9CI)
(CA INDEX NAME)



RN 774607-58-8 CAPLUS


CN Boronic acid, [4-[[2-amino-6-(5-chloro-2-methylphenyl)-4-pyrimidinyl]amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774607-59-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(4-chlorophenyl)-6-[5-chloro-2-(2-propenyloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 774607-60-2 CAPLUS

CN Benzeneethanol, 4-[[2-amino-6-(5-chloro-2-ethylphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 774607-61-3 CAPLUS

CN Benzeneethanol, 4-[[6-(5-chloro-2-methylphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 774607-62-4 CAPLUS


CN 2,4-Pyrimidinediamine, 6-[5-bromo-2-(phenoxy)methyl]phenyl]-N4-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 774607-63-5 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[5-bromo-2-[(4-nitrophenoxy)methyl]phenyl]-N4-(4-


chlorophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774607-64-6 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[4-chloro-3-(trifluoromethyl)phenyl]-6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)




RN 774607-65-7 CAPLUS

CN 4-Pyrimidinamine, 6-[5-bromo-2-(methoxymethyl)phenyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 774607-66-8 CAPLUS

CN 4-Pyrimidinamine, 6-[5-bromo-2-(methoxymethyl)phenyl]-N-(4-bromophenyl)- (9CI) (CA INDEX NAME)




RN 774607-67-9 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[5-bromo-2-[(2-methoxyphenoxy)methyl]phenyl]-N4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 774607-68-0 CAPLUS

CN Benzamide, 4-[[2-amino-6-[5-bromo-2-(methoxymethyl)phenyl]-4-pyrimidinyl]amino]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 774607-69-1 CAPLUS


CN Benzamide, 5-[[2-amino-6-(5-bromo-2-methoxyphenyl)-4-pyrimidinyl]amino]-2-chloro-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 774607-70-4 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[5-bromo-2-[(4-methoxyphenoxy)methyl]phenyl]-N4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 774607-71-5 CAPLUS

CN Benzamide, 4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 774607-72-6 CAPLUS


CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-chlorophenyl)-N4-(4-chlorophenyl)-

(9CI) (CA INDEX NAME)




RN 774607-73-7 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[5-bromo-2-[(2-methoxyphenyl)methoxy]phenyl]-N4-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 774607-74-8 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-chlorophenyl)-N4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 774607-75-9 CAPLUS

CN 4-Pyrimidinamine, 6-(5-bromo-2-ethoxyphenyl)-N-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 774607-76-0 CAPLUS

CN Benzeneethanol, 4-[[6-[5-bromo-2-(methoxymethyl)phenyl]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 774607-77-1 CAPLUS

CN 4-Pyrimidinamine, 6-(5-bromo-2-ethoxyphenyl)-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



IT 710335-04-9P 774607-83-9P 774608-01-4P

774608-04-7P 774608-16-1P 774608-20-7P


774608-24-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrimidine derivs. with lysophosphatidic acid acyltransferase β (LPAAT- β) inhibitory activity)


RN 710335-04-9 CAPLUS

CN Phenol, 2-[2-amino-6-[(4-chlorophenyl)amino]-4-pyrimidinyl]-4-chloro- (9CI) (CA INDEX NAME)




RN 774607-83-9 CAPLUS

CN Benzoic acid, 4-[[2-amino-6-(5-chloro-2-methylphenyl)-4-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 774608-01-4 CAPLUS

CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-, [4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 774608-04-7 CAPLUS


CN Benzoic acid, 4-[[6-(5-chloro-2-ethoxyphenyl)-2-(methylamino)-4-pyrimidinyl]amino]-, monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 774608-16-1 CAPLUS

CN 2-Oxazolepropanoic acid, 4-[4-[[2-amino-6-(5-chloro-2-methylphenyl)-4-pyrimidinyl]amino]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 774608-20-7 CAPLUS


CN Benzenebutanoic acid, 4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 774608-24-1 CAPLUS

CN Benzenecaproic acid, 4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



IT 774606-59-6P 774606-60-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prodrug; preparation of pyrimidine derivs. with lysophosphatidic acid acyltransferase β (LPAAT- β) inhibitory activity)

RN 774606-59-6 CAPLUS

CN L-Aspartic acid, 4-[[4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]phenyl]methyl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 774606-60-9 CAPLUS

CN L-Alanine, [4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 16 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:550744 CAPLUS
 DN 141:89118
 TI Preparation of biaryl derivatives having differential tumor cytotoxicity
 IN Chyba, Jason; Deveraux, Quinn; Hampton, Garret; King, Fred
 PA IRM Llc, Bermuda
 SO U.S. Pat. Appl. Publ., 11 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004132786	A1	20040708	US 2003-739667	20031218
	WO 2004058713	A1	20040715	WO 2003-US40686	20031218
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003299750	A1	20040722	AU 2003-299750	20031218
PRAI	US 2002-435853P	P	20021220		
	US 2003-491132P	P	20030729		
	WO 2003-US40686	W	20031218		

OS MARPAT 141:89118

AB Novel biaryl derivs. (I) [R1 = HO, C1-6 alkoxy, halo-substituted-C1-6 alkoxy, halo-substituted C1-6 alkyl; R2 = H, halo, C1-6 alkoxy, halo-substituted C1-6 alkoxy, C1-6 alkyl, halo-substituted C1-6 alkyl; R3 = halo, C1-6 alkoxy, halo-substituted C1-6 alkoxy, C1-6 alkyl, halo-substituted C1-6 alkyl, -YNR4R5 (wherein Y = a bond, C5-6 heteroarylene; R4 = H, C1-6 alkyl; R5 = C6-10 aryl substituted with one to three radicals selected from the group chosen from halo, C1-6 alkyl, C1-6 alkoxy, halo-substituted C1-6 alkyl, halo-substituted C1-6 alkoxy, and PhO; or R4 and R5 together with the nitrogen to which R4 and R5 are attached form C3-8 heterocycloalkyl substituted with Ph optionally substituted with one to three radicals selected from the group chosen from halo, C1-6 alkoxy, halo-substituted C1-6 alkoxy, C1-6 alkyl and halo-substituted C1-6 alkyl); Z = -XNR6CO-, -XNR6CONR7- or -XS(O)2NR7- (wherein X = a bond, C1-6 alkylene; R6, R7 = H, C1-6 alkyl)] and the pharmaceutically acceptable salts, hydrates, solvates and isomers thereof are prepared This invention is also related to the uses of the compds. I in various medicinal applications, including the treatment, prevention and control of proliferative diseases such as tumors, and to pharmaceutical compns. comprising these compds. The compds. I can be used to treat or prevent diseases or disorders that involve the activity of macrophage migration inhibitory factor-1 (MIF-1) and/or adenosine kinase. Thus, 20 mL CH2Cl2 was added to a 4-(Morpholino)aniline resin (4.40 g, 3.52 mmol) and the solution was allowed to stand at room temperature for one hour, followed by adding Et3N (4.9 mL, 35 mmol) and 4-chlorobenzoyl chloride (2.24 mL, 17 mmol), and the reaction mixture was placed on a shaker and shaken overnight at room temperature The resin was then filtered and washed consecutively with MeOH, DMF, and CH2Cl2 (4+20 mL each) to give, after vacuum drying,

the product, N-[4-(morpholin-4-yl)phenyl]-4-chlorobenzamide bound to resin, which (1.0 g, .apprx.0.8 mmol) was aminated by 4-(trifluoromethoxy)aniline (0.55 mL, 4.0 mmol) in the presence of Pd2(dba)3 (0.091 g, 0.10 mmol) and IPrHCl ligand (0.085 g, 0.20 mmol) in 15 mL dioxane in a glass vial under shaking at 90°, cooled to room temperature to give, after filtering the resin and washing consecutively with MeOH, DMF, and CH2Cl2 (4+10 mL each) and cleaving the resin by treatment with a mixture of 50% CF3CO2H, 45% CH2Cl2, and 5% H2O, and purification using HPLC, N-[4-(Morpholin-4-yl)phenyl]-4-[(4-trifluoromethoxyphenyl)amino]benzamide (II). II showed IC50 of 26 nM against SW620 cell line.


IT **714962-05-7P**, 3-[6-[(4-Trifluoromethoxyphenyl)amino]pyrimidin-4-yl]benzoic acid

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of biaryl derivs. having differential tumor cytotoxicity as antitumor agents)

RN 714962-05-7 CAPLUS

CN Benzoic acid, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




IT **714962-03-5P**, 3-[6-[(4-Trifluoromethoxyphenyl)amino]pyrimidin-4-yl]-N-(2-trifluoromethylbenzyl)benzamide **714962-06-8P**, 4-Methoxy-N-[3-[6-[(4-trifluoromethoxyphenyl)amino]pyrimidin-4-yl]phenyl]benzenesulfonamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of biaryl derivs. having differential tumor cytotoxicity as antitumor agents)


RN 714962-03-5 CAPLUS

CN Benzamide, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-N-[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 714962-06-8 CAPLUS

CN Benzenesulfonamide, 4-methoxy-N-[3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




L12 ANSWER 17 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:467883 CAPLUS
 DN 141:38627
 TI Preparation of 2,4,6-trisubstituted pyrimidines as phosphatidylinositol
 (pi) 3-kinase inhibitors and their use in the treatment of cancer
 IN Nuss, John M.; Pecchi, Sabina; Renhowe, Paul A.
 PA Chiron Corporation, USA
 SO PCT Int. Appl., 151 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004048365	A1	20040610	WO 2003-US37294	20031121
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2507100	AA	20040610	CA 2003-2507100	20031121
	AU 2003295776	A1	20040618	AU 2003-295776	20031121
	US 2004176385	A1	20040909	US 2003-719896	20031121
	EP 1575940	A1	20050921	EP 2003-786980	20031121
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003016485	A	20051011	BR 2003-16485	20031121
	CN 1735607	A	20060215	CN 2003-80108239	20031121
	JP 2006514118	T2	20060427	JP 2005-510381	20031121
	NO 2005002927	A	20050708	NO 2005-2927	20050615
PRAI	US 2002-428473P	P	20021121		
	US 2003-438568P	P	20030107		
	US 2003-523081P	P	20031119		
	WO 2003-US37294	W	20031121		
OS	MARPAT 141:38627				
AB	Title compds. I [Y = (un)substituted alk(en/yn)yl, hetero/aryl, heterocyclyl; X = a direct link, NH and derivs., CH2 and derivs., O, S, SO, SO2, etc.; R1 = H, alkyl, CO2H, halo, OH and derivs., NH2 and derivs.; R2 = (un)substituted hetero/aryl, heterocyclyl; W = NH2 and derivs., (un)substituted alkyl, cyclyl containing at least one heteroatom; with provisos; their stereoisomers, tautomers, pharmaceutically acceptable salts, esters, or prodrugs] were prepared as phosphatidylinositol (pi) 3-kinase inhibitors for treating neoplasm. A solid phase synthesis is given for pyrimidine II•2CF3CO2H. Selected I displayed an IC50 < 20 µM in a cell proliferation assay.				
IT	701243-13-2P , 3-[6-(1H-Indazol-5-ylamino)-2-[(2-methoxyethyl)amino]pyrimidin-4-yl]phenol RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (phosphatidylinositol 3-kinase inhibitor; preparation of 2,4,6-trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors for treating neoplasm)				

RN 701243-13-2 CAPLUS

CN Phenol, 3-[6-(1H-indazol-5-ylamino)-2-[(2-methoxyethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 18 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:453205 CAPLUS

DN 141:23547

TI Preparation of amino heterocycles as vanilloid receptor (VR1) modulators, in particular antagonists, for treating pain and/or inflammation

IN Blurton, Peter; Burkamp, Frank; Fletcher, Stephen Robert; Hollingworth, Gregory John; Jones, A. Brian; Mciver, Edward Giles; Moyes, Christopher Richard; Rogers, Lauren

PA Merck Sharp & Dohme Limited, UK

SO PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004046133	A1	20040603	WO 2003-GB4969	20031114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2506025	AA	20040603	CA 2003-2506025	20031114
AU 2003283581	A1	20040615	AU 2003-283581	20031114
EP 1562934	A1	20050817	EP 2003-775557	20031114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006512323	T2	20060413	JP 2004-552870	20031114
US 2006040947	A1	20060223	US 2005-534584	20050511
PRAI GB 2002-26724	A	20021115		
WO 2003-GB4969	W	20031114		

OS MARPAT 141:23547

AB Title compds. I [wherein V = NH and derivs., O, S, SO, SO₂; W, X = independently CH or N; Y = N, CH, C-Ar₂, with the proviso that at least one, but no more than two, of W, X, and Y are N; Z = CH or C-Ar₂ with the proviso that when Y = N or CH, then Z = C-Ar₂, and when Y = Ar₂, then Z = CH; Ar₁ = fused 9- or 10-membered heterobicyclic ring, containing 1-4 heteroatoms selected from N, O, and S wherein at least one of the rings is aromatic; Ar₂ = (un)substituted (un)fused Ph, pyridinyl, pyridazinyl, pyrimidinyl, and pyrazinyl; R₁ = halo, OH, oxo, CN, NO₂, SH and derivs., SO₂H and derivs., CONH₂ and derivs., halo/hydroxy/cyclo/cycloalkyl/alkyl, halo/hydroxy/cyclo/alkoxy, alkenyl, alkynyl etc.; R₂ = H, halo, OH, halo/cyclo/alkyl, halo/alkoxy, (un)substituted phenyl; n = 0-3; and their pharmaceutically acceptable salts, N-oxides, and prodrugs] were prepared as vanilloid receptor (VR1) modulators, in particular antagonists, for treating conditions or diseases in which pain and/or inflammation predominates. For example, 3-Methyl-7-(trifluoromethyl)isoquinolin-5-amine (preparation given) was arylated with 4-Chloro-6-(4-trifluoromethylphenyl)pyrimidine (preparation given) to give the diheterocyclyl amine II in 40% yield. I bound to the VR1 receptor with an IC₅₀ < 1 μM, and in the majority of cases, < 200 nM. I are predominantly VR1 antagonists with a few of them VR1 partial antagonists and VR1 partial agonists. Thus, I and their pharmaceutical compns. are useful for

treating pain and/or inflammation.


IT **697740-00-4P**, N-[6-(4-Trifluoromethylphenyl)pyrimidin-4-yl]isoquinolin-5-amine **697740-01-5P**, 3-Methyl-N-[6-(4-trifluoromethylphenyl)pyrimidin-4-yl]isoquinolin-5-amine **697740-02-6P**, 1-Methyl-N-[6-(4-trifluoromethylphenyl)pyrimidin-4-yl]isoquinolin-5-amine **697740-04-8P**, 6,8-Difluoro-3-methyl-N-[6-(4-trifluoromethylphenyl)pyrimidin-4-yl]isoquinolin-5-amine **697740-05-9P**, 3-Methyl-7-trifluoromethyl-N-[6-(4-trifluoromethylphenyl)pyrimidin-4-yl]isoquinolin-5-amine **697740-06-0P**, 8-Fluoro-3-methyl-N-[6-(4-trifluoromethylphenyl)pyrimidin-4-yl]isoquinolin-5-amine **697740-07-1P**, 6-Fluoro-3-methyl-N-[6-(4-trifluoromethylphenyl)pyrimidin-4-yl]isoquinolin-5-amine **697740-08-2P**, 3-Methyl-N-[2-methyl-6-(4-trifluoromethylphenyl)pyrimidin-4-yl]isoquinolin-5-amine **697740-09-3P**, 3-Methyl-N-[6-(4-trifluoromethylphenyl)pyrimidin-4-yl]cinnolin-5-amine **697740-10-6P**, 1-Methyl-N-[6-(4-trifluoromethylphenyl)pyrimidin-4-yl]-1H-indazol-4-amine **697740-11-7P**, N-[6-(4-Trifluoromethylphenyl)pyrimidin-4-yl]-1H-indazol-4-amine **697740-12-8P**, 6-Fluoro-1-methyl-N-[6-(4-trifluoromethylphenyl)pyrimidin-4-yl]-1H-indazol-4-amine **697740-13-9P**, 1-Methyl-6-trifluoromethyl-N-[6-(4-trifluoromethylphenyl)pyrimidin-4-yl]-1H-indazol-4-amine **697740-15-1P**, 1,3-Dimethyl-5-[[6-(4-trifluoromethylphenyl)pyrimidin-4-yl]amino]quinolin-2(1H)-one **697740-18-4P**, N-[5-Methoxy-6-(4-trifluoromethylphenyl)pyrimidin-4-yl]isoquinolin-5-amine **697740-19-5P**, N-[5-Methyl-6-(4-trifluoromethylphenyl)pyrimidin-4-yl]isoquinolin-5-amine **697740-20-8P**, N-[6-[2,4-Bis(Trifluoromethyl)phenyl]pyrimidin-4-yl]isoquinolin-5-amine **697740-23-1P**, 1-[2-[6-(Isoquinolin-5-ylamino)pyrimidin-4-yl]benzyl]piperidin-4-one **697740-24-2P**, 3-[6-(Isoquinolin-5-ylamino)pyrimidin-4-yl]benzaldehyde **697740-25-3P**, N-[6-(4-Ethylphenyl)pyrimidin-4-yl]isoquinolin-5-amine **697740-26-4P**, N-[6-[3-(1H-Pyrazol-1-yl)phenyl]pyrimidin-4-yl]isoquinolin-5-amine **697740-27-5P**, N-[6-(3-Fluorophenyl)pyrimidin-4-yl]isoquinolin-5-amine **697740-28-6P**, N-[6-(4-Dimethylaminophenyl)pyrimidin-4-yl]isoquinolin-5-amine **697740-30-0P**, N-[6-(3,5-Dichlorophenyl)pyrimidin-4-yl]isoquinolin-5-amine **697740-31-1P**, N-[6-(4-Benzyloxyphenyl)pyrimidin-4-yl]isoquinolin-5-amine **697740-32-2P**, N-[6-(4-Trifluoromethoxyphenyl)pyrimidin-4-yl]isoquinolin-5-amine **697740-33-3P**, N-[6-[3,5-Bis(Trifluoromethyl)phenyl]pyrimidin-4-yl]isoquinolin-5-amine **697740-35-5P**, N-[6-(4-tert-Butylphenyl)pyrimidin-4-yl]isoquinolin-5-amine **697740-36-6P**, 1-[4-[6-(Isoquinolin-5-ylamino)pyrimidin-4-yl]phenyl]ethanone **697740-37-7P**, 4-[6-(Isoquinolin-5-ylamino)pyrimidin-4-yl]benzonitrile **697740-38-8P**, 3-[6-(Isoquinolin-5-ylamino)pyrimidin-4-yl]benzoic acid **697740-39-9P**, N-[6-(3-Trifluoromethylphenyl)pyrimidin-4-yl]isoquinolin-5-amine **697740-40-2P**, N-[6-(3-Methylphenyl)pyrimidin-4-yl]isoquinolin-5-amine **697740-41-3P**, N-[6-(2,4,6-Trimethylphenyl)pyrimidin-4-yl]isoquinolin-5-amine **697740-42-4P**, N-[6-[2-Fluoro-3-(pyridin-3-yl)phenyl]pyrimidin-4-yl]isoquinolin-5-amine **697740-43-5P**, N-[6-(4-Methylsulfonylphenyl)pyrimidin-4-yl]isoquinolin-5-amine **697740-45-7P**, N-[6-(4-Ethoxyphenyl)pyrimidin-4-yl]isoquinolin-5-amine **697740-46-8P**, N-[6-(3-Nitrophenyl)pyrimidin-4-yl]isoquinolin-5-amine **697740-47-9P**, N-[6-(4-Chlorophenyl)pyrimidin-4-yl]isoquinolin-5-amine **697740-48-0P**,

N-[6-(Biphenyl-4-yl)pyrimidin-4-yl]isoquinolin-5-amine
697740-50-4P, N-[6-(3-Isopropylphenyl)pyrimidin-4-yl]isoquinolin-5-amine
697740-51-5P, N-[6-(4-Methylthiophenyl)pyrimidin-4-yl]isoquinolin-5-amine
697740-52-6P, N-[6-(2,5-Difluorophenyl)pyrimidin-4-yl]isoquinolin-5-amine
697740-53-7P, 4-[6-(Isoquinolin-5-ylamino)pyrimidin-4-yl]phenol
697740-54-8P, N-[6-(4-Methoxyphenyl)pyrimidin-4-yl]isoquinolin-5-amine
697740-55-9P, N-(6-Phenylpyrimidin-4-yl)isoquinolin-5-amine
697740-56-0P, N-[2-Methyl-6-(4-trifluoromethylphenyl)pyrimidin-4-yl]-6-fluoro-3-methyl-isoquinolin-5-amine
697740-57-1P, N-[6-(4-Chlorophenyl)pyrimidin-4-yl]-6-fluoro-3-methylisoquinolin-5-amine
697740-58-2P, 6-Fluoro-3-methyl-N-[6-(4-trifluoromethoxyphenyl)pyrimidin-4-yl]isoquinolin-5-amine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(VR1 antagonist; preparation of amino heterocycles as vanilloid receptor (VR1) modulators, in particular antagonists, for treating pain and/or inflammation)


RN 697740-00-4 CAPLUS

CN 5-Isoquinolinamine, N-[6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI)
 (CA INDEX NAME)




RN 697740-01-5 CAPLUS

CN 5-Isoquinolinamine, 3-methyl-N-[6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 697740-02-6 CAPLUS

CN 5-Isoquinolinamine, 1-methyl-N-[6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 697740-04-8 CAPLUS

CN 5-Isoquinolinamine, 6,8-difluoro-3-methyl-N-[6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 697740-05-9 CAPLUS

CN 5-Isoquinolinamine, 3-methyl-7-(trifluoromethyl)-N-[6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 697740-06-0 CAPLUS

CN 5-Isoquinolinamine, 8-fluoro-3-methyl-N-[6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 697740-07-1 CAPLUS

CN 5-Isoquinolinamine, 6-fluoro-3-methyl-N-[6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 697740-08-2 CAPLUS

CN 5-Isoquinolinamine, 3-methyl-N-[2-methyl-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 697740-09-3 CAPLUS

CN 5-Cinnolinamine, 3-methyl-N-[6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 697740-10-6 CAPLUS

CN 1H-Indazol-4-amine, 1-methyl-N-[6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 697740-11-7 CAPLUS

CN 1H-Indazol-4-amine, N-[6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 697740-12-8 CAPLUS

CN 1H-Indazol-4-amine, 6-fluoro-1-methyl-N-[6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 697740-13-9 CAPLUS

CN 1H-Indazol-4-amine, 1-methyl-6-(trifluoromethyl)-N-[6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 697740-15-1 CAPLUS

CN 2(1H)-Quinolinone, 1,3-dimethyl-5-[[6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 697740-18-4 CAPLUS


CN 5-Isoquinolinamine, N-[5-methoxy-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 697740-19-5 CAPLUS
 CN 5-Isoquinolinamine, N-[5-methyl-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 697740-20-8 CAPLUS
 CN 5-Isoquinolinamine, N-[6-[2,4-bis(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 697740-23-1 CAPLUS
 CN 4-Piperidinone, 1-[[2-[6-(5-isoquinolinylamino)-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 697740-24-2 CAPLUS

CN Benzaldehyde, 3-[6-(5-isoquinolinylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 697740-25-3 CAPLUS


CN 5-Isoquinolinamine, N-[6-(4-ethylphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 697740-26-4 CAPLUS


CN 5-Isoquinolinamine, N-[6-[3-(1H-pyrazol-1-yl)phenyl]-4-pyrimidinyl]- (9CI)

(CA INDEX NAME)




RN 697740-27-5 CAPLUS

CN 5-Isoquinolinamine, N-[6-(3-fluorophenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 697740-28-6 CAPLUS

CN 5-Isoquinolinamine, N-[6-[4-(dimethylamino)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 697740-30-0 CAPLUS

CN 5-Isoquinolinamine, N-[6-(3,5-dichlorophenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 697740-31-1 CAPLUS

CN 5-Isoquinolinamine, N-[6-[4-(phenylmethoxy)phenyl]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 697740-32-2 CAPLUS

CN 5-Isoquinolinamine, N-[6-[4-(trifluoromethoxy)phenyl]-4-pyrimidinyl]-
(9CI) (CA INDEX NAME)




RN 697740-33-3 CAPLUS

CN 5-Isoquinolinamine, N-[6-[3,5-bis(trifluoromethyl)phenyl]-4-pyrimidinyl]-
(9CI) (CA INDEX NAME)




RN 697740-35-5 CAPLUS

CN 5-Isoquinolinamine, N-[6-[4-(1,1-dimethylethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 697740-36-6 CAPLUS

CN Ethanone, 1-[4-[6-(5-isoquinolinylamino)-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 697740-37-7 CAPLUS

CN Benzonitrile, 4-[6-(5-isoquinolinylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 697740-38-8 CAPLUS

CN Benzoic acid, 3-[6-(5-isoquinolinylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 697740-39-9 CAPLUS

CN 5-Isoquinolinamine, N-[6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 697740-40-2 CAPLUS

CN 5-Isoquinolinamine, N-[6-(3-methylphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 697740-41-3 CAPLUS

CN 5-Isoquinolinamine, N-[6-(2,4,6-trimethylphenyl)-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 697740-42-4 CAPLUS

CN 5-Isoquinolinamine, N-[6-[2-fluoro-3-(3-pyridinyl)phenyl]-4-pyrimidinyl]-
(9CI) (CA INDEX NAME)




RN 697740-43-5 CAPLUS

CN 5-Isoquinolinamine, N-[6-[4-(methylsulfonyl)phenyl]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 697740-45-7 CAPLUS

CN 5-Isoquinolinamine, N-[6-(4-ethoxyphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 697740-46-8 CAPLUS

CN 5-Isoquinolinamine, N-[6-(3-nitrophenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 697740-47-9 CAPLUS


CN 5-Isoquinolinamine, N-[6-(4-chlorophenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 697740-48-0 CAPLUS
 CN 5-Isoquinolinamine, N-(6-[1,1'-biphenyl]-4-yl-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 697740-50-4 CAPLUS
 CN 5-Isoquinolinamine, N-[6-[3-(1-methylethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 697740-51-5 CAPLUS
 CN 5-Isoquinolinamine, N-[6-[4-(methylthio)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 697740-52-6 CAPLUS
 CN 5-Isoquinolinamine, N-[6-(2,5-difluorophenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 697740-53-7 CAPLUS
 CN Phenol, 4-[6-(5-isoquinolinylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 697740-54-8 CAPLUS
 CN 5-Isoquinolinamine, N-[6-(4-methoxyphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 697740-55-9 CAPLUS

CN 5-Isoquinolinamine, N-(6-phenyl-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 697740-56-0 CAPLUS

CN 5-Isoquinolinamine, 6-fluoro-3-methyl-N-[2-methyl-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 697740-57-1 CAPLUS

CN 5-Isoquinolinamine, N-[6-(4-chlorophenyl)-4-pyrimidinyl]-6-fluoro-3-methyl- (9CI) (CA INDEX NAME)




RN 697740-58-2 CAPLUS


CN 5-Isoquinolinamine, 6-fluoro-3-methyl-N-[6-[4-(trifluoromethoxy)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



L12 ANSWER 19 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:303311 CAPLUS
 DN 141:64387
 TI Synthesis, SAR, and antitumor properties of diamino-C,N-diarylpyrimidine positional isomers: inhibitors of lysophosphatidic acid acyltransferase- β
 AU Gong, Baoqing; Hong, Feng; Kohm, Cory; Jenkins, Scott; Tulinsky, John; Bhatt, Rama; de Vries, Peter; Singer, Jack W.; Klein, Peter
 CS Cell Therapeutics, Inc., Seattle, WA, 98119, USA
 SO Bioorganic & Medicinal Chemistry Letters, (2004), 14(9), 2303-2308
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science B.V.
 DT Journal
 LA English
 OS CASREACT 141:64387
 AB 2,4-Diamino-N4,6-diarylpyrimidines were identified as potent, isoform specific inhibitors of lysophosphatidic acid acyltransferase- β (LPAAT- β). Active inhibitors also blocked proliferation of tumor cell lines in vitro. The effect of one of the synthesized compds. (2j) in an in vivo tumor model was investigated.
 IT 76369-32-9P 710334-85-3P 710334-86-4P
 710334-87-5P 710334-94-4P 710334-95-5P
 710334-96-6P 710334-97-7P 710334-98-8P
 710334-99-9P 710335-00-5P 710335-01-6P
 710335-02-7P 710335-03-8P 710335-04-9P
 710335-05-0P 710335-06-1P 710335-07-2P
 710335-08-3P 710335-09-4P 710335-10-7P
 710335-11-8P 710335-12-9P 710335-13-0P
 710335-14-1P 710335-15-2P 710335-16-3P
 710335-17-4P 710335-18-5P 710335-19-6P
 710335-20-9P 710335-21-0P 710335-23-2P
 710335-24-3P 710335-25-4P 710335-26-5P
 710335-27-6P 710336-16-6P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (synthesis, SAR, and antitumor properties of diamino-C,N-diarylpyrimidine positional isomers, inhibitors of lysophosphatidic acid acyltransferase- β)
 RN 76369-32-9 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-(4-chlorophenyl)-6-phenyl- (9CI) (CA INDEX NAME)




RN 710334-85-3 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methoxyphenyl)-N4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 710334-86-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(4-bromophenyl)-6-(5-chloro-2-methoxyphenyl)-
(9CI) (CA INDEX NAME)




RN 710334-87-5 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methoxyphenyl)-N4-1H-indazol-6-yl-
(9CI) (CA INDEX NAME)



RN 710334-94-4 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(4-chlorophenyl)-6-(2,5-dichlorophenyl)- (9CI)
(CA INDEX NAME)




RN 710334-95-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(4-chlorophenyl)-6-(5-fluoro-2-methylphenyl)-


(9CI) (CA INDEX NAME)




RN 710334-96-6 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methylphenyl)-N4-(4-chlorophenyl)-
(9CI) (CA INDEX NAME)

RN 710334-97-7 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(4-bromophenyl)-6-(5-chloro-2-methylphenyl)-
(9CI) (CA INDEX NAME)

RN 710334-98-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(3-bromophenyl)-6-(5-chloro-2-methylphenyl)-
(9CI) (CA INDEX NAME)


RN 710334-99-9 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-methylphenyl)-N4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 710335-00-5 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-methylphenyl)-N4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 710335-01-6 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-methylphenyl)-N4-(4-bromophenyl)- (9CI) (CA INDEX NAME)




RN 710335-02-7 CAPLUS

CN Phenol, 3-[2-amino-6-[(4-chlorophenyl)amino]-4-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 710335-03-8 CAPLUS

CN Phenol, 2-[2-amino-6-[(4-chlorophenyl)amino]-4-pyrimidinyl]-4-bromo- (9CI)
(CA INDEX NAME)




RN 710335-04-9 CAPLUS

CN Phenol, 2-[2-amino-6-[(4-chlorophenyl)amino]-4-pyrimidinyl]-4-chloro- (9CI)
(CA INDEX NAME)



RN 710335-05-0 CAPLUS


CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-(2-chlorophenyl)- (9CI)
(CA INDEX NAME)



RN 710335-06-1 CAPLUS


CN Benzenemethanol, 4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-

pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 710335-07-2 CAPLUS

CN Benzenethanol, 4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 710335-08-3 CAPLUS

CN Benzenepropanol, 4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 710335-09-4 CAPLUS


CN Benzeneacetic acid, 4-[[2-amino-6-(5-chloro-2-ethoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 710335-10-7 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-(4-nitrophenyl)-
(9CI) (CA INDEX NAME)

RN 710335-11-8 CAPLUS


CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-(3-nitrophenyl)-
(9CI) (CA INDEX NAME)

RN 710335-12-9 CAPLUS


CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-1H-indazol-6-yl-
(9CI) (CA INDEX NAME)

RN 710335-13-0 CAPLUS


CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-ethoxyphenyl)-N4-phenyl- (9CI) (CA
INDEX NAME)



RN 710335-14-1 CAPLUS


CN 2,4-Pyrimidinediamine, 6-(5-bromo-2-ethoxyphenyl)-N4-(4-chlorophenyl)-
(9CI) (CA INDEX NAME)

RN 710335-15-2 CAPLUS

CN Benzoic acid, 4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]-
(9CI) (CA INDEX NAME)


RN 710335-16-3 CAPLUS

CN Benzeneacetic acid, 4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 710335-17-4 CAPLUS

CN Boronic acid, [4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 710335-18-5 CAPLUS

CN Benzonitrile, 4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 710335-19-6 CAPLUS

CN Benzonitrile, 3-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 710335-20-9 CAPLUS

CN Benzamide, 4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 710335-21-0 CAPLUS

CN Benzamide, 4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 710335-23-2 CAPLUS

CN Benzeneacetamide, 4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 710335-24-3 CAPLUS


CN Benzenecarboximidamide, 4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 710335-25-4 CAPLUS


CN Ethanone, 1-[4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 710335-26-5 CAPLUS

CN Ethanone, 1-[4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]phenyl]-, oxime (9CI) (CA INDEX NAME)




RN 710335-27-6 CAPLUS

CN Ethanone, 1-[4-[[2-amino-6-(5-bromo-2-ethoxyphenyl)-4-pyrimidinyl]amino]phenyl]-, O-methyloxime (9CI) (CA INDEX NAME)




RN 710336-16-6 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(5-chloro-2-ethoxyphenyl)-N4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)



L12 ANSWER 20 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:264063 CAPLUS
DN 140:423223
TI Combinatorial Synthesis of Substituted Biaryls and Heterocyclic Arylamines
AU Ma, Yao; Margarida, Laura; Brookes, Jeseca; Makara, Gergely M.; Berk, Scott C.
CS NeoGenesis Pharmaceuticals, Inc.; Cambridge, MA, 02139, USA
SO Journal of Combinatorial Chemistry (2004), 6(3), 426-430
CODEN: JCCHFF; ISSN: 1520-4766
PB American Chemical Society
DT Journal
LA English
OS CASREACT 140:423223
AB In this paper, we report very general conditions that enable palladium-mediated coupling reactions on the solid support. A wide variety of biaryls and arylamines (including pyrimidines) have been synthesized using this protocol. The chemical facilitates a combinatorial approach to the production of large nos. of medicinally relevant heterocyclic structures.
IT **691858-67-0P**
RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)
(combinatorial synthesis of substituted biaryls and heterocyclic arylamines via palladium-mediated coupling reactions on a solid support)
RN 691858-67-0 CAPLUS
CN 4-Pyrimidinamine, N-(4-methoxyphenyl)-6-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 21 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:142963 CAPLUS

DN 140:199334

TI Preparation of 2,4-pyrimidinediamines as IgE and/or IgG receptor modulators for treatment of autoimmune diseases

IN Singh, Rajinder; Argade, Ankush; Payan, Donald G.; Clough, Jeffrey; Keim, Holger; Sylvain, Catherine; Li, Hui; Bhamidipati, Somasekhar

PA Rigel Pharmaceuticals, USA

SO PCT Int. Appl., 811 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004014382	A1	20040219	WO 2003-US24087	20030729
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2492325	AA	20040219	CA 2003-2492325	20030729
	AU 2003265336	A1	20040225	AU 2003-265336	20030729
	EP 1534286	A1	20050601	EP 2003-784871	20030729
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003013059	A	20050705	BR 2003-13059	20030729
	CN 1678321	A	20051005	CN 2003-821120	20030729
	JP 2006514989	T2	20060518	JP 2005-506142	20030729
	US 2005038243	A1	20050217	US 2004-858343	20040601
	US 7060827	B2	20060613		
	US 2005209230	A1	20050922	US 2004-911684	20040803
	SE 2005000203	A	20050329	SE 2005-203	20050127
	NO 2005001069	A	20050228	NO 2005-1069	20050228
	US 2006025410	A1	20060202	US 2005-149105	20050608
	US 2006035916	A1	20060216	US 2005-148746	20050608
	US 2006058292	A1	20060316	US 2005-149418	20050608
PRAI	US 2002-399673P	P	20020729		
	US 2003-443949P	P	20030131		
	US 2003-452339P	P	20030306		
	US 2003-631029	A	20030729		
	US 2002-353267P	P	20020201		
	US 2002-353333P	P	20020201		
	US 2002-434277P	P	20021217		
	US 2003-355543	A1	20030131		
	WO 2003-US24087	W	20030729		

OS MARPAT 140:199334

AB The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compds., as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Title compds. I [wherein L1 and L2 = independently a bond or a linker; R2 = (un)substituted alkyl, (hetero)cycloalkyl, or (hetero)aryl; R4 = H or R2; R5 = R6 or (un)substituted alkyl, alkenyl, or alkynyl; R6 =

independently H, an electroneg. group, protected alc. or thiol, haloalkyl(oxy), halo, CN, NC, OCN, SCN, NO, NO₂, N₃, or (un)substituted amino, sulfamoyl(oxy), acyl, carboxy, carbamoyl, (hetero)aryl(alkyl), etc.; with provisos and exclusions; and salts, hydrates, solvates, N-oxides, and prodrugs thereof] were prepared as inhibitors of the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators. For example, coupling of 2,4-dichloropyrimidine with 4-ethoxyaniline in EtOH provided N2,N4-bis(4-ethoxyphenyl)-2,4-pyrimidinediamine (II). The latter inhibited degranulation of bone marrow derived mast cells challenged with anti-IgE and ionomycin with IC₅₀ values of 4.5 μ M and 4.4 μ M, resp. Thus, I and their pharmaceutical compns. are useful in the treatment and prevention of diseases characterized by, caused by, or associated with the release of chemical mediators via degranulation of mast, basophil, neutrophil, or eosinophil cells and other processes effected by activation of the IgE and/or IgG receptor signaling cascades. Specific examples of autoimmune diseases that can be treated or prevented with I and their pharmaceutical compns. include rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis (no data).


IT 575487-13-7P 575487-14-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(IgE and/or IgG receptor modulator; preparation of pyrimidinediamines as IgE and/or IgG receptor modulators for treatment of autoimmune diseases)


RN 575487-13-7 CAPLUS

CN 2,4-Pyrimidinediamine, N,N'-bis(2,3-dihydro-1,4-benzodioxin-6-yl)-6-phenyl- (9CI) (CA INDEX NAME)



RN 575487-14-8 CAPLUS

CN Phenol, 3,3'-[(6-phenyl-2,4-pyrimidinediyl)diimino]bis- (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 22 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:610204 CAPLUS

DN 139:164801

TI Preparation of 2,4-pyrimidinediamines as IgE and/or IgG receptor modulators for treatment of allergic diseases, inflammatory conditions, and tissue destruction

IN Singh, Rajinder; Argade, Ankush; Payan, Donald G.; Molineaux, Susan; Holland, Sacha J.; Clough, Jeffrey; Keim, Holger; Bhamidipati, Somasekhar; Sylvain, Catherine; Li, Weigun; Rossi, Alexander B.

PA Rigel Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 648 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003063794	A2	20030807	WO 2003-US3022	20030131
	WO 2003063794	A3	20031204		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2474277	AA	20030807	CA 2003-2474277	20030131
	US 2004029902	A1	20040212	US 2003-355543	20030131
	EP 1471915	A2	20041103	EP 2003-707654	20030131
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	JP 2005516046	T2	20050602	JP 2003-563490	20030131
	CN 1625400	A	20050608	CN 2003-803180	20030131
	BR 2003007355	A	20060411	BR 2003-7355	20030131
	US 2005038243	A1	20050217	US 2004-858343	20040601
	US 7060827	B2	20060613		
	US 2005209230	A1	20050922	US 2004-911684	20040803
	NO 2004003632	A	20041026	NO 2004-3632	20040831
	US 2006025410	A1	20060202	US 2005-149105	20050608
	US 2006035916	A1	20060216	US 2005-148746	20050608
	US 2006058292	A1	20060316	US 2005-149418	20050608
PRAI	US 2002-353267P	P	20020201		
	US 2002-353333P	P	20020201		
	US 2002-399673P	P	20020729		
	US 2002-434277P	P	20021217		
	US 2003-355543	A1	20030131		
	WO 2003-US3022	W	20030131		

OS MARPAT 139:164801

AB Title compds. I [wherein L1 and L2 = independently a bond or a linker; R2 = (un)substituted alkyl, (hetero)cycloalkyl, or (hetero)aryl; R4 = H or R2; R5 = R6 or (un)substituted alkyl, alkenyl, or alkynyl; R6 = independently H, an electroneg. group, protected alc. or thiol, haloalkyl(oxy), halo, CN, NC, OCN, SCN, NO, NO2, N3, or (un)substituted amino, sulfamoyl(oxy), acyl, carboxy, carbamoyl, (hetero)aryl(alkyl), etc.; with provisos and exclusions; and salts, hydrates, solvates,

N-oxides, and prodrugs thereof] were prepared as inhibitors of the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators. For example, coupling of 2,4-dichloropyrimidine with 4-ethoxyaniline in EtOH provided N2,N4-bis(4-ethoxyphenyl)-2,4-pyrimidinediamine (II). The latter inhibited degranulation of bone marrow derived mast cells challenged with anti-IgE and ionomycin with IC50 values of 4.5 μ M and 4.4 μ M, resp. Thus, I and their pharmaceutical compns. are useful in the treatment and prevention of diseases characterized by, caused by, or associated with the release of chemical mediators via degranulation of mast, basophil, neutrophil, or eosinophil cells and other processes effected by activation of the IgE and/or IgG receptor signaling cascades. The treatment and prevention of allergic diseases, low grade scarring, diseases associated with tissue destruction, diseases associated with tissue inflammation, inflammation, and scarring are targeted uses (no data).


IT 575487-13-7P 575487-14-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(IgE and/or IgG receptor modulator; preparation of pyrimidinediamines as IgE and/or IgG receptor modulators for treatment of allergic diseases, inflammatory conditions, and tissue destruction)


RN 575487-13-7 CAPLUS

CN 2,4-Pyrimidinediamine, N,N'-bis(2,3-dihydro-1,4-benzodioxin-6-yl)-6-phenyl- (9CI) (CA INDEX NAME)



RN 575487-14-8 CAPLUS

CN Phenol, 3,3'-[(6-phenyl-2,4-pyrimidinediyl)diimino]bis- (9CI) (CA INDEX NAME)



L12 ANSWER 23 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:927396 CAPLUS

DN 138:13955

TI Preparation of phenol and hydroxynaphthalene based inhibitors of protein kinase for the treatment of disease

IN Cao, Sheldon Xiaodong; Bounaud, Pierre-Yves; Chen, Xiaohua; Chung, Hyun-Ho; Dumas, David Paul; Kc, Sunil Kumar; Min, Changhee; Yang, Jae Young; Long, Mellissa C.

PA LG Biomedical Institute, USA

SO PCT Int. Appl., 286 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002096867	A2	20021205	WO 2002-US16920	20020528
	WO 2002096867	A3	20040304		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2002310187	A1	20021209	AU 2002-310187	20020528
	US 2003187007	A1	20031002	US 2002-158030	20020528
	US 2003208067	A1	20031106	US 2002-158103	20020528
	EP 1412327	A2	20040428	EP 2002-737248	20020528
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2004534779	T2	20041118	JP 2003-500047	20020528
PRAI	US 2001-294792P	P	20010530		
	WO 2002-US16920	W	20020528		

OS MARPAT 138:13955

AB Phenol and hydroxynaphthalene derivs. I [X = O, S, amine, alkylamine, alkynylamine, arylamine, and heteroarylamine; R1 = (un)substituted 5- or 6-membered aromatic or heteroarom. ring, -(X1)mCOX2-, wherein X1 = alkylene, alkenylene, alkynylene, aryl and heteroaryl, X2 = H, alkyl, aryl, heteroaryl, OH, alkoxy, amino, substituted amine, m = 0 or 1, or R1 = -C(X3)=N-NX4-C(=E)-NX5X6 wherein X3 = H, alkyl, aryl, alkylaryl, heteroaryl, and amino and E = O, S, and substituted amine with X4, X5, and X6 independently equal to H, alkyl, aryl, and heteroaryl; R2, R3, and R4 = H, alkyl, alkylene, halo, alkoxy, etc.; or R2 and R3 or R3 and R4 may be taken together to form an (un)substituted aromatic or heteroarom. ring; R5 = H, (un)substituted-alkyl, -aryl, -heterocycle, etc.; R6 = H, alkyl, alkene, alkyne, aryl, and heteroaryl] are prepared and disclosed as inhibitors of protein kinase. Thus, II was prepared by cyclocondensation of 5'-bromo-2'-methoxyacetophenone with N,N-dimethylformamide di-Et acetal with subsequent Suzuki coupling with 4-methoxyphenylboronic acid. In assays to determine cyclin dependent kinase activity, specifically against CDK2 and CDK5, II possessed IC50 values of 0-0.5 μ M. II proved highly specific for CDK2 and CDK5 and was further evaluated by in vitro tumor cell efficacy tests against numerous cancers. The present invention is directed in part towards methods of modulating the function of protein

kinases with phenol- and hydroxynaphthalene-based compds. The methods incorporate cells that express a protein kinase. In addition, the invention describes methods of preventing and treating protein kinase-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to phenol- and hydroxynaphthalene-based compds. and pharmaceutical compns. comprising these compds.


IT 477727-07-4P 477727-18-7P 477727-19-8P
477727-20-1P 477727-28-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of phenol and hydroxynaphthalene based inhibitors of protein kinase)


RN 477727-07-4 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[(4-methoxyphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 477727-18-7 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[(3-chlorophenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 477727-19-8 CAPLUS


CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[(4-chlorophenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 477727-20-1 CAPLUS


CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[(3-methoxyphenyl)amino]-4-

pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 477727-28-9 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[(2-fluoro-4-hydroxyphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



L12 ANSWER 24 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:353449 CAPLUS

DN 136:369729

TI Preparation of N6-(2-aminopyrimidin-4-yl)-quinoline-4,6-diamines as N-type calcium channel antagonists for the treatment of pain

IN Chaudhari, Bipinchandra; Chapdelaine, Marc; Hostetler, Greg; Kemp, Lucius; McCauley, John

PA Astrazeneca AB, Swed.

SO PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002036586	A1	20020510	WO 2001-SE2388	20011031
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002012894	A5	20020515	AU 2002-12894	20011031
	EP 1339706	A1	20030903	EP 2001-981239	20011031
	EP 1339706	B1	20060419		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004513125	T2	20040430	JP 2002-539345	20011031
	US 2004058945	A1	20040325	US 2003-415785	20031002
	US 6815447	B2	20041109		
PRAI	SE 2000-4053	A	20001106		
	WO 2001-SE2388	W	20011031		

OS MARPAT 136:369729

AB The title compds. [I; R1 = NE1E2 (wherein E1 = H, Me; E2 = H, alkyl, phenylalkyl); R2 = E3, E4 (E3 = alkyl, alkoxy, alkoxyalkyl; E4 = substituted Ph); R3 = E5, E6 (E5 = NH2, perfluoroalkyl, alkyl, alkoxyalkyl, phenylalkoxy, phenoxyalkyl; E6 = Ph substituted at one or two positions)], useful for the treatment of pain, were prepared Thus, reacting 2-phenylquinoline-4,6-diamine with 4-chloro-6-(4-fluorophenyl)pyrimidin-2-amine (preparation given) afforded 92% I [R1 = NH2; R2 = Ph; R3 = 4-FC6H4]. Compds. I generally had a binding affinity for the N-type calcium channel, as measured by the FLIPR assay, of $\leq 10 \mu\text{M}$.

IT 423182-53-0P 423182-55-2P 423182-56-3P
 423182-58-5P 423182-59-6P 423182-60-9P
 423182-61-0P 423182-63-2P 423182-64-3P
 423182-65-4P 423182-66-5P 423182-67-6P
 423182-68-7P 423182-69-8P 423182-70-1P
 423182-71-2P 423182-72-3P 423182-73-4P
 423182-74-5P 423182-75-6P 423182-76-7P
 423182-77-8P 423182-78-9P 423182-79-0P
 423182-80-3P 423182-81-4P 423182-82-5P
 423182-83-6P 423182-84-7P 423182-85-8P
 423182-86-9P 423182-87-0P 423182-90-5P
 423182-91-6P 423182-93-8P 423182-94-9P
 423182-95-0P 423182-96-1P 423182-97-2P


423182-98-3P 423182-99-4P 423183-00-0P
 423183-01-1P 423183-02-2P 423183-03-3P
 423183-04-4P 423183-05-5P 423183-06-6P
 423183-07-7P 423183-08-8P 423183-09-9P
 423183-10-2P 423183-11-3P 423183-12-4P
 423183-13-5P 423183-14-6P 423183-15-7P
 423183-16-8P 423183-17-9P 423183-18-0P
 423183-19-1P 423183-20-4P 423183-21-5P
 423183-22-6P 423183-23-7P 423183-24-8P
 423183-25-9P 423183-26-0P 423183-27-1P
 423183-29-3P 423183-37-3P 423183-39-5P
 423183-40-8P 423183-41-9P 423183-42-0P
 423183-43-1P 423183-44-2P 423183-45-3P
 423183-46-4P 423183-47-5P 423183-48-6P
 423183-50-0P 423183-51-1P 423183-52-2P
 423183-53-3P 423183-54-4P 423183-55-5P
 423183-56-6P 423183-57-7P 423183-59-9P
 423183-60-2P 423183-61-3P 423183-62-4P
 423183-63-5P 423183-64-6P 423183-65-7P
 423183-66-8P 423183-67-9P 423183-68-0P
 423183-69-1P 423183-70-4P 423183-71-5P
 423183-72-6P 423183-73-7P 423183-74-8P
 423183-75-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of N6-(2-aminopyrimidin-4-yl)-quinoline-4,6-diamines as N-type
 calcium channel antagonists for the treatment of pain)


RN 423182-53-0 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-fluorophenyl)-4-pyrimidinyl]-2-
 phenyl- (9CI) (CA INDEX NAME)




RN 423182-55-2 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(4-fluorophenyl)-4-pyrimidinyl]-2-
 phenyl- (9CI) (CA INDEX NAME)




RN 423182-56-3 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(4-chlorophenyl)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423182-58-5 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423182-59-6 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(4-chlorophenyl)-4-pyrimidinyl]-2-phenyl-N4-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 423182-60-9 CAPLUS

CN Benzonitrile, 4-[2-amino-6-[[2-phenyl-4-[(phenylmethyl)amino]-6-quinolinyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 423182-61-0 CAPLUS

CN Benzonitrile, 4-[2-amino-6-[(4-amino-2-methyl-6-quinolinyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 423182-63-2 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(4-chlorophenyl)-4-pyrimidinyl]-2-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 423182-64-3 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-methoxyphenyl)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 423182-65-4 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(4-chlorophenyl)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 423182-66-5 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(4-methoxyphenyl)-4-pyrimidinyl]-2-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 423182-67-6 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-methoxyphenyl)-4-pyrimidinyl]-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 423182-68-7 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[3-(phenylmethoxy)phenyl]-4-pyrimidinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 423182-69-8 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-methoxyphenyl)-4-pyrimidinyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 423182-70-1 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(4-chlorophenyl)-4-pyrimidinyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 423182-71-2 CAPLUS


CN 4,6-Quinolinediamine, N6-[2-amino-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-2-(propoxymethyl)- (9CI) (CA INDEX NAME)



RN 423182-72-3 CAPLUS


CN 4,6-Quinolinediamine, N6-[2-amino-6-[3-(phenylmethoxy)phenyl]-4-

pyrimidinyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 423182-73-4 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]-2-pentyl- (9CI) (CA INDEX NAME)




RN 423182-74-5 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-2-pentyl- (9CI) (CA INDEX NAME)




RN 423182-75-6 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]-2-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423182-76-7 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-2-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423182-77-8 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 423182-78-9 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 423182-79-0 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(4-methoxyphenyl)-4-pyrimidinyl]-2-(2-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 423182-80-3 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-2-(2-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 423182-81-4 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]-2-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 423182-82-5 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-methoxyphenyl)-4-pyrimidinyl]-2-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 423182-83-6 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(4-methoxyphenyl)-4-pyrimidinyl]-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 423182-84-7 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(4-chlorophenyl)-4-pyrimidinyl]-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 423182-85-8 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]-2-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 423182-86-9 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-2-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 423182-87-0 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 423182-90-5 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[4-(phenoxymethyl)phenyl]-4-pyrimidinyl]-2-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 423182-91-6 CAPLUS


CN 4,6-Quinolinediamine, N6-[2-amino-6-[3-(phenoxymethyl)phenyl]-4-pyrimidinyl]-2-(2-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 423182-93-8 CAPLUS


CN 4,6-Quinolinediamine, N6-[2-amino-6-[4-(phenylmethoxy)phenyl]-4-pyrimidinyl]-2-(2-chlorophenyl)- (9CI) (CA INDEX NAME)

pyrimidinyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 423182-94-9 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-chlorophenyl)-4-pyrimidinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 423182-95-0 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-chlorophenyl)-4-pyrimidinyl]-2-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423182-96-1 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(4-methoxyphenyl)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423182-97-2 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-chlorophenyl)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423182-98-3 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(4-methoxyphenyl)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 423182-99-4 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-chlorophenyl)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 423183-00-0 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-chlorophenyl)-4-pyrimidinyl]-2-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 423183-01-1 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[4-(phenylmethoxy)phenyl]-4-pyrimidinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 423183-02-2 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[3-(phenylmethoxy)phenyl]-4-pyrimidinyl]-2-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 423183-03-3 CAPLUS


CN 4,6-Quinolinediamine, N6-[2-amino-6-[3-(phenylmethoxy)phenyl]-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 423183-04-4 CAPLUS


CN 4,6-Quinolinediamine, N6-[2-amino-6-[3-(phenylmethoxy)phenyl]-4-

pyrimidinyl]-2-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-05-5 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[4-(phenylmethoxy)phenyl]-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-06-6 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[4-(phenylmethoxy)phenyl]-4-pyrimidinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 423183-07-7 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(4-chlorophenyl)-4-pyrimidinyl]-2-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-08-8 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-methoxyphenyl)-4-pyrimidinyl]-2-(4-cyclohexylphenyl)- (9CI) (CA INDEX NAME)




RN 423183-09-9 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-fluorophenyl)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-10-2 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(4-chlorophenyl)-4-pyrimidinyl]-2-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 423183-11-3 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-2-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 423183-12-4 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-methoxyphenyl)-4-pyrimidinyl]-2-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-13-5 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 423183-14-6 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-methoxyphenyl)-4-pyrimidinyl]-2-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 423183-15-7 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(4-chlorophenyl)-4-pyrimidinyl]-2-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 423183-16-8 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-fluorophenyl)-4-pyrimidinyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 423183-17-9 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[3-(phenylmethoxy)phenyl]-4-pyrimidinyl]-2-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-18-0 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[3-(phenylmethoxy)phenyl]-4-pyrimidinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 423183-19-1 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 423183-20-4 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-2-(4-cyclohexylphenyl)- (9CI) (CA INDEX NAME)




RN 423183-21-5 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[4-(phenylmethoxy)phenyl]-4-pyrimidinyl]-2-(4-cyclohexylphenyl)- (9CI) (CA INDEX NAME)




RN 423183-22-6 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(4-chlorophenyl)-4-pyrimidinyl]-2-(4-cyclohexylphenyl)- (9CI) (CA INDEX NAME)




RN 423183-23-7 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[4-(phenylmethoxy)phenyl]-4-pyrimidinyl]-2-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-24-8 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 423183-25-9 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-methoxyphenyl)-4-pyrimidinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 423183-26-0 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 423183-27-1 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(4-methoxyphenyl)-4-pyrimidinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 423183-29-3 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(4-methoxyphenyl)-4-pyrimidinyl]-2-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 423183-37-3 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]-2-(4-cyclohexylphenyl)- (9CI) (CA INDEX NAME)




RN 423183-39-5 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-methoxyphenyl)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-40-8 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]-2-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 423183-41-9 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-chlorophenyl)-4-pyrimidinyl]-2-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-42-0 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-2-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-43-1 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]-2-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-44-2 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-chlorophenyl)-4-pyrimidinyl]-2-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-45-3 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-2-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-46-4 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-chlorophenyl)-4-pyrimidinyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 423183-47-5 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-chlorophenyl)-4-pyrimidinyl]-2-(4-cyclohexylphenyl)- (9CI) (CA INDEX NAME)




RN 423183-48-6 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[3-(phenylmethoxy)phenyl]-4-pyrimidinyl]-2-(4-cyclohexylphenyl)- (9CI) (CA INDEX NAME)




RN 423183-50-0 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[3-(phenylmethoxy)phenyl]-4-pyrimidinyl]-2-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-51-1 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(4-butylphenyl)-4-pyrimidinyl]-2-(4-cyclohexylphenyl)- (9CI) (CA INDEX NAME)




RN 423183-52-2 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-methoxyphenyl)-4-pyrimidinyl]-2-pentyl- (9CI) (CA INDEX NAME)




RN 423183-53-3 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-fluorophenyl)-4-pyrimidinyl]-2-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-54-4 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-fluorophenyl)-4-pyrimidinyl]-2-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-55-5 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-methoxyphenyl)-4-pyrimidinyl]-2-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-56-6 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(3-chlorophenyl)-4-pyrimidinyl]-2-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-57-7 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(4-chlorophenyl)-4-pyrimidinyl]-2-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-59-9 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-2-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-60-2 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-chlorophenyl)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-61-3 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(4-butylphenyl)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-62-4 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-chlorophenyl)-4-pyrimidinyl]-2-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-63-5 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-chlorophenyl)-4-pyrimidinyl]-2-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-64-6 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-chlorophenyl)-4-pyrimidinyl]-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 423183-65-7 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-fluorophenyl)-4-pyrimidinyl]-2-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 423183-66-8 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(4-butylphenyl)-4-pyrimidinyl]-2-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 423183-67-9 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(4-butylphenyl)-4-pyrimidinyl]-2-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-68-0 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-ethoxy-4-fluorophenyl)-4-pyrimidinyl]-2-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-69-1 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-chlorophenyl)-4-pyrimidinyl]-2-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-70-4 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-2-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-71-5 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-fluorophenyl)-4-pyrimidinyl]-2-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-72-6 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(4-bromophenyl)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 423183-73-7 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-chlorophenyl)-4-pyrimidinyl]-2-(4-cyclohexylphenyl)- (9CI) (CA INDEX NAME)




RN 423183-74-8 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-ethoxy-4-fluorophenyl)-4-pyrimidinyl]-2-(3-fluorophenyl)-N4,N4-dimethyl- (9CI) (CA INDEX NAME)



RN 423183-75-9 CAPLUS

CN 4,6-Quinolinediamine, N6-[2-amino-6-(2-fluorophenyl)-4-pyrimidinyl]-2-(3-fluorophenyl)-N4,N4-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 25 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:122964 CAPLUS

DN 136:167384

TI Preparation of 4-pyrimidinamines as neuroprotectants.

IN Grant, Elfrida R.; Brown, Frank K.; Zivin, Robert Allan; McMillan, Michael; Zhong, Zhong; Scott, Malcolm; Reitz, Allen B.; Ross, Tina Morgan

PA Ortho-McNeil Pharmaceutical, Inc., USA

SO PCT Int. Appl., 92 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002012198	A2	20020214	WO 2001-US24659	20010806
	WO 2002012198	A3	20020606		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2419030	AA	20020214	CA 2001-2419030	20010806
	AU 2001081120	A5	20020218	AU 2001-81120	20010806
	EP 1313713	A2	20030528	EP 2001-959581	20010806
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	BR 2001013165	A	20030715	BR 2001-13165	20010806
	JP 2004505952	T2	20040226	JP 2002-518176	20010806
	NZ 524100	A	20050128	NZ 2001-524100	20010806
	ZA 2003001868	A	20040625	ZA 2003-1868	20030306
PRAI	US 2000-223791P	P	20000808		
	WO 2001-US24659	W	20010806		

OS MARPAT 136:167384


AB Pharmaceutical compns. comprising a pharmaceutically acceptable carrier [I; R9 = H, thienyl, furanyl, pyrrolyl, (substituted) Ph, pyridinyl, pyridinyl, naphthyl, benzo[b]thien-2-yl, 2-benzofuranyl, pyrimidinyl, 2,4-bis(methoxyphenyl)-5-pyrimidinyl; R10 = cyanoalkyl, alkylamino, dialkylamino, hydroxyalkylamino, hydroxydialkylamino; R11 = H, alkyl], are claimed. Thus, a mixture of N-(2-aminoethyl)-N'-(6-biphenyl-3-ylpyrimidin-4-yl)-N-ethylbenzene-1,4-diamine (preparation given), N-benzoylalanine, diisopropylethylamine, HBTU, and DMF was stirred overnight at room temperature to give N-[1-[[2-[4-(6-biphenyl-3-ylpyrimidin-4-ylamino)phenyl]ethylamino]ethylcarbamoyl]ethyl]benzamide. Tested compds. in a differentiated P19 cell assay using 3 mM glutamate showed neuroprotectant activity with IC50 = 0.07 μ M to >1 μ M.

IT 397850-40-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 4-pyrimidinamines as neuroprotectants)

RN 397850-40-7 CAPLUS


CN 1,4-Benzenediamine, N-(2-aminoethyl)-N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl- (9CI) (CA INDEX NAME)



RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(preparation of 4-pyrimidinamines as neuroprotectants)

RN 397851-04-6 CAPLUS

CN Ethanol, 2-[[4-[(6-[1,1'-biphenyl]-3-yl)-4-pyrimidinyl]amino]phenyl]ethylamino]- (9CI) (CA INDEX NAME)




397850-37-2P 397850-38-3P 397850-39-4P
397850-41-8P 397850-42-9P 397850-43-0P
397850-44-1P 397850-45-2P 397850-46-3P
397850-47-4P 397850-48-5P 397850-49-6P
397850-50-9P 397850-51-0P 397850-52-1P
397850-53-2P 397850-54-3P 397850-55-4P
397850-56-5P 397850-57-6P 397850-58-7P
397850-59-8P 397850-60-1P 397850-61-2P
397850-62-3P 397850-63-4P 397850-64-5P
397850-65-6P 397850-66-7P 397850-67-8P
397850-68-9P 397850-69-0P 397850-70-3P
397850-71-4P 397850-72-5P 397850-73-6P
397850-74-7P 397850-75-8P 397850-76-9P
397850-77-0P 397850-78-1P 397850-79-2P
397850-80-5P 397850-81-6P 397850-82-7P
397850-83-8P 397850-84-9P 397850-85-0P
397850-86-1P 397850-87-2P 397850-88-3P
397850-89-4P 397850-90-7P 397850-91-8P
397850-92-9P 397850-93-0P 397850-94-1P
397850-95-2P 397850-96-3P 397850-97-4P
397850-98-5P 397850-99-6P 397851-00-2P
397851-01-3P 397851-02-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-pyrimidinamines as neuroprotectants)

RN 397850-34-9 CAPLUS

CN Benzamide, N-[2-[[2-[[4-[(6-[1,1'-biphenyl]-3-yl)-4-pyrimidinyl]amino]phenyl]ethylamino]ethyl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 397850-35-0 CAPLUS


CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]hexahydro-2-oxo-, (3aS,4S,6aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B





RN 397850-36-1 CAPLUS

CN Hexadecanamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl] - (9CI) (CA INDEX NAME)




RN 397850-37-2 CAPLUS

CN Butanamide, N-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[4-[ethyl[2-[(1-oxobutyl)amino]ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 397850-38-3 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[(cyclohexylmethyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-39-4 CAPLUS

CN Alanine, N-benzoyl-, 2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl ester (9CI) (CA INDEX NAME)




RN 397850-41-8 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-(dimethylamino)ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-42-9 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(3-methoxypropyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-43-0 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[(3-chlorophenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-44-1 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[(2,4-dimethoxyphenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-45-2 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[(2-ethoxyphenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-46-3 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-(propylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 397850-47-4 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[(2,5-difluorophenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-48-5 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[[(1R,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-1-phenanthrenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 397850-49-6 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(2-phenylethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-50-9 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[3,4-dimethoxyphenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-51-0 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[3-(diethylamino)propyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-52-1 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[(4-bromo-2-pyridinyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-53-2 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[2-(dimethylamino)ethyl](phenylmethyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-54-3 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[butyl(phenylmethyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-55-4 CAPLUS

CN 1,4-Benzenediamine, N-[2-([1,1'-biphenyl]-4-ylamino)ethyl]-N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-56-5 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(2-furanylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-57-6 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[3-iodophenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-58-7 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(2,2,2-trifluoroethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-59-8 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[3,4-difluorophenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-60-1 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-
[[2-(2-thienyl)ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)

RN 397850-61-2 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(3,5-
dimethyl-2-pyridinyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)

RN 397850-62-3 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-
[(2-phenylethyl)(phenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)


RN 397850-63-4 CAPLUS

CN Acetamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-
pyrimidinyl)amino]phenyl]ethylamino]ethyl]-2-ethoxy-N-(phenylmethyl)-
(9CI) (CA INDEX NAME)




RN 397850-64-5 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-methoxyphenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-65-6 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[4-bromophenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 397850-66-7 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[[3,5-bis(trifluoromethyl)phenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 397850-67-8 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-(3-methoxyphenyl)ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— OMe

RN 397850-68-9 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[3,4,5-trimethoxyphenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 397850-69-0 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-(4-methoxyphenyl)ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— OMe


RN 397850-70-3 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-(1H-imidazol-4-yl)ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-71-4 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[2-(trifluoromethyl)phenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-72-5 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-(phenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-73-6 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(3-methoxyphenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-74-7 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(3-methylphenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-75-8 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[(3,5-dimethoxyphenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-76-9 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[(2-bromophenyl)methyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 397850-77-0 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[2-(4-bromophenyl)ethyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B

—Br

RN 397850-78-1 CAPLUS


CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[4-fluorophenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-79-2 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(1-naphthalenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 397850-80-5 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[(2-phenoxyethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-81-6 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[4-(trifluoromethyl)phenyl]methyl]amino]ethyl- (9CI) (CA INDEX NAME)




RN 397850-82-7 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-(butylamino)ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-83-8 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-bis(phenylmethyl)amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-84-9 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-(3-pyridinylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 397850-85-0 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[(2-methylphenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-86-1 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[[(2-fluorophenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-87-2 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-88-3 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-[ethyl(phenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 397850-89-4 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 397850-90-7 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 397850-91-8 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-(1H-imidazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 397850-92-9 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-[2-(3,4-dihydro-2(1H)-isoquinolinyl)ethyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 397850-93-0 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-ethyl-N-[2-(hexahydro-1H-azepin-1-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 397850-94-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 397850-95-2 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanoic acid, hexahydro-2-oxo-, 2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl ester, (3aS,4S,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A






RN 397850-96-3 CAPLUS

CN Ethanol, 2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]-, benzoate (ester) (9CI) (CA INDEX NAME)




RN 397850-97-4 CAPLUS

CN Benzeneacetamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]-α-chloro- (9CI) (CA INDEX NAME)



RN 397850-98-5 CAPLUS


CN 3-Pyridinecarboxamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)amino]phenyl]ethylamino]ethyl]-6-nitro- (9CI) (CA INDEX NAME)



RN 397850-99-6 CAPLUS


CN [1,1'-Biphenyl]-4-carboxamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl-4-

pyrimidinyl)amino]phenyl]ethylamino]ethyl]- (9CI) (CA INDEX NAME)




RN 397851-00-2 CAPLUS

CN Benzamide, N-[2-[[4-[(6-[1,1'-biphenyl]-3-yl)-4-pyrimidinyl)amino]phenyl]ethyl]amino]ethyl]-4-butoxy- (9CI) (CA INDEX NAME)




RN 397851-01-3 CAPLUS

CN Benzamide, N-(6-[1,1'-biphenyl]-3-yl)-4-pyrimidinyl)-N-[4-[ethyl[2-[[4-(trifluoromethyl)benzoyl]amino]ethyl]amino]phenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 397851-02-4 CAPLUS

CN Benzamide, N-(6-[1,1'-biphenyl]-3-yl)-4-pyrimidinyl)-N-[4-[ethyl[2-[[3-fluorobenzoyl]amino]ethyl]amino]phenyl]-3-fluoro- (9CI) (CA INDEX NAME)




IT 397851-06-8 397851-07-9 397851-08-0
 397851-10-4 397851-14-8 397851-15-9
 397851-16-0 397851-17-1 397851-18-2
 397851-19-3 397851-20-6 397851-21-7
 397851-22-8 397851-24-0 397851-25-1
 397851-26-2 397851-27-3 397851-34-2
 397851-35-3 397851-37-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(preparation of 4-pyrimidinamines as neuroprotectants)


RN 397851-06-8 CAPLUS

CN 1,4-Benzenediamine, N,N-dimethyl-N'-[6-[4-(phenylmethoxy)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 397851-07-9 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 397851-08-0 CAPLUS

CN 1,4-Benzenediamine, N'-[6-[3,5-bis(trifluoromethyl)phenyl]-4-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 397851-10-4 CAPLUS

CN Ethanol, 2-[ethyl[4-[[6-[4-(trifluoromethoxy)phenyl]-4-pyrimidinyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 397851-14-8 CAPLUS

CN Ethanol, 2-[[4-[(6-[1,1'-biphenyl]-4-yl)-4-pyrimidinyl]amino]phenyl]ethylamino]- (9CI) (CA INDEX NAME)




RN 397851-15-9 CAPLUS

CN Ethanol, 2-[[4-[[6-[3,5-bis(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]phenyl]ethylamino]- (9CI) (CA INDEX NAME)




RN 397851-16-0 CAPLUS

CN Ethanol, 2-[ethyl[4-[[6-(3-nitrophenyl)-4-pyrimidinyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 397851-17-1 CAPLUS

CN Ethanol, 2-[ethyl[4-[[6-[4-(methylthio)phenyl]-4-pyrimidinyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 397851-18-2 CAPLUS

CN Ethanol, 2-[ethyl[4-[[6-(2-phenoxyphenyl)-4-pyrimidinyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 397851-19-3 CAPLUS

CN Benzonitrile, 4-[6-[[4-(dimethylamino)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 397851-20-6 CAPLUS

CN 1,4-Benzenediamine, N,N-dimethyl-N'-[6-(2-phenoxyphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 397851-21-7 CAPLUS


CN Benzonitrile, 4-[6-[[4-[ethyl(2-hydroxyethyl)amino]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 397851-22-8 CAPLUS

CN Phenol, 4-[6-[[4-(4-phenyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]-
(9CI) (CA INDEX NAME)

RN 397851-24-0 CAPLUS


CN 1,4-Benzenediamine, N,N-dimethyl-N'-[6-[2-(phenylmethoxy)phenyl]-4-
pyrimidinyl]- (9CI) (CA INDEX NAME)

RN 397851-25-1 CAPLUS

CN Carbamic acid, [[4-[6-[[4-[ethyl(2-hydroxyethyl)amino]phenyl]amino]-4-
pyrimidinyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX
NAME)


RN 397851-26-2 CAPLUS

CN Ethanol, 2-[[4-[[6-[3-(dimethylamino)phenyl]-4-
pyrimidinyl]amino]phenyl]ethylamino]- (9CI) (CA INDEX NAME)




RN 397851-27-3 CAPLUS

CN 1,4-Benzenediamine, N'-[6-[4-(dimethylamino)phenyl]-4-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 397851-34-2 CAPLUS

CN 9H-Carbazol-3-amine, N-[6-(3,4-dimethoxyphenyl)-4-pyrimidinyl]-9-ethyl- (9CI) (CA INDEX NAME)




RN 397851-35-3 CAPLUS

CN 9H-Carbazol-3-amine, 9-ethyl-N-[6-(3,4,5-trimethoxyphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 397851-37-5 CAPLUS

CN 9H-Carbazol-3-amine, 9-ethyl-N-[6-[4-(4-methyl-1-piperazinyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




IT **397851-03-5P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 4-pyrimidinamines as neuroprotectants)

RN 397851-03-5 CAPLUS

CN 1,4-Benzenediamine, N'-(6-[1,1'-biphenyl]-3-yl-4-pyrimidinyl)-N-(2-chloroethyl)-N-ethyl- (9CI) (CA INDEX NAME)



L12 ANSWER 28 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1999:295955 CAPLUS

DN 131:67655

TI Use of the Suzuki reaction for the synthesis of aryl-substituted heterocycles as corticotropin-releasing hormone (CRH) antagonists

AU Cocuzza, Anthony J.; Chidester, Dennis R.; Culp, Steven; Fitzgerald, Lawrence; Gilligan, Paul

CS Chemical and Physical Sciences Department, DuPont Pharmaceuticals Company, Wilmington, DE, 19880-0500, USA

SO Bioorganic & Medicinal Chemistry Letters (1999), 9(7), 1063-1066
CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier Science Ltd.

DT Journal

LA English

AB The Suzuki reaction has been used to synthesize a variety of aryl-substituted heterocyclic antagonists of the CRH1 receptor. Examples with several different heterocyclic cores are potent CRH receptor ligands.


IT 219840-93-4P 219840-94-5P

RL: BPR (Biological process); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)

(aryl-substituted heterocycles as corticotropin-releasing hormone antagonists, and preparation thereof using Suzuki reaction)


RN 219840-93-4 CAPLUS

CN 4-Pyrimidinamine, N-(2-bromo-4,6-dimethoxyphenyl)-2-methyl-5-nitro-6-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 219840-94-5 CAPLUS

CN 4,5-Pyrimidinediamine, N4-(2-bromo-4,6-dimethoxyphenyl)-2-methyl-6-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 29 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1999:48709 CAPLUS

DN 130:125084

TI Aryl- and arylamino-substituted heterocycles as corticotropin releasing hormone (CRF) antagonists

IN Cocuzza, Anthony J.; Hobbs, Frank W.; Beck, James P.; Gilligan, Paul J.

PA Du Pont Pharmaceuticals Company, USA

SO PCT Int. Appl., 86 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9901439	A1	19990114	WO 1998-US13840	19980702
	W: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2296014	AA	19990114	CA 1998-2296014	19980702
	AU 9881810	A1	19990125	AU 1998-81810	19980702
	EP 994860	A1	20000426	EP 1998-931783	19980702
	R: CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
	US 6103737	A	20000815	US 1998-109395	19980702
	JP 2002510322	T2	20020402	JP 1999-507408	19980702
PRAI	US 1997-51745P	P	19970703		
	WO 1998-US13840	W	19980702		

OS MARPAT 130:125084

AB Corticotropin releasing factor (CRF) antagonists I and their stereoisomers and pharmaceutically acceptable salts are disclosed [wherein Y = CR2 or N; Z = CH or N; K = CR5 or N; R1 = alk(en/yn)yl, Cl, F, cyano, CF3; R2R4 = E-F where E and F = CR9 and/or CR9'; or R2R4 = A:D where A and D = CH, CR10, or N, provided that A:D is oriented to form imidazole but not pyrazole; or R2R4 = A-D where A = NR9 and D = CO, oriented to form an imidazolone; R3 = Ph, naphthyl, pyridinyl, or pyrimidinyl, all substituted by R8; R4 = (un)substituted alkyl, allyl, or propargyl; R5 = 1-4 of alk(en/yn)yl, cycloalkyl, halo, NO2, cyano, NR6R7, OR7, COR7, C(:NOR9)R7, SOnR7, etc.; or 2 R5 moieties may form CR9R9'CR9R9'O, CR9:CR9'O, etc.; R6, R7 = H or (un)substituted alkyl, cycloalkyl, (CH2)mPh or (CH2)m-heteroaryl; R8 = alk(en/yn)yl, cycloalkyl, Ph, heteroaryl, halo, NO2, cyano, NR6R7, OR7, etc., with provisos; R9, R9' = H, alkyl; n = 0-2; m = 0-6]. Also disclosed is their use in treating psychiatric disorders and neurol. diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders, as well as treatment of immunol., cardiovascular or heart-related diseases, and colonic hypersensitivity associated with psychopathol. disturbance and stress in mammals. For example, condensation of 2-BrC6H4COCH3 with MeC(OMe)2NMe2 gave 2-BrC6H4COCH:MeNMe2, which underwent cyclocondensation with (2-bromo-4-isopropylphenyl)guanidine-HCl, followed by N-alkylation of the resultant aminopyrimidine with EtI and NaH in DMSO, to give title compound II. Some I were active (no data) in an assay for inhibition of CRF-stimulated adenylate cyclase activity.

IT 199728-09-1P 199728-10-4P 219840-93-4P

219840-94-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of aryl-and arylamino-substituted heterocycles as

corticotropin releasing hormone antagonists)


RN 199728-09-1 CAPLUS

CN 4-Pyrimidinamine, N-[2-bromo-4-(1-methylethyl)phenyl]-2-methyl-5-nitro-6-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 199728-10-4 CAPLUS

CN 4,5-Pyrimidinediamine, N4-[2-bromo-4-(1-methylethyl)phenyl]-2-methyl-6-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 219840-93-4 CAPLUS

CN 4-Pyrimidinamine, N-(2-bromo-4,6-dimethoxyphenyl)-2-methyl-5-nitro-6-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 219840-94-5 CAPLUS

CN 4,5-Pyrimidinediamine, N4-(2-bromo-4,6-dimethoxyphenyl)-2-methyl-6-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 32 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1993:625904 CAPLUS
 DN 119:225904
 TI Ring-chain transformations. XI. Synthesis of semicyclic
 3-(aminoalkylideneamino)-3-aryl-2-propenenitriles and their ring-chain
 transformation to 2-(ω -aminoalkyl)-6-aryl-4-halo-5-
 pyrimidinecarbonitriles
 AU Paetzel, Michael; Ushmajev, Alexej; Liebscher, Juergen
 CS Inst. Org. Chem., Humboldt-Univ., Berlin, W-1040, Germany
 SO Synthesis (1993), (5), 525-9
 CODEN: SYNTBF; ISSN: 0039-7881
 DT Journal
 LA English
 OS CASREACT 119:225904
 AB Semicyclic 3-aryl-2-aza-3-methylthio-2-propeniminium iodides I ($n = 1, 2, 3$, $R = \text{Me, Et, R1} = \text{aryl}$) react with CH-acidic acetonitriles $R_2\text{CH}_2\text{CN}$ ($R_2 = \text{NC, p-O}_2\text{N- or p-ClC}_6\text{H}_4$) by elimination of methanethiol affording
 3-(1-alkyl-2-pyrrolidinylideneamino)-, 3-(1-alkyl-2-piperidinylideneamino)-
 and 3-(1-alkylhexahydro-1H-azepin-2-ylideneamino)-3-aryl-2-
 propenenitriles II. Further addition of hydrogen halides to the cyano group
 of 2-cyano-substituted II gives rise to a ring chain transformation
 reaction. The resulting 4-halo-2-[ω -(methylamino)alkyl]-5-
 pyrimidinecarbonitrile hydrohalides III.HX ($X = \text{halo}$) can be isolated or
 hydrolyzed during workup to 3,4-dihydro-4-oxo derivs. Reaction of the
 III.HX with amines causes either reversed ring chain transformation to the
 starting compds. II or substitution of the halo substituent resulting in
 III.HX ($X = \text{amino group}$).
 IT **150832-35-2P 150832-36-3P 150832-37-4P**
150832-38-5P 150832-39-6P 150832-41-0P
150832-42-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 150832-35-2 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 4-(4-methoxyphenyl)-2-[3-(methylamino)propyl]-6-
 (phenylamino)-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr


RN 150832-36-3 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 4-(4-methoxyphenyl)-2-[3-(methylamino)propyl]-6-
 (phenylamino)-15N-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 150832-37-4 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(4-methoxyphenyl)-6-[(4-methoxyphenyl)amino]-2-[3-(methylamino)propyl]-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr


RN 150832-38-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[(4-chlorophenyl)amino]-6-(4-methoxyphenyl)-2-[3-(methylamino)propyl]-, monohydrobromide (9CI) (CA INDEX NAME)




● HBr

RN 150832-39-6 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 4-(4-methoxyphenyl)-2-[3-(methylamino)propyl]-6-(methylphenylamino)-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 150832-41-0 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 4-(4-chlorophenyl)-2-[3-(methylanilino)propyl]-6-(phenylanilino)-, monohydrobromide (9CI) (CA INDEX NAME)




● HBr

RN 150832-42-1 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 4-(4-methoxyphenyl)-2-[4-(methylanilino)butyl]-6-(phenylanilino)-, monohydrobromide (9CI) (CA INDEX NAME)

10/671,070 (Species)

(phenylamino)-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

L12 ANSWER 33 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1992:448480 CAPLUS

DN 117:48480

TI Synthesis and biological activities of some new pyrimidine derivatives

AU Seada, M.; Abdel-Halim, A. M.; Ibrahim, S. S.; Abdel-Megid, M.

CS Fac. Educat., Ain Shams Univ., Roxy, Egypt

SO Asian Journal of Chemistry (1992), 4(3), 544-52

CODEN: AJCHEW; ISSN: 0970-7077

DT Journal

LA English

AB Synthesis of 4-chloro-5-cyano-2-methyl-6-phenylpyrimidine (I, R = Cl) and its reactions with acetamide hydrochloride, guanidine hydrochloride, cyanoacetamide, benzil monohydrazone, sodium azide, semicarbazide hydrochloride, acid hydrazides, active methylene compds., aromatic amines and thiourea were investigated. Also, the reactions of 5-cyano-2-methyl-6-phenyl-4(3H)-pyrimidinethione I (R = SH) with Et iodide, Et chloroacetate, phenacyl bromide, acrylonitrile and heterocyclic chlorides are reported. A number of products from these two series of reactions, including aminocyanopyridopyrimidinone II and (phenylbutadienyl)pyrimidine III were evaluated for bactericidal and fungicidal activity.


IT 142271-18-9P 142271-19-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and bactericidal and fungicidal activity of)


RN 142271-18-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-methyl-4-[(4-methylphenyl)amino]-6-phenyl-(9CI) (CA INDEX NAME)



RN 142271-19-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[(4-methoxyphenyl)amino]-2-methyl-6-phenyl-(9CI) (CA INDEX NAME)



L12 ANSWER 34 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1989:515128 CAPLUS

DN 111:115128

TI Azolopyrimidines and pyrimidoquinazolines from 4-chloropyrimidines

AU El-Reedy, A. M.; Ali, A. S.; Ayyad, A. O.

CS Fac. Sci., Univ. Cairo, Giza, Egypt

SO Journal of Heterocyclic Chemistry (1989), 26(2), 313-16

CODEN: JHTCAD; ISSN: 0022-152X

DT Journal

LA English

OS CASREACT 111:115128


AB 5-Cyano-3,4-dihydro-6-phenyl-2-substituted pyrimidinones reacted with phosphorus oxychloride to give the corresponding 4-chloropyrimidine derivs. I (R = Ph, NPh, NHCH₂Ph, R₁ = Cl). Compds. I (R₁ = Cl) reacted with aniline and hydrazine to yield I (R = Ph, NPh, NHCH₂Ph; R₁ = NPh, NHNH₂). The hydrazino derivs. could be converted into the triazolo- and tetrazolopyrimidines II (R₂ = Ph, NHCH₂Ph) and III by the action of CS₂ and nitrous acid, resp. The reaction of I (R = NPh, NHCH₂Ph; R₁ = Cl) with phenylhydrazine afforded directly the 5-amino-4,6-diphenyl-6H-2-substituted pyrazolopyrimidines IV (same R₂). The 4-chloro derivative I (R = Ph, R₁ = Cl) reacted with anthranilic acid to form the 5-cyano-2,4-diphenyl-6-(o-carboxyphenylamino)pyrimidine, which could be cyclized into the 4-cyano-1,3-diphenyl-10H-pyrimido[6,1-b]quinazolin-10-one by heating with acetic anhydride.

IT 122379-70-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 122379-70-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-phenyl-2,6-bis(phenylamino)- (9CI) (CA INDEX NAME)



L12 ANSWER 35 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1986:478951 CAPLUS
 DN 105:78951
 TI Pyrimidine derivatives and their use
 IN Takaya, Takao; Murata, Masayoshi; Ito, Kiyotaka
 PA Fujisawa Pharmaceutical Co., Ltd. , Japan
 SO Eur. Pat. Appl., 87 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 168262	A2	19860115	EP 1985-305004	19850712
	EP 168262	A3	19870513		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	US 4725600	A	19880216	US 1985-751867	19850705
	JP 61044872	A2	19860304	JP 1985-154545	19850712
PRAI	GB 1984-17852	A	19840713		
	GB 1984-23667	A	19840919		
	GB 1984-30456	A	19841203		

OS MARPAT 105:78951


AB Aminopyrimidines I [R = heterocycle, (un)substituted aryl; R1 = H, halo, alkyl, (un)substituted aryl; R2 = amino, (un)substituted aryloxy, heterocycle; R3 = H, alkyl, halo, alkylthio, amino, hydrazino, heterocycle], their tautomeric forms, such as II [R4 = (un)substituted aryl; R5 = H, alkyl; other R as above], and their condensed-ring derivs. were prepared as anticoagulants, cardiotonics, and antihypertensives. Thus, MeC(:NH)NH2.HCl was cyclocondensed with 3,4-(MeO)2C6H3COCH2CO2Et and methylated to give pyrimidinone III. This was chlorinated with POC13 and iminated with 2,4,6-Me3C6H2NH2 to give pyrimidinimine II. In dogs, 0.1 mg IV/kg i.v. gave a 72% increase in heart contraction rate.

IT **103554-93-4P 103555-00-6P 103555-01-7P**
103555-02-8P 103555-13-1P 103555-16-4P
103555-19-7P 103555-22-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as cardiovascular agent and anticoagulant)

RN 103554-93-4 CAPLUS


CN 4-Pyrimidinamine, 6-(3,4-dimethoxyphenyl)-2-methyl-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 103555-00-6 CAPLUS

CN 4-Pyrimidinamine, 6-(3,4-dimethoxyphenyl)-N,2-dimethyl-N-(2,4,6-

trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 103555-01-7 CAPLUS

CN 4-Pyrimidinamine, 6-(3,4-dimethoxyphenyl)-N-(2,4,6-trimethylphenyl)- (9CI)
(CA INDEX NAME)


RN 103555-02-8 CAPLUS

CN 4-Pyrimidinamine, 6-(3,4-dimethoxyphenyl)-N-methyl-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 103555-13-1 CAPLUS

CN 4-Pyrimidinamine, 6-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 103555-16-4 CAPLUS

CN 4-Pyrimidinamine, 6-(3,4-dimethoxyphenyl)-N,2,5-trimethyl-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 103555-19-7 CAPLUS

CN 1,4-Benzenediamine, N-[6-(3,4-dimethoxyphenyl)-2-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 103555-22-2 CAPLUS


CN Methanesulfonamide, N-[4-[[6-(3,4-dimethoxyphenyl)-2-methyl-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




L12 ANSWER 36 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1984:156563 CAPLUS
 DN 100:156563
 TI Studies on pyrazolo[3,4-d]pyrimidine derivatives. XIII. Aryl migration of 4-aryl-1H-pyrazolo[3,4-d]pyrimidines to 4-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidine-4-carboxylic acids
 AU Higashino, Takeo; Matsushita, Yasuhiko; Takemoto, Masumi; Hayashi, Eisaku
 CS Shizuoka Coll. Pharm., Shizuoka, 422, Japan
 SO Chemical & Pharmaceutical Bulletin (1983), 31(11), 3951-8
 CODEN: CPBTAL; ISSN: 0009-2363
 DT Journal
 LA English
 OS CASREACT 100:156563
 AB Treating pyrazolopyrimidines I (R = Ph, 2-, 4-MeOC6H4, 2-, 4-ClC6H4, 4-BrC6H4, 4-FC6H4, 4-NCC6H4) with NaOH in Me2SO gave pyrazolopyrimidines II (R1 = CO2H, R2 = H) which were oxidized with K3Fe(CN)6 to II (R1R2 = bond). Treating II (R = Ph, 4-MeOC6H4, 4-O2NC6H4, Me; R1R2 = bond) with NaOH in Me2SO gave the corresponding pyrimidinecarbonitriles III.
 IT **76990-17-5P 89549-69-9P 89549-70-2P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 76990-17-5 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 4-phenyl-6-(phenylamino)- (9CI) (CA INDEX NAME)




RN 89549-69-9 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 4-(4-methoxyphenyl)-6-(phenylamino)- (9CI) (CA INDEX NAME)



RN 89549-70-2 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 4-(4-nitrophenyl)-6-(phenylamino)- (9CI) (CA INDEX NAME)



L12 ANSWER 37 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1983:488150 CAPLUS
 DN 99:88150
 TI N2-1H-Benzimidazol-2-yl-N4-phenyl-2,4-pyrimidinediamines and
 N2-1H-benzimidazol-2-yl-5,6,7,8-tetrahydro-N4-phenyl-2,4-
 quinazolinediamines as potential antifilarial agents
 AU Angelo, Mario M.; Ortwine, Daniel; Worth, Donald F.; Werbel, Leslie M.
 CS Warner-Lambert/Parke-Davis Pharm. Res. Div., Warner-Lambert Co., Ann
 Arbor, MI, 48106, USA
 SO Journal of Medicinal Chemistry (1983), 26(9), 1311-16
 CODEN: JMCMAR; ISSN: 0022-2623
 DT Journal
 LA English
 AB Title compds. I [R = 5,6-Cl₂, 5-Bz; R₁ = Me, CF₃, Ph; R₂ = H; R₁R₂ =
 (CH₂)₄; R₃ = H, Me, Et; NR₄R₅ = NEt₂, pyrrolidino, NHet,
 4-methylpiperazinyl, PhNEt; R₆ = H, Ph] were prepared, but showed no
 antifilarial activity. Thus, treating cyanamide II with
 2,4,5-H₂NC₁₂C₆H₂NH₂ gave benzimidazole III, whose chlorination followed by
 amination with 2,5-HO(NH₂)C₆H₃CH₂NEt₂ gave I (R = 5,6-Cl₂, R₁R₂ = (CH₂)₄,
 R₃ = R₆ = H, NR₄R₅ = NEt₂).
 IT **86260-67-5P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and antifilarial activity of)
 RN 86260-67-5 CAPLUS
 CN Phenol, 4-[[2-[(5,6-dichloro-1H-benzimidazol-2-yl)amino]-6-phenyl-4-
 pyrimidinyl]amino]-2-[(diethylamino)methyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L12 ANSWER 38 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1983:488149 CAPLUS

DN 99:88149

TI Synthesis and antifilarial activity of N-[4-[[4-alkoxy-3-
[(dialkylamino)methyl]phenyl]amino]-2-pyrimidinyl]-N'-phenylguanidines

AU Angelo, Mario; Ortwine, Daniel; Worth, Donald; Werbel, Leslie M.; McCall, John W.

CS Warner-Lambert/Parke-Davis Pharm. Res. Div., Warner-Lambert Co., Ann Arbor, MI, 48106, USA

SO Journal of Medicinal Chemistry (1983), 26(9), 1258-67

CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

AB Title compds. I [R = Ph, 4-ClC₆H₄, 4-MeOC₆H₄, 4-F₃CC₆H₄, 4-PhOC₆H₄, 4-BzC₆H₄, 3,4-Cl₂C₆H₃; R₁ = CF₃, Ph; R₂ = H; R₁R₂ = (CH₂)₄; R₃ = H, Me, CHMe₂, PhCH₂; NR₄R₅ = NMe₂, NHet, NMeEt, NEt₂, NHCH₂CH(CH₂)₅; R₆ = H, Ph] were prepared E.g., treating PhNH₂ with H₂NC(:NH)NHCN gave PhNHC(:NH)NHC(:NH)NH₂, cyclocondensation of which with F₃CCOCH₂CO₂Et gave pyrimidine II. Chlorination of II followed by condensation with 2,5-(HO)(H₂N)C₆H₃CH₂NMe₂ gave I (R = R₂ = R₃ = R₆ = H, R₁ = CF₃, NR₄R₅ = NMe₂). Antifilarial activity of I was confined to adult *Litomosoides carinii*. Structure activity relationship was discussed.


IT **86177-55-1P 86177-56-2P 86196-43-2P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and anthelmintic activity of)


RN 86177-55-1 CAPLUS

CN Guanidine, N-(3,4-dichlorophenyl)-N'-[4-[[3-[(ethylamino)methyl]-4-methoxyphenyl]amino]-6-phenyl-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 86177-56-2 CAPLUS

CN Guanidine, N-(3,4-dichlorophenyl)-N'-[4-[[3-[(diethylamino)methyl]-4-ethoxyphenyl]amino]-6-phenyl-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 86196-43-2 CAPLUS


CN Guanidine, N-(3,4-dichlorophenyl)-N'-[4-[[3-[(diethylamino)methyl]-4-hydroxyphenyl]amino]-6-phenyl-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




L12 ANSWER 39 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1981:139730 CAPLUS
 DN 94:139730
 TI Syntheses with nitriles. 60. Preparation of 4-amino-5-cyano-6-phenylpyrimidines from 2-amino-1,1-dicyano-2-phenylethene
 AU Mittelbach, Martin; Juneck, Hans
 CS Inst. Org. Chem., Univ. Graz, Graz, A-8010, Austria
 SO Journal of Heterocyclic Chemistry (1980), 17(7), 1385-7
 CODEN: JHTCAD; ISSN: 0022-152X
 DT Journal
 LA English
 OS CASREACT 94:139730
 AB The reaction of 2-amino-1,1-dicyanobut-1-ene and 2-amino-1,1-dicyano-2-phenylethene, resp., with DMF dimethylacetal provided the corresponding (N,N-dimethylaminomethylene)amino derivs. 2-[(N,N-Dimethylaminomethylene)amino]-1,1-dicyano-2-phenylethene was converted into 4-amino-5-cyano-6-phenylpyrimidines, e.g. I, by treatment with primary aliphatic and aromatic amines. The structure of the reaction products was confirmed by ¹³C NMR spectroscopy.
 IT **76990-17-5P 76990-18-6P 76990-19-7P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 76990-17-5 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 4-phenyl-6-(phenylamino)- (9CI) (CA INDEX NAME)



RN 76990-18-6 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 4-[(2-methoxyphenyl)amino]-6-phenyl- (9CI) (CA INDEX NAME)




RN 76990-19-7 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 4-[(4-methoxyphenyl)amino]-6-phenyl- (9CI) (CA INDEX NAME)




L12 ANSWER 40 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1981:65606 CAPLUS
 DN 94:65606
 TI A novel and convenient synthesis of 2-amino-4-(N-alkyl-N-arylaminopyrimidines using polarized ketene S,S- and S,N-acetals. Part 13
 AU Kumar, A.; Aggarwal, V.; Ila, H.; Junjappa, H.
 CS Dep. Chem., North-Eastern Hill Univ., Shilong, 793 003, India
 SO Synthesis (1980), (9), 748-51
 CODEN: SYNTBF; ISSN: 0039-7881
 DT Journal
 LA English
 OS CASREACT 94:65606
 AB Ketene S,N-acetals $\text{EtO}_2\text{CC}(\text{CN})\text{:C}(\text{SMe})\text{NRR1}$ ($\text{R} = \text{Ph}, 4\text{-Me-}, 4\text{-MeO-}, 4\text{-Cl-}, 4\text{-FC6H4}$; $\text{R1} = \text{H}$; $\text{NRR1} = \text{morpholino}$), generated in situ by treating ketene S,S-acetals $\text{EtO}_2\text{CC}(\text{CN})\text{:C}(\text{SMe})_2$ with amines RR1NH_2 , were treated with guanidine nitrate to give 47-57% aminopyrimidones I. $\text{R}_2\text{COCH:C}(\text{SMe})\text{NHR}_3$ ($\text{R}_2 = \text{H}, \text{Ph}, 4\text{-MeC}_6\text{H}_4, 4\text{-BrC}_6\text{H}_4$; $\text{R}_3 = \text{Ph}, 4\text{-ClC}_6\text{H}_4, \text{Et}$), obtained in 75-85% yield by treating R_2COMe with R_3NCS , were treated with guanidine nitrate to give 28-50% II.
 IT **76369-29-4P 76369-30-7P 76369-31-8P 76369-32-9P**
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 76369-29-4 CAPLUS
 CN 2,4-Pyrimidinediamine, N4,6-diphenyl- (9CI) (CA INDEX NAME)


Same as #47



RN 76369-30-7 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(4-methoxyphenyl)-N4-phenyl- (9CI) (CA INDEX NAME)




RN 76369-31-8 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(4-bromophenyl)-N4-phenyl- (9CI) (CA INDEX NAME)




RN 76369-32-9 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(4-chlorophenyl)-6-phenyl- (9CI) (CA INDEX NAME)




L12 ANSWER 41 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1980:446364 CAPLUS
 DN 93:46364
 TI 3-Cyanopyridine derivatives from arylidenemalononitriles and
 N-monosubstituted arylacetamides
 AU Robev, S.
 CS Dep. Pharmacol., Fac. Med., Sofia, 1431, Bulg.
 SO Heterocycles (1980), 14(4), 461-4
 CODEN: HTCYAM; ISSN: 0385-5414
 DT Journal
 LA English
 AB Iminopyridines I (R = H, Me, Cl; R1 = H, Cl; R2 = Ph, 4-ClC6H4,
 2-naphthyl, 4-MeC6H4, 2-MeOC6H4, 2-pyridyl) were obtained in 40-80% yield
 by treating 4-RC6H4NHC(:NH)CH2C6H4R1-4 with R2CH:C(CN)2 in the melt at
 100-10°. 4-Anilino-6-aryl-2-benzyl-5-cyanopyrimidines were formed
 as by-products. I rearranged on treatment with NaOPr-PrOH to give 58-75%
 II. II (R = R1 = H, R2 = Ph) cyclized on heating on H3PO4 to give 60%
 III.
 IT **74115-89-2P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 74115-89-2 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 4-phenyl-6-(phenylamino)-2-(phenylmethyl)- (9CI)
 (CA INDEX NAME)



L12 ANSWER 42 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1979:6337 CAPLUS
 DN 90:6337
 TI Acylketene-S,S- and acylketene-S,N-acetals as building blocks for
 heterocycles: 5-cyanopyrimidines
 AU Rudolf, W. D.; Augustin, M.
 CS Sekt. Chem., Martin-Luther-Univ., Halle/Saale, Ger. Dem. Rep.
 SO Journal fuer Praktische Chemie (Leipzig) (1978), 320(4), 576-84
 CODEN: JPCEAO; ISSN: 0021-8383
 DT Journal
 LA German
 OS CASREACT 90:6337
 AB Cyanopyrimidines I (R = Me, Ph, 4-O₂NC₆H₄, NH₂, SMe; R₁ = Ph, 4-BrC₆H₄,
 4-ClC₆H₄, 3,4-Cl₂C₆H₃, 2-furyl, 2-thienyl; R₂ = SMe) were prepared in 56-91%
 yield by cyclocondensation of H₂NCR:NH with R₁COC(CN):C(SMe)₂ in the
 presence of NEt₃. I (R = Me, Ph, NH₂, SMe, R₁ = Ph, R₂ = NHPH) were
 similarly obtained in 52-63% yield from H₂NCR:NH and NCCBz:C(SMe)NHPH. I
 (R = Me, NH₂, R₁ = Ph, R₂ = OEt) were obtained when H₂NCR:NH was treated
 with NCC(COPh):C(SMe)₂ in the presence of NaOEt.
 IT **68364-56-7P 68364-57-8P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 68364-56-7 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 2-methyl-4-phenyl-6-(phenylamino)- (9CI) (CA
 INDEX NAME)



RN 68364-57-8 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 2-amino-4-phenyl-6-(phenylamino)- (9CI) (CA
 INDEX NAME)



L12 ANSWER 43 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1976:478153 CAPLUS

DN 85:78153

TI 4-Amino-6-arylpyrimidines and salts useful for relaxation of smooth muscle in a mammal

IN De Angelis, Gerald G.; Hess, Hans J. E.

PA Pfizer Inc., USA

SO U.S., 25 pp. Division of U.S. 3,895,112.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3950525	A	19760413	US 1975-567356	19750411
	US 3859288	A	19750107	US 1971-182220	19710920
	US 3895112	A	19750715	US 1973-371483	19730619
PRAI	US 1971-182220	A3	19710920		
	US 1973-371483	A3	19730619		
	US 1975-78216	A2	19751005		
	US 1970-78216	A2	19701005		


AB Pyrimidinamines I (R = Ph, substituted phenyl, furyl, thienyl, naphthyl; R1 and R2 = H, alkyl, hydroxyalkyl, aminoalkyl; NR1R2 = heterocyclic; R3 = H, Me, Et, Pr, CHMe2) (100 compds.) were prepared and have platelet aggregation-inhibiting and bronchodilator properties. Thus, I (R = Ph, R1 = R2 = Et, R3 = H) were obtained by Grignard reaction of PhBr with NCCH2CO2Et, condensation of H2NCPh:CHCO2Et with HCONH2, chlorination of 4-hydroxy-6-phenylpyrimidine, and amination of the 4-chloro compound

IT **60084-61-9P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 60084-61-9 CAPLUS


CN Benzoic acid, 3-[(6-phenyl-4-pyrimidinyl)amino]-, ethyl ester,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L12 ANSWER 44 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1976:59528 CAPLUS
 DN 84:59528
 TI Arylpyrimidines, inhibitors of platelet aggregation and bronchodilators
 IN De Angelis, Gerald G.; Hess, Hans J. E.
 PA Pfizer Inc., USA
 SO U.S., 27 pp. Division of U.S. 3,859,288.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3908012	A	19750923	US 1973-371420	19730619
	US 3707560	A	19721226	US 1970-78216	19701005
	US 3859288	A	19750107	US 1971-182220	19710920
	DK 130971	B	19750512	DK 1973-1429	19730316
	US 3890321	A	19750617	US 1973-371563	19730619
	CA 978531	A2	19751125	CA 1973-176049	19730710
	CA 978532	A2	19751125	CA 1974-191086	19740128
	FI 55834	C	19791010	FI 1977-3287	19771102
	FI 55834	B	19790629		
PRAI	US 1970-78216	A2	19701005		
	US 1971-182220	A3	19710920		
	FI 1971-2734	A	19710930		
	DK 1971-4801	A	19711001		
	CA 1971-124312	A3	19711004		
AB	About 100 pyrimidines I (R = Ph, p-ClC ₆ H ₄ , 2-furyl, 2-thienyl, 3-H ₂ NC ₆ H ₄ , etc., R ₁ = H, Me, Et, Pr; R ₂ = Et ₂ N, MeNH, Bu ₂ N, 1-pyrrolidinyl, piperidino, etc.) were prepared by substitution of I (R = Cl) or treating chlorobenzothienopyrimidines with amines followed by cleaving. Thus, NCCH ₂ CO ₂ Et was treated with PhMgBr and the H ₂ NCPh:CHCO ₂ Et cyclized with HCONH ₂ to give I (R = Ph, R ₁ = H, R ₂ = OH), which was chlorinated with POCl ₃ and treated with Et ₂ NH to give I (R = Ph, R ₁ = H, R ₂ = Et ₂ N). At 10-4 μ I (R = Ph, R ₁ = H, R ₂ = Et ₂ N) inhibited in vitro platelet aggregations by 99%. At 60 mg/kg I (R = 3-O ₂ NC ₆ H ₄ , R ₁ = H, R ₂ = Et ₂ N) gave 20% protection against histamine induced bronchoconstriction in guinea pigs.				
IT	36822-94-3P RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN	36822-94-3 CAPLUS				
CN	Benzoic acid, 2-[(6-phenyl-4-pyrimidinyl)amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)				



● HCl

L12 ANSWER 45 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1972:448506 CAPLUS
 DN 77:48506
 TI 6-Arylpyrimidines for inhibiting thrombocyte aggregation and as
 bronchodilators
 IN De Angelis, Gerald G.; Hess, Hans J. E.
 PA Pfizer Inc.
 SO Ger. Offen., 87 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2149249	A	19720413	DE 1971-2149249	19711002
	DE 2149249	B2	19741107		
	DE 2149249	C3	19750703		
	US 3707560	A	19721226	US 1970-78216	19701005
	FI 55502	C	19790810	FI 1971-2734	19710930
	FI 55502	B	19790430		
	DK 131858	B	19750915	DK 1971-4801	19711001
	ZA 7106615	A	19720628	ZA 1971-6615	19711004
	ES 395676	A1	19741016	ES 1971-395676	19711004
	GB 1373535	A	19741113	GB 1971-46158	19711004
	GB 1373536	A	19741113	GB 1973-38316	19711004
	CA 988519	A1	19760504	CA 1971-124312	19711004
	SE 385885	C	19761104	SE 1971-12534	19711004
	SE 385885	B	19760726		
	SE 390304	B	19761213	SE 1974-10488	19711004
	BE 773484	A1	19720405	BE 1971-3448	19711005
	NL 7113670	A	19720407	NL 1971-13670	19711005
	NL 168511	B	19811116		
	NL 168511	C	19820416		
	FR 2110227	A5	19720602	FR 1971-35815	19711005
	FR 2110227	B1	19750207		
	CH 542218	A	19731115	CH 1973-7729	19711005
	AT 314540	B	19740410	AT 1971-8580	19711005
	AT 315856	B	19740610	AT 1973-148	19711005
	AT 316563	B	19740725	AT 1973-149	19711005
	AT 317229	B	19740826	AT 1973-6054	19711005
	CH 554346	A	19740930	CH 1972-15321	19711005
	CH 554876	A	19741015	CH 1971-14529	19711005
	CH 554875	A	19741015	CH 1972-15214	19711005
	JP 56048511	B4	19811116	JP 1971-78237	19711005
	AU 7134259	A1	19730412	AU 1971-34259	19711006
	DK 130971	B	19750512	DK 1973-1429	19730316
	CA 978531	A2	19751125	CA 1973-176049	19730710
	ES 420211	A1	19760316	ES 1973-420211	19731102
	ES 420209	A1	19760601	ES 1973-420209	19731102
	ES 420210	A1	19760601	ES 1973-420210	19731102
	CA 978532	A2	19751125	CA 1974-191086	19740128
	SE 7410488	A	19740816	SE 1974-10488	19740816
	FI 55834	C	19791010	FI 1977-3287	19771102
	FI 55834	B	19790629		
	JP 56036468	A2	19810409	JP 1980-110163	19800811
	JP 57008107	B4	19820215		
PRAI	US 1970-78216	A	19701005		
	FI 1971-2734	A	19710930		

DK 1971-4801 A 19711001

CA 1971-124312 A3 19711004


AB 4-Amino-6-arylpyrimidines (I), useful for inhibition of thrombocyte aggregation and as bronchodilators, were prepared by reaction of RMgX with $R_1CH(CN)CO_2Et$ to give $ArC(NH_2):CR_1CO_2Et$, which was condensed with $HCONH_2$ to give the 4-hydroxy analog of I, treated with $POCl_3$, and R_2R_3NH . Other methods included reaction of substituted o-chlorobenzonitrile with $NaSCH_2CO_2Me$ to give a 2-amino-3-methoxydihydrobenzo[b]thiophene which was condensed with $HCONH_2$ to give a 4-hydroxy-[1]benzothieno[3,2-d]pyrimidine, treatment with $POCl_3$, R_2R_3NH , then H over Raney Ni, or by condensation of $RCOCHR_1CO_2Et$ with $(NH_2)_2CS$ to give a 6-aryl-2-mercapto-4-hydroxypyrimidine which was hydrogenated over Raney Ni, treated with $POCl_3$, then R_2R_3NH . About 75 I [R = Ph, substituted phenyl, 2-furyl, 2-thienyl; R_1 = H, Et, Pr; R_2 = H, C1-4 alkyl, allyl; R_3 = H, C1-4 alkyl, CF_3CH_2 , allyl, $Me_2N(CH_2)_2$, 3-picolyl; or R_2R_3 = $(CH_2)_4-6$, $(CH_2)_2O(CH_2)_2$, or $(CH_2)_2NMe(CH_2)_2$] were prepared

IT 36822-94-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 36822-94-3 CAPLUS

CN Benzoic acid, 2-[(6-phenyl-4-pyrimidinyl)amino]-, ethyl ester,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L12 ANSWER 46 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1968:459179 CAPLUS
DN 69:59179
TI Substituted heteroaromatic anthranilic acids with antiinflammatory activity
AU Falch, E.; Weis, J.; Natvig, T.
CS Res. Div., Pharmacia AS, Copenhagen-Vanløse, Den.
SO Journal of Medicinal Chemistry (1968), 11(3), 608-11
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
AB Anthranilic acids (I and II) containing heteroaromatic N-substituents were prepared by the reaction of appropriately substituted chloro heterocycles with anthranilic acid in HCl or substituted methylthio heterocycles with anthranilic acid in alkaline solution. The reaction of o-BrC₆H₄CO₂H with 5-amino-4-carboxy-2,6-dihydropyrimidine gave N-[5-(4-carboxy-2,6-dihydropyrimidinyl)]anthranilic acid. The exchange of the o-xylyl moiety in mefenamic acid with heteroaromatic rings significantly lowers the antinflammatory activity.
IT **17174-00-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 17174-00-4 CAPLUS
CN Benzoic acid, 2-[(2-methyl-6-phenyl-4-pyrimidinyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L12 ANSWER 47 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1955:60839 CAPLUS

DN 49:60839

OREF 49:11726h-i,11727a-b

TI 2-Amino-4-substituted amino-6-arylpyrimidines

IN Hitchings, Geo. H.; Russell, Peter B.

PA Burroughs Wellcome and Co. (U.S.A.) Inc.

DT Patent

LA Unavailable

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2691655		19541012	US 1952-289907	19520524
AB	2-Amino-4-substituted amino-6-arylpyrimidines, useful as growth inhibitors for rapidly growing virus are prepared from the corresponding 4-hydroxypyrimidine by conversion to the 4-chloropyrimidine and subsequent reaction with the appropriate amine. Thus, 47 g. BzCHPrCO ₂ Et, refluxed 6 hrs. with 12 g. guanidine carbonate in 200 ml. EtOH, gives 2-amino-4-hydroxy-5-propyl-6-phenylpyrimidine (I), m. 311-13°, obtained by dilution of the reaction mixture with 500 ml. H ₂ O and recrystn. of the precipitate from EtOH; the 5-benzyl analog (II), m. 340°, was prepared similarly from BzCH(CH ₂ Ph)CO ₂ Et. Refluxing 10 g. I with 50 ml. POCl ₃ until solution was achieved, removing the excess POCl ₃ , and suspending the residue in iced aqueous NH ₄ OH gave 2-amino-4-chloro-5-propyl-6-phenylpyrimidine (III). Similarly, II yields the 5-benzyl analog (IV) of III; heating 5 g. III with 100 ml. of a saturated solution of MeNH ₂ in EtOH in				


a

bomb for 16 hrs. at 150° gives 4.2 g. 4-MeNH analog of III, m. 198°, and IV gives the 4-MeNH analog of IV, m. 177°. Refluxing 5 g. III with 25 ml. of PhNH₂ 5 hrs., cooling, and recrystg. the precipitate from EtOH, gives needles of the 4-PhNH analog of III, m. 171°; 4-PhNH analog of IV, m. 211°. The following compds. are obtained by analogous procedures: 2-amino-4-methylamino-6-(2-naphthyl)pyrimidine, m. 238-9°; 2-amino-4-methylamino-6-phenylpyrimidine, m. 195-6°, and its 4-PhNH, m. 305-6° (decomposition), 4-(p-ClC₆H₄NH), m. 304-5°, and 4-(p-MeOC₆H₄NH) analogs, m. 259-63°.


IT 76369-29-4, Pyrimidine, 2-amino-4-anilino-6-phenyl-
 76369-32-9, Pyrimidine, 2-amino-4-p-chloroanilino-6-phenyl-
 856971-90-9, Pyrimidine, 2-amino-4-p-bromoanilino-5-methyl-6-phenyl-
 856972-24-2, Pyrimidine, 2-amino-4-(p-bromophenyl)-5-butyl-6-p-chloroanilino-
 856973-34-7, Pyrimidine, 2-amino-4-(p-chlorophenyl)-6-o-toluidino-
 857436-02-3, Pyrimidine, 2-amino-5-butyl-4-(p-nitrophenyl)-6-p-toluidino-
 859208-77-8, Pyrimidine, 2-amino-4-anilino-5-benzyl-6-phenyl-
 859208-80-3, Pyrimidine, 2-amino-4-anilino-6-phenyl-5-propyl-
 859208-83-6, Pyrimidine, 2-amino-4-p-anisidino-5-benzyl-6-(o-chlorophenyl)-
 875233-37-7, Pyrimidine, 2-amino-4-p-anisidino-6-phenyl-
 (preparation of)

RN 76369-29-4 CAPLUS


CN 2,4-Pyrimidinediamine, N4,6-diphenyl- (9CI) (CA INDEX NAME)




RN 76369-32-9 CAPLUS
CN 2,4-Pyrimidinediamine, N4-(4-chlorophenyl)-6-phenyl- (9CI) (CA INDEX NAME)




RN 856971-90-9 CAPLUS
CN Pyrimidine, 2-amino-4-p-bromoanilino-5-methyl-6-phenyl- (5CI) (CA INDEX NAME)




RN 856972-24-2 CAPLUS
CN Pyrimidine, 2-amino-4-(p-bromophenyl)-5-butyl-6-p-chloroanilino- (5CI) (CA INDEX NAME)




RN 856973-34-7 CAPLUS
CN Pyrimidine, 2-amino-4-(p-chlorophenyl)-6-o-toluidino- (5CI) (CA INDEX NAME)




RN 857436-02-3 CAPLUS
 CN Pyrimidine, 2-amino-5-butyl-4-(p-nitrophenyl)-6-p-toluidino- (5CI) (CA INDEX NAME)




RN 859208-77-8 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED



RN 859208-80-3 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 859208-83-6 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED



RN 875233-37-7 CAPLUS

CN Pyrimidine, 2-amino-4-p-anisidino-6-phenyl- (5CI) (CA INDEX NAME)



L12 ANSWER 48 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1954:7533 CAPLUS

DN 48:7533

OREF 48:1445e-i

TI Therapeutically useful pyrimidines


PA Burroughs Wellcome & Co. (U.S.A.) Inc.; Wellcome Foundation Ltd.

DT Patent

LA Unavailable

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 681712		19521029	GB 1949-23768	19490914
AB	<p>Physiologically active compds. were prepared, represented by N:C(NH2)N:CR3.CR2:CR1 (I) where R1 is Ph, 2-ClOH7, p-ClC6H4, p-BrC6H4, or p-O2NC6H4; R2 is H, PhCH2, or straight- or branched-chain alkyl radical of not more than 7 C atoms; and R3 is NH2, straight- or branched-chain alkyl amino of not more than 7 C atoms, or a MeC6H4NH, PhCH2NH, PhNH, p-ClC6H4NH, p-BrC6H4NH, p-MeOC6H4NH, or p-EtOC6H4NH, Cl, or HO. The compds. were prepared from the p-HO derivs. (prepared by refluxing guanidine carbonate in alc. with the appropriate oxo ester), which were converted to the corresponding Cl derivs. with POCl3, and the Cl derivative, treated with the corresponding amine gave I (R3 = NHR). The following I (R1, R2, R3, and m.p. given) are disclosed: Ph, H, Cl, 148° (from aqueous EtOH); Ph, H, NH2, 162° (from EtOH); Ph, Me, HO, 287°; Ph, Me, Cl, 127-8°; Ph, Me, NH2, 196-7° (from EtOH); Ph, Pr, HO, decompose 311-13°; Ph, Pr, Cl, -; Ph, Pr, NH2, 165-6° (from aqueous EtOH); Ph, PhCH2, HO, decompose 334° (from EtOH); Ph, PhCH2, Cl, -; Ph, PhCH2, NH2, 222-3° (from aqueous EtOH); Ph, H, NHMe, 195-6° (from H2O); Ph, H, NHPH, decompose 305-6° (from HOAc); Ph, H, p-ClC6H4NH, 304-5° (from HOAc); Ph, H, p-MeOC6H4NH, 259-63° (from HOAc); p-ClC6H4, H, HO, decompose 344-7° (from HOAc); p-ClC6H4, H, Cl, -; p-ClC6H4, H, NH2, 161-2° (from aqueous EtOH); p-ClC6H4, Me, HO, 331-3° (from aqueous EtOH); p-ClC6H4, Me, Cl, -; p-ClC6H4, Me, NH2, 184-5° (from aqueous EtOH); p-O2NC6H4, H, HO, decompose 334° (from HOAc); p-O2NC6H4, H, Cl, -; p-O2NC6H4, H, NH2, decompose 239° (from EtOH); 2-ClOH7, H, HO, -; 2-ClOH7, H, Cl, -; 2-ClOH7, H, NH2, 205-6° (from aqueous EtOH); 2-ClOH7, H, NHMe, 238-9° (from aqueous MeOH).</p>				
IT	<p>76369-29-4, Pyrimidine, 2-amino-4-anilino-6-phenyl- 76369-32-9, Pyrimidine, 2-amino-4-p-chloroanilino-6-phenyl- 875233-37-7, Pyrimidine, 2-amino-4-p-anisidino-6-phenyl- (preparation of)</p>				
RN	76369-29-4 CAPLUS				
CN	2,4-Pyrimidinediamine, N4,6-diphenyl- (9CI) (CA INDEX NAME)				



Same as # 47


RN 76369-32-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(4-chlorophenyl)-6-phenyl- (9CI) (CA INDEX NAME)



RN 875233-37-7 CAPLUS

CN Pyrimidine, 2-amino-4-p-anisidino-6-phenyl- (5CI) (CA INDEX NAME)



L12 ANSWER 12 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:260034 CAPLUS

DN 142:336376

TI Preparation of pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases

IN Choidas, Axel; Backes, Alexander; Cotten, Matt; Engkvist, Ola; Felber, Beatrice; Freisleben, Achim; Godl, Klaus; Greff, Zoltan; Habenberger, Peter; Hafenbradl, Doris; Hartung, Christian; Herget, Thomas; Hoppe, Edmund; Klebl, Bert; Missio, Andrea; Mueller, Gerhard; Schwab, Wilfried; Zech, Birgit; Bravo, Jose; Harris, John; Le, Joelle; Macritchie, Jackie; Savic, Vladimir; Sherborne, Brad; Simpson, Don; Simpson, Don

PA Axxima Pharmaceuticals AG, Germany

SO PCT Int. Appl., 211 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005026129	A1	20050324	WO 2004-EP10353	20040915
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	EP 2003-20888	A	20030915		
	US 2003-504527P	P	20030922		
	EP 2004-10308	A	20040430		
	US 2004-569806P	P	20040512		

OS MARPAT 142:336376


AB The invention is related to the preparation of title compds. I, and/or stereoisomeric forms and/or pharmaceutically acceptable salts [wherein R1 = H, (un)substituted alk(en/yn)yl; R2, R4 = independently H, F, Cl, Br, I, CN, NH2, NO2, (un)substituted alk(en/yn)yl; R3 = F, Cl, Br, I, (un)substituted hetero/aryl, etc.; X = R5-[LR6]m; R5 = (un)substituted hetero/aryl, heterocyclyl, cycloalkyl, etc.; R6 = H, (un)substituted alkyl, hetero/aryl, heterocyclyl, etc.; L = NRSO2, NRSO; R = H, (un)substituted alkyl, SO2-alkyl, etc.] as protein kinase inhibitors for use in the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunol. diseases, autoimmune diseases, bipolar and clin. disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke. The invention is also related to a medium comprising at least one of compds. I in an immobilized form and its use for enriching, purifying and/or depleting nucleotide binding proteins which bind to the immobilized I. General preparation procedures and 5 individual synthetic examples are given. I have an inhibitory effect on the protein kinase activity of various protein kinases, such as Abl, CDK1, CDK5, etc. Selected I had an inhibitory effect on CDK9 and CDK2 with IC50 values in the range of 1 to 1000 nM. I were potent inhibitors of HIV and HCMV replication in cell cultures; for example II showed inhibition of HCMV replication in HFF

cells.

- IT **848636-28-2P 848636-35-1P**, N-[6-(2-Methoxyphenyl)pyrimidin-4-yl]benzene-1,4-diamine
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of 4,6-disubstituted aminopyrimidines as modulators of protein kinases)
- RN 848636-28-2 CAPLUS
- CN Benzoic acid, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



- RN 848636-35-1 CAPLUS
- CN 1,4-Benzenediamine, N-[6-(2-methoxyphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



- IT **848636-16-8P**, N-[5-[6-(4-Methoxyphenyl)pyrimidin-4-ylamino]-2-methylphenyl]methanesulfonamide **848636-22-6P**, 1-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]pyrrolidin-2-one **848636-23-7P**, N-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]acetamide **848636-25-9P**, N-[5-[6-(3-Aminophenyl)pyrimidin-4-ylamino]-2-methylphenyl]methanesulfonamide **848636-27-1P**, 4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]benzamide **848636-32-8P**, N-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]-2,2-dimethylpropionamide **848636-46-4P**, N-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]methanesulfonamide **848636-50-0P**, N-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]-3-methyl-2-phenylbutyramide **848636-51-1P**, 1-Cyclohexyl-3-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]urea **848636-55-5P**, N-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]-3,3-dimethylbutyramide **848636-59-9P**, 2-Dimethylamino-N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]acetamide **848636-61-3P**, 2-[[[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]carbonyl]methyl]piperidine-1-carboxylic acid tert-butyl ester **848636-66-8P**, N-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]guanidine **848636-67-9P**, N-tert-Butyl-4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]benzamide **848636-72-6P**, N-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]-2-(piperidin-2-yl)acetamide

848636-75-9P, [4-(Benzoxazol-2-yl)phenyl][6-(2-methoxyphenyl)pyrimidin-4-yl]amine **848636-76-0P**, [4-(1H-Benzimidazol-2-yl)phenyl][6-(2-methoxyphenyl)pyrimidin-4-yl]amine
848636-77-1P, 3-Diethylamino-N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]propionamide **848636-84-0P**, N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]-2-phenylacetamide
848636-88-4P, 3-[6-[4-(2,2-Dimethylpropionylamino)phenyl]amino]pyrimidin-4-yl]benzoic acid **848636-94-2P**, (S)-2-Amino-N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]-2-phenylethanamide
848636-95-3P, (S)-N-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]-2-methylamino-2-phenylethanamide **848636-98-6P**, N-[4-[6-(2-Benzoyloxyphenyl)pyrimidin-4-yl]amino]phenyl]-2,2-dimethylpropionamide **848637-08-1P**, 4-[6-(2-Benzoyloxyphenyl)pyrimidin-4-yl]amino]benzamide **848637-13-8P**, N-[5-[6-(3-Methoxyphenyl)pyrimidin-4-ylamino]-2-methylphenyl]methanesulfonamide **848637-14-9P**, 2-Dimethylamino-N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]-2-phenylacetamide **848637-15-0P**, 3-Amino-N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]propionamide **848637-17-2P**, N-[3-[6-[3-[(Methylsulfonyl)amino]-4-methylphenyl]amino]pyrimidin-4-yl]phenyl]acetamide **848637-18-3P**, N-[5-[6-(3-Hydroxyphenyl)pyrimidin-4-ylamino]-2-methylphenyl]methanesulfonamide
848637-19-4P, N-[2-Methyl-5-(6-phenylpyrimidin-4-ylamino)phenyl]methanesulfonamide **848637-20-7P**, N-[2-Methyl-5-[6-(3-trifluoromethylphenyl)pyrimidin-4-ylamino]phenyl]methanesulfonamide **848637-21-8P**, N-[5-[6-[3-[(Methylsulfonyl)amino]phenyl]pyrimidin-4-yl]amino]-2-methylphenyl]methanesulfonamide **848637-24-1P**, 1-(Benzodioxol-5-yl)-3-[4-[6-(2-methoxyphenyl)pyrimidin-4-yl]amino]phenyl]urea **848637-25-2P**, 1-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]-3-(4-methylbenzyl)urea
848637-26-3P, 1-tert-Butyl-3-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]urea **848637-27-4P**, 2,2-Dimethyl-N-[4-[6-(2-trifluoromethylphenyl)pyrimidin-4-ylamino]phenyl]propionamide
848637-28-5P, 3-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]benzamide
848637-29-6P, Propane-1-sulfonic acid N-[5-[6-(3-aminophenyl)pyrimidin-4-ylamino]-2-methylphenyl]amide **848637-30-9P**, 4-[6-(3-Aminophenyl)pyrimidin-4-ylamino]benzenesulfonamide
848637-31-0P, N-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]-2-methyl-2-methylaminopropionamide **848637-32-1P**, N-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]-3-methylphenyl]-2,2-dimethylpropionamide **848637-34-3P**, N-[3-[6-(3-Aminophenyl)pyrimidin-4-ylamino]phenyl]methanesulfonamide
848637-35-4P, N-[3-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]-2,2-dimethylpropionamide **848637-36-5P**, N-[6-(2-Methoxyphenyl)pyrimidin-4-yl]-2-methylbenzene-1,4-diamine
848637-37-6P, N-[6-(2-Methoxyphenyl)pyrimidin-4-yl]benzene-1,3-diamine **848637-39-8P**, 2,2-Dimethyl-N-[4-[6-(2-vinylphenyl)pyrimidin-4-ylamino]phenyl]propionamide **848637-40-1P**, N-[4-[6-(2-Fluorophenyl)pyrimidin-4-ylamino]phenyl]-2,2-dimethylpropionamide **848637-44-5P**, N-[4-[6-(2-Ethylphenyl)pyrimidin-4-ylamino]phenyl]-2,2-dimethylpropionamide
848637-45-6P, N-[4-[6-(Biphenyl-2-yl)pyrimidin-4-ylamino]phenyl]-2,2-dimethylpropionamide **848637-52-5P**, (2S,3S)-2-Amino-3-methylpentanoic acid N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]amide **848637-55-8P**, (S)-2-Amino-N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]-3-methylbutanamide
848637-58-1P, 2-Amino-N-[4-[6-(2-methoxyphenyl)pyrimidin-4-

ylamino]phenyl]-2-(naphthalen-2-yl)acetamide **848637-62-7P**,
 3-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]benzenesulfonamide
848637-64-9P, N-[6-(2-Methoxyphenyl)-5-methylpyrimidin-4-yl]benzene-1,4-diamine **848637-65-0P**, Propane-2-sulfonic acid
 N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]amide
848637-66-1P, Propane-1-sulfonic acid N-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenyl]amide **848637-68-3P**,
 N-[5-[[6-(2-Benzyloxyphenyl)pyrimidin-4-yl]amino]-2-methylphenyl]methanesulfonamide **848637-69-4P**,
 N-[5-[[6-(3-Dimethylaminophenyl)pyrimidin-4-yl]amino]-2-methylphenyl]methanesulfonamide **848637-70-7P**,
 N-[5-[6-(2-Isopropoxyphenyl)pyrimidin-4-ylamino]-2-methylphenyl]methanesulfonamide **848637-71-8P**
848637-72-9P, Propane-1-sulfonic acid N-[4-[6-(2-methoxyphenyl)-5-methylpyrimidin-4-ylamino]phenyl]amide **848637-74-1P**,
 N-[5-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]-2-methylphenyl]methanesulfonamide **848637-75-2P**,
 N-[5-[6-(3-Cyanophenyl)pyrimidin-4-ylamino]-2-methylphenyl]methanesulfonamide **848637-77-4P**,
 N-[5-[6-(3-Formylphenyl)pyrimidin-4-ylamino]-2-methylphenyl]methanesulfonamide **848637-78-5P**,
 N-[5-[6-(2-Hydroxymethylphenyl)pyrimidin-4-ylamino]-2-methylphenyl]methanesulfonamide **848637-87-6P**,
 N-[5-[6-(4-Hydroxymethylphenyl)pyrimidin-4-ylamino]-2-methylphenyl]methanesulfonamide **848637-93-4P**,
 N-[5-[6-(2-Hydroxyphenyl)pyrimidin-4-ylamino]-2-methylphenyl]methanesulfonamide **848637-94-5P**,
 (E)-3-[3-[6-[[3-[(Methylsulfonyl)amino]-4-methylphenyl]amino]pyrimidin-4-yl]phenyl]-2-propenoic acid methyl ester **848637-95-6P**,
 N-[5-[6-(3-Hydroxymethylphenyl)pyrimidin-4-ylamino]-2-methylphenyl]methanesulfonamide **848637-96-7P**,
 N-Butyl-3-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]benzenesulfonamide
848637-97-8P, (3-Methylsulfonylphenyl)[6-(2-methoxyphenyl)pyrimidin-4-yl]amine **848638-09-5P**,
 N-[5-[[6-(2-Methoxymethylphenyl)pyrimidin-4-yl]amino]-2-methylphenyl]methanesulfonamide **848638-16-4P**,
 N-[6-(2-Methoxyphenyl)-2-methylpyrimidin-4-yl]benzene-1,4-diamine
848638-17-5P, N-[6-(4-Methoxyphenyl)-2-methylpyrimidin-4-yl]benzene-1,4-diamine **848638-26-6P**, 3-[6-(3-Aminophenyl)pyrimidin-4-ylamino]benzenesulfonamide **848638-27-7P**,
 3-[6-(4-Methoxyphenyl)pyrimidin-4-ylamino]benzenesulfonamide
848638-29-9P, N-(2-Diethylaminoethyl)-4-[[6-(2-methoxyphenyl)pyrimidin-4-yl]amino]benzamide **848638-47-1P**,
 2-Chloro-5-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]benzenesulfonamide
848638-49-3P, N-Allyl-3-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]benzenesulfonamide **848638-50-6P**, N-Benzyl-3-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]benzenesulfonamide **848638-53-9P**,
 3-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]-N-methylbenzenesulfonamide
848638-54-0P, N-[6-(2-Methoxyphenyl)pyrimidin-4-yl]-N-(3-sulfamoylphenyl)acetamide **848638-55-1P**, N,N-Diallyl-3-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]benzenesulfonamide **848638-56-2P**,
 3-[[6-(2-Benzyloxyphenyl)pyrimidin-4-yl]amino]benzenesulfonamide
848638-58-4P, [6-(2-Methoxyphenyl)pyrimidin-4-yl](4-trifluoromethylsulfonylphenyl)amine **848638-59-5P**,
 (4-Methylsulfonylphenyl)[6-(2-methoxyphenyl)pyrimidin-4-yl]amine
848638-61-9P, 4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]-N-propylbenzenesulfonamide **848638-62-0P**, 4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]benzenesulfonamide **848638-63-1P**

, 4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]-N,N-dimethylbenzenesulfonamide **848638-64-2P**, N-(2-Methoxyethyl)-4-[[6-(2-methoxyphenyl)pyrimidin-4-yl]amino]benzenesulfonamide **848638-65-3P**, [6-(2-Benzoyloxyphenyl)pyrimidin-4-yl](3-methylsulfonylphenyl)amine **848638-66-4P**, 2-[6-[(3-methylsulfonylphenyl)amino]pyrimidin-4-yl]phenol **848638-67-5P**, [6-(3-Aminophenyl)pyrimidin-4-yl](3-methylsulfonylphenyl)amine **848638-68-6P**, 5-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]-2-methylbenzenesulfonic acid **848638-69-7P**, 2-[[3-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]sulfonyl]ethanol **848638-70-0P**, (2-Fluoro-5-methylsulfonylphenyl)[6-(2-methoxyphenyl)pyrimidin-4-yl]amine **848638-71-1P**, [6-(2-Aminophenyl)pyrimidin-4-yl](3-methylsulfonylphenyl)amine **848638-72-2P**, [6-(2-Methoxyphenyl)pyrimidin-4-yl](3-trifluoromethylsulfonylphenyl)amine **848638-73-3P**, (3-Methylsulfonylphenyl)[6-(2-Phenoxyphenyl)pyrimidin-4-yl]amine **848638-74-4P**, [6-(2-Butoxyphenyl)pyrimidin-4-yl](3-methylsulfonylphenyl)amine **848638-75-5P**, (3-Ethenylsulfonylphenyl)[6-(2-methoxyphenyl)pyrimidin-4-yl]amine **848638-77-7P**, 2-Chloro-4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]benzoic acid methyl ester **848638-79-9P**, 4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]-3-methylbenzoic acid methyl ester **848638-80-2P**, [6-(3-Aminophenyl)pyrimidin-4-yl](1-methylsulfonyl-2,3-dihydro-1H-indol-6-yl)amine **848638-82-4P**, **848638-83-5P**, (1H-Indazol-6-yl)[6-(2-methoxyphenyl)pyrimidin-4-yl]amine **848638-84-6P**, 1-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]butan-1-one **848638-88-0P**, [3-([1,3]Dioxan-2-yl)phenyl][6-(2-methoxyphenyl)pyrimidin-4-yl]amine **848638-89-1P**, (3-Methoxyphenyl)[6-(2-methoxyphenyl)pyrimidin-4-yl]amine **848638-90-4P**, (4-Methoxyphenyl)[6-(2-Methoxyphenyl)pyrimidin-4-yl]amine **848638-92-6P**, [6-(2-Methoxyphenyl)pyrimidin-4-yl][4-(morpholin-4-yl)phenyl]amine **848638-93-7P**, (2-Fluorophenyl)[6-(2-methoxyphenyl)pyrimidin-4-yl]amine **848638-95-9P**, (4-Butylphenyl)[6-(2-methoxyphenyl)pyrimidin-4-yl]amine **848638-98-2P**, 1-Dimethylamino-3-[4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]phenoxy]-3-propan-2-ol **848638-99-3P**, N-[6-(4-Methoxyphenyl)-5-methylpyrimidin-4-yl]benzene-1,4-amine **848639-00-9P**, N-[6-(3-Aminophenyl)-5-methylpyrimidin-4-yl]benzene-1,4-amine **848639-04-3P**, 4-[[6-[2-[2-(Morpholin-4-yl)ethoxy]phenyl]pyrimidin-4-yl]amino]benzoic acid methyl ester **848639-05-4P**, 2-Methoxy-4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]benzoic acid methyl ester **848639-06-5P**, [4-[[6-(2-Benzoyloxyphenyl)pyrimidin-4-yl]amino]phenyl]acetic acid **848639-07-6P**, [6-(2-Methoxyphenyl)pyrimidin-4-yl](3-nitrophenyl)amine **848639-08-7P**, [3-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]methanol **848639-09-8P**, N-[6-(2-Benzoyloxyphenyl)pyrimidin-4-yl]phenylamine **848639-10-1P**, N-[6-(2-Methoxyphenyl)pyrimidin-4-yl]phenylamine **848639-11-2P**, (4-Fluorophenyl)[6-(2-methoxyphenyl)pyrimidin-4-yl]amine **848639-13-4P**, [6-(2-Methoxyphenyl)pyrimidin-4-yl](3-methylsulfonylphenyl)amine **848639-15-6P**, 3-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenol **848639-16-7P**, 1-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]ethanone **848639-17-8P**, 2-Chloro-4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]benzoic acid **848639-19-0P**, [6-(2-Benzoyloxyphenyl)pyrimidin-4-yl](1-methylsulfonyl-2,3-dihydro-1H-indol-6-yl)amine **848639-21-4P**, 4-[6-(2-Aminophenyl)pyrimidin-4-ylamino]benzoic acid methyl ester **848639-22-5P**,


[6-(2-Methoxyphenyl)pyrimidin-4-yl](4-methylsulfonylphenyl)amine
848639-24-7P, 1-[4-[6-(2-Benzyloxyphenyl)pyrimidin-4-yl]amino]phenoxy]-3-dimethylaminopropan-2-ol **848639-25-8P**,
 (1-Methylsulfonyl-2,3-dihydro-1H-indol-6-yl)[6-(2-methoxyphenyl)pyrimidin-4-yl]amine **848639-28-1P**, 1-[3-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]ethanone **848639-29-2P**, [6-(2-Methoxyphenyl)pyrimidin-4-yl][4-(piperidin-1-yl)phenyl]amine
848639-30-5P, 3-Hydroxy-4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]benzoic acid methyl ester **848639-31-6P**,
 2-Hydroxy-4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]benzoic acid methyl ester **848639-32-7P**, 4-Aminobutane-1-sulfonic acid
 N-[5-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]-2-methylphenyl]amide **848639-33-8P**, [3-[6-[3-(4-Aminobutan-1-ylsulfonylamino)-4-methylphenyl]amino]pyrimidin-4-yl]phenyl]carbamic acid
 9H-fluoren-9-ylmethyl ester **848639-34-9P**, 3-Methoxy-4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]benzoic acid methyl ester
848639-35-0P, 4-[6-[2-[2-(Piperidin-1-yl)ethoxy]phenyl]pyrimidin-4-yl]amino]benzoic acid methyl ester **848639-36-1P**,
 4-[6-[2-(2-Dimethylaminoethoxy)phenyl]pyrimidin-4-yl]amino]benzoic acid methyl ester **848639-37-2P**, 4-[6-[2-(2-Diisopropylaminoethoxy)phenyl]pyrimidin-4-yl]amino]benzoic acid methyl ester **848639-38-3P**, 4-[6-[2-(2-Diethylaminoethoxy)phenyl]pyrimidin-4-yl]amino]benzoic acid methyl ester **848639-50-9P**,
 4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]-N-methylbenzenesulfonamide **848639-51-0P**, (1,1-Dioxo-1H-benzo[b]thiophen-6-yl)[6-(2-methoxyphenyl)pyrimidin-4-yl]amine **848639-52-1P**,
 N-Acetyl-4-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]benzenesulfonamide **848639-56-5P**, [6-(2-Fluoro-6-methoxyphenyl)pyrimidin-4-yl](3-methylsulfonylphenyl)amine **848639-57-6P**, [6-(4-Fluoro-2-methoxyphenyl)pyrimidin-4-yl](3-methylsulfonylphenyl)amine
848639-58-7P, [6-(5-Fluoro-2-methoxyphenyl)pyrimidin-4-yl](3-methylsulfonylphenyl)amine **848639-60-1P**, 2-[4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]phenyl]ethanol **848639-62-3P**,
 [6-(2-Methoxyphenyl)pyrimidin-4-yl](1-methyl-1H-indazol-6-yl)amine **848639-66-7P**, [6-(2-Methoxyphenyl)pyrimidin-4-yl][1-[6-(2-methoxyphenyl)pyrimidin-4-yl]-1H-indazol-5-yl]amine **848639-67-8P**,
 (1H-Indol-5-yl)[6-(2-methoxyphenyl)pyrimidin-4-yl]amine **848639-68-9P**, (3-Methylsulfinylphenyl)[6-(2-methoxyphenyl)pyrimidin-4-yl]amine **848639-69-0P**,
 (1H-Indazol-5-yl)[6-(2-methoxyphenyl)pyrimidin-4-yl]amine **848639-74-7P**, 3-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]-N,N-dimethylbenzenesulfonamide **848639-75-8P**, N-Ethyl-3-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]benzenesulfonamide **848639-76-9P**,
 3-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]-N-propylbenzenesulfonamide **848639-77-0P**, [6-(2-Methoxyphenyl)pyrimidin-4-yl](2-methyl-1H-indol-5-yl)amine **848639-78-1P**, N-(2-Methoxyethyl)-3-[6-(2-methoxyphenyl)pyrimidin-4-yl]amino]benzenesulfonamide **848639-79-2P**,
 N-tert-Butyl-3-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]benzenesulfonamide **848639-83-8P**, 5-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]-2-methylbenzenesulfonamide
848639-84-9P, N-(2-Methoxyethyl)-5-[6-(2-methoxyphenyl)pyrimidin-4-yl]amino]-2-methylbenzenesulfonamide **848639-85-0P**,
 N-(2-Hydroxyethyl)-5-[6-(2-methoxyphenyl)pyrimidin-4-yl]amino]-2-methylbenzenesulfonamide **848639-86-1P**, N,N-Diethyl-N'-[6-(2-methoxyphenyl)pyrimidin-4-yl]benzene-1,4-diamine **848639-87-2P**,
 1-(4-Chloro-3-trifluoromethylphenyl)-3-[5-[6-(2-methoxyphenyl)pyrimidin-4-yl]amino]-2-methylphenyl]urea **848639-88-3P**, 1-Cyclohexyl-3-[5-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]-2-methylphenyl]urea

848639-89-4P, [6-(2-Methoxyphenyl)pyrimidin-4-yl][4-(pyrrolidin-1-yl)phenyl]amine **848639-90-7P**, 4-Chloro-N-[6-(2-methoxyphenyl)pyrimidin-4-yl]benzene-1,3-diamine **848639-91-8P**, 1-Isopropyl-3-[5-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]-2-methylphenyl]urea **848639-92-9P**, 1-[5-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]-2-methylphenyl]-3-[2-(morpholin-4-yl)ethyl]urea **848639-93-0P**, 1-(2-Dimethylaminoethyl)-3-[5-[6-(2-methoxyphenyl)pyrimidin-4-yl]amino]-2-methylphenyl]urea **848639-94-1P**, (4-Chloro-3-nitrophenyl)[6-(2-methoxyphenyl)pyrimidin-4-yl]amine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 4,6-disubstituted aminopyrimidines as modulators of protein kinases)


RN 848636-16-8 CAPLUS

CN Methanesulfonamide, N-[5-[[6-(4-methoxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 848636-22-6 CAPLUS

CN 2-Pyrrolidinone, 1-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 848636-23-7 CAPLUS

CN Acetamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 848636-25-9 CAPLUS

CN Methanesulfonamide, N-[5-[[6-(3-aminophenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 848636-27-1 CAPLUS

CN Benzamide, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 848636-32-8 CAPLUS

CN Propanamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 848636-46-4 CAPLUS

CN Methanesulfonamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 848636-50-0 CAPLUS

CN Benzeneacetamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-
α-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 848636-51-1 CAPLUS

CN Urea, N-cyclohexyl-N'-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)




RN 848636-55-5 CAPLUS

CN Butanamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-3,3-
dimethyl- (9CI) (CA INDEX NAME)




RN 848636-59-9 CAPLUS

CN Acetamide, 2-(dimethylamino)-N-[4-[[6-(2-methoxyphenyl)-4-
pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 848636-61-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 2-[2-[[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 848636-66-8 CAPLUS

CN Guanidine, [4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 848636-67-9 CAPLUS

CN Benzamide, N-(1,1-dimethylethyl)-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 848636-72-6 CAPLUS

CN 2-Piperidineacetamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 848636-75-9 CAPLUS

CN 4-Pyrimidinamine, N-[4-(2-benzoxazolyl)phenyl]-6-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 848636-76-0 CAPLUS

CN 4-Pyrimidinamine, N-[4-(1H-benzimidazol-2-yl)phenyl]-6-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 848636-77-1 CAPLUS


CN Propanamide, 3-(diethylamino)-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 848636-84-0 CAPLUS


CN Benzeneacetamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-

(9CI) (CA INDEX NAME)



RN 848636-88-4 CAPLUS


CN Benzoic acid, 3-[6-[[4-[(2,2-dimethyl-1-oxopropyl)amino]phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 848636-94-2 CAPLUS

CN Benzeneacetamide, α -amino-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 848636-95-3 CAPLUS


CN Benzeneacetamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- α -(methylamino)-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 848636-98-6 CAPLUS

CN Propanamide, 2,2-dimethyl-N-[[4-[[6-[2-(phenylmethoxy)phenyl]-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 848637-08-1 CAPLUS

CN Benzamide, 4-[[6-[2-(phenylmethoxy)phenyl]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 848637-13-8 CAPLUS

CN Methanesulfonamide, N-[5-[[6-(3-methoxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 848637-14-9 CAPLUS

CN Benzeneacetamide, α -(dimethylamino)-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


RN 848637-15-0 CAPLUS

CN Propanamide, 3-amino-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 848637-17-2 CAPLUS

CN Acetamide, N-[3-[6-[[4-methyl-3-[(methylsulfonyl)amino]phenyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 848637-18-3 CAPLUS

CN Methanesulfonamide, N-[5-[[6-(3-hydroxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 848637-19-4 CAPLUS

CN Methanesulfonamide, N-[2-methyl-5-[(6-phenyl-4-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 848637-20-7 CAPLUS

CN Methanesulfonamide, N-[2-methyl-5-[[6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 848637-21-8 CAPLUS

CN Methanesulfonamide, N-[3-[6-[[4-methyl-3-[(methylsulfonyl)amino]phenyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 848637-24-1 CAPLUS

CN Urea, N-1,3-benzodioxol-5-yl-N'-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 848637-25-2 CAPLUS

CN Urea, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-N'-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 848637-26-3 CAPLUS

CN Urea, N-(1,1-dimethylethyl)-N'-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 848637-27-4 CAPLUS

CN Propanamide, 2,2-dimethyl-N-[4-[[6-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 848637-28-5 CAPLUS

CN Benzamide, 3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 848637-29-6 CAPLUS

CN 1-Propanesulfonamide, N-[5-[[6-(3-aminophenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 848637-30-9 CAPLUS

CN Benzenesulfonamide, 4-[[6-(3-aminophenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 848637-31-0 CAPLUS


CN Propanamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-2-methyl-2-(methylamino)- (9CI) (CA INDEX NAME)



RN 848637-32-1 CAPLUS


CN Propanamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-3-

methylphenyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 848637-34-3 CAPLUS

CN Methanesulfonamide, N-[3-[[6-(3-aminophenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 848637-35-4 CAPLUS

CN Propanamide, N-[3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 848637-36-5 CAPLUS

CN 1,4-Benzenediamine, N1-[6-(2-methoxyphenyl)-4-pyrimidinyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 848637-37-6 CAPLUS

CN 1,3-Benzenediamine, N-[6-(2-methoxyphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 848637-39-8 CAPLUS

CN Propanamide, N-[4-[[6-(2-ethenylphenyl)-4-pyrimidinyl]amino]phenyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 848637-40-1 CAPLUS

CN Propanamide, N-[4-[[6-(2-fluorophenyl)-4-pyrimidinyl]amino]phenyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 848637-44-5 CAPLUS

CN Propanamide, N-[4-[[6-(2-ethylphenyl)-4-pyrimidinyl]amino]phenyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 848637-45-6 CAPLUS


CN Propanamide, N-[4-[[6-[1,1'-biphenyl]-2-yl]-4-pyrimidinyl]amino]phenyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 848637-52-5 CAPLUS

CN Pentanamide, 2-amino-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-3-methyl-, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 848637-55-8 CAPLUS


CN Butanamide, 2-amino-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]-3-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 848637-58-1 CAPLUS

CN 2-Naphthaleneacetamide, α-amino-N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 848637-62-7 CAPLUS

CN Benzenesulfonamide, 3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (9CI)
(CA INDEX NAME)




RN 848637-64-9 CAPLUS

CN 1,4-Benzenediamine, N-[6-(2-methoxyphenyl)-5-methyl-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 848637-65-0 CAPLUS

CN 2-Propanesulfonamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 848637-66-1 CAPLUS

CN 1-Propanesulfonamide, N-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 848637-68-3 CAPLUS

CN Methanesulfonamide, N-[2-methyl-5-[[6-[2-(phenylmethoxy)phenyl]-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 848637-69-4 CAPLUS

CN Methanesulfonamide, N-[5-[[6-[3-(dimethylamino)phenyl]-4-pyrimidinyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 848637-70-7 CAPLUS

CN Methanesulfonamide, N-[2-methyl-5-[[6-[2-(1-methylethoxy)phenyl]-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 848637-71-8 CAPLUS

CN 1-Propanesulfonamide, N-[4-[[6-(2-methoxyphenyl)-5-methyl-4-pyrimidinyl]amino]phenyl]-N-(propylsulfonyl)- (9CI) (CA INDEX NAME)




RN 848637-72-9 CAPLUS

CN 1-Propanesulfonamide, N-[4-[[6-(2-methoxyphenyl)-5-methyl-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 848637-74-1 CAPLUS

CN Methanesulfonamide, N-[5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 848637-75-2 CAPLUS

CN Methanesulfonamide, N-[5-[[6-(3-cyanophenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 848637-77-4 CAPLUS

CN Methanesulfonamide, N-[5-[[6-(3-formylphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 848637-78-5 CAPLUS

CN Methanesulfonamide, N-[5-[[6-[2-(hydroxymethyl)phenyl]-4-pyrimidinyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 848637-87-6 CAPLUS

CN Methanesulfonamide, N-[5-[[6-[4-(hydroxymethyl)phenyl]-4-pyrimidinyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)



RN 848637-93-4 CAPLUS


CN Methanesulfonamide, N-[5-[[6-(2-hydroxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)



RN 848637-94-5 CAPLUS


CN 2-Propenoic acid, 3-[3-[6-[[4-methyl-3-[(methanesulfonyl)amino]phenyl]amino]-4-pyrimidinyl]phenyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 848637-95-6 CAPLUS

CN Methanesulfonamide, N-[5-[[6-[3-(hydroxymethyl)phenyl]-4-pyrimidinyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 848637-96-7 CAPLUS

CN Benzenesulfonamide, N-butyl-3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 848637-97-8 CAPLUS


CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[3-(methanesulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 848638-09-5 CAPLUS

CN Methanesulfonamide, N-[5-[[6-[2-(methoxymethyl)phenyl]-4-


pyrimidinyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 848638-16-4 CAPLUS

CN 1,4-Benzenediamine, N-[6-(2-methoxyphenyl)-2-methyl-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)

RN 848638-17-5 CAPLUS


CN 1,4-Benzenediamine, N-[6-(4-methoxyphenyl)-2-methyl-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)

RN 848638-26-6 CAPLUS

CN Benzenesulfonamide, 3-[[6-(3-aminophenyl)-4-pyrimidinyl]amino]- (9CI) (CA
INDEX NAME)


RN 848638-27-7 CAPLUS

CN Benzenesulfonamide, 3-[[6-(4-methoxyphenyl)-4-pyrimidinyl]amino]- (9CI)
(CA INDEX NAME)




RN 848638-29-9 CAPLUS

CN Benzamide, N-[2-(diethylamino)ethyl]-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 848638-47-1 CAPLUS

CN Benzenesulfonamide, 2-chloro-5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 848638-49-3 CAPLUS

CN Benzenesulfonamide, 3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 848638-50-6 CAPLUS

CN Benzenesulfonamide, 3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 848638-53-9 CAPLUS

CN Benzenesulfonamide, 3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N-methyl- (9CI) (CA INDEX NAME)




RN 848638-54-0 CAPLUS

CN Acetamide, N-[3-(aminosulfonyl)phenyl]-N-[6-(2-methoxyphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 848638-55-1 CAPLUS

CN Benzenesulfonamide, 3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N,N-di-2-propenyl- (9CI) (CA INDEX NAME)




RN 848638-56-2 CAPLUS

CN Benzenesulfonamide, 3-[[6-[2-(phenylmethoxy)phenyl]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 848638-58-4 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[4-[(trifluoromethyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 848638-59-5 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 848638-61-9 CAPLUS

CN Benzenesulfonamide, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N-propyl- (9CI) (CA INDEX NAME)




RN 848638-62-0 CAPLUS


CN Benzenesulfonamide, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 848638-63-1 CAPLUS
 CN Benzenesulfonamide, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 848638-64-2 CAPLUS
 CN Benzenesulfonamide, N-(2-methoxyethyl)-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 848638-65-3 CAPLUS
 CN 4-Pyrimidinamine, N-[3-(methanesulfonyl)phenyl]-6-[2-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 848638-66-4 CAPLUS
 CN Phenol, 2-[6-[[3-(methanesulfonyl)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 848638-67-5 CAPLUS

CN 4-Pyrimidinamine, 6-(3-aminophenyl)-N-[3-(methylsulfonyl)phenyl]- (9CI)
(CA INDEX NAME)




RN 848638-68-6 CAPLUS

CN Benzenesulfonic acid, 5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 848638-69-7 CAPLUS

CN Ethanol, 2-[[3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 848638-70-0 CAPLUS


CN 4-Pyrimidinamine, N-[2-fluoro-5-(methylsulfonyl)phenyl]-6-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 848638-71-1 CAPLUS

CN 4-Pyrimidinamine, 6-(2-aminophenyl)-N-[3-(methylsulfonyl)phenyl]- (9CI)
(CA INDEX NAME)

RN 848638-72-2 CAPLUS


CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[3-[(trifluoromethyl)sulfonyl]phenyl]- (9CI)
(CA INDEX NAME)

RN 848638-73-3 CAPLUS

CN 4-Pyrimidinamine, N-[3-(methylsulfonyl)phenyl]-6-(2-phenoxyphenyl)- (9CI)
(CA INDEX NAME)


RN 848638-74-4 CAPLUS

CN 4-Pyrimidinamine, 6-(2-butoxyphenyl)-N-[3-(methylsulfonyl)phenyl]- (9CI)
(CA INDEX NAME)




RN 848638-75-5 CAPLUS

CN 4-Pyrimidinamine, N-[3-(ethenylsulfonyl)phenyl]-6-(2-methoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 848638-77-7 CAPLUS

CN Benzoic acid, 2-chloro-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 848638-79-9 CAPLUS

CN Benzoic acid, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-3-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 848638-80-2 CAPLUS

CN 1H-Indol-6-amine, N-[6-(3-aminophenyl)-4-pyrimidinyl]-2,3-dihydro-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 848638-82-4 CAPLUS

CN Benzeneacetic acid, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (9CI)
(CA INDEX NAME)




RN 848638-83-5 CAPLUS

CN 1H-Indazol-6-amine, N-[6-(2-methoxyphenyl)-4-pyrimidinyl]- (9CI) (CA
INDEX NAME)




RN 848638-84-6 CAPLUS

CN 1-Butanone, 1-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI)
(CA INDEX NAME)




RN 848638-88-0 CAPLUS

CN 4-Pyrimidinamine, N-[3-(1,3-dioxan-2-yl)phenyl]-6-(2-methoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 848638-89-1 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 848638-90-4 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 848638-92-6 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 848638-93-7 CAPLUS

CN 4-Pyrimidinamine, N-(2-fluorophenyl)-6-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 848638-95-9 CAPLUS

CN 4-Pyrimidinamine, N-(4-butylphenyl)-6-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 848638-98-2 CAPLUS

CN 2-Propanol, 1-(dimethylamino)-3-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 848638-99-3 CAPLUS

CN 1,4-Benzenediamine, N-[6-(4-methoxyphenyl)-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 848639-00-9 CAPLUS

CN 1,4-Benzenediamine, N-[6-(3-aminophenyl)-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 848639-04-3 CAPLUS

CN Benzoic acid, 4-[[6-[2-[2-(4-morpholinyl)ethoxy]phenyl]-4-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 848639-05-4 CAPLUS

CN Benzoic acid, 2-methoxy-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 848639-06-5 CAPLUS

CN Benzeneacetic acid, 4-[[6-[2-(phenylmethoxy)phenyl]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 848639-07-6 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 848639-08-7 CAPLUS

CN Benzenemethanol, 3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 848639-09-8 CAPLUS

CN 4-Pyrimidinamine, N-phenyl-6-[2-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 848639-10-1 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 848639-11-2 CAPLUS

CN 4-Pyrimidinamine, N-(4-fluorophenyl)-6-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 848639-13-4 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[3-(methythio)phenyl]- (9CI) (CA INDEX NAME)




RN 848639-15-6 CAPLUS

CN Phenol, 3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 848639-16-7 CAPLUS

CN Ethanone, 1-[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 848639-17-8 CAPLUS


CN Benzoic acid, 2-chloro-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 848639-19-0 CAPLUS
 CN 1H-Indol-6-amine, 2,3-dihydro-1-(methylsulfonyl)-N-[6-[2-(phenylmethoxy)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 848639-21-4 CAPLUS
 CN Benzoic acid, 4-[[6-(2-aminophenyl)-4-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 848639-22-5 CAPLUS
 CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 848639-24-7 CAPLUS
 CN 2-Propanol, 1-(dimethylamino)-3-[4-[[6-[2-(phenylmethoxy)phenyl]-4-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 848639-25-8 CAPLUS

CN 1H-Indol-6-amine, 2,3-dihydro-N-[6-(2-methoxyphenyl)-4-pyrimidinyl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 848639-28-1 CAPLUS

CN Ethanone, 1-[3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 848639-29-2 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[4-(1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 848639-30-5 CAPLUS

CN Benzoic acid, 3-hydroxy-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 848639-31-6 CAPLUS

CN Benzoic acid, 2-hydroxy-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 848639-32-7 CAPLUS

CN 1-Butanesulfonamide, 4-amino-N-[5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 848639-33-8 CAPLUS

CN Carbamic acid, [3-[6-[[3-[[4-(aminobutyl)sulfonyl]amino]-4-methylphenyl]amino]-4-pyrimidinyl]phenyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)




RN 848639-34-9 CAPLUS

CN Benzoic acid, 3-methoxy-4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 848639-35-0 CAPLUS

CN Benzoic acid, 4-[[6-[2-[2-(1-piperidinyl)ethoxy]phenyl]-4-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 848639-36-1 CAPLUS

CN Benzoic acid, 4-[[6-[2-[2-(dimethylamino)ethoxy]phenyl]-4-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 848639-37-2 CAPLUS

CN Benzoic acid, 4-[[6-[2-[2-bis(1-methylethyl)amino]ethoxy]phenyl]-4-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 848639-38-3 CAPLUS


CN Benzoic acid, 4-[[6-[2-[2-(diethylamino)ethoxy]phenyl]-4-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 848639-50-9 CAPLUS

CN Benzenesulfonamide, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N-methyl-
(9CI) (CA INDEX NAME)

RN 848639-51-0 CAPLUS


CN 4-Pyrimidinamine, N-(1,1-dioxidobenzo[b]thien-6-yl)-6-(2-methoxyphenyl)-
(9CI) (CA INDEX NAME)

RN 848639-52-1 CAPLUS

CN Acetamide, N-[[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]sulfonyl]-
(9CI) (CA INDEX NAME)


RN 848639-56-5 CAPLUS

CN 4-Pyrimidinamine, 6-(2-fluoro-6-methoxyphenyl)-N-[3-(methylsulfonyl)phenyl]-
(9CI) (CA INDEX NAME)




RN 848639-57-6 CAPLUS

CN 4-Pyrimidinamine, 6-(4-fluoro-2-methoxyphenyl)-N-[3-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 848639-58-7 CAPLUS

CN 4-Pyrimidinamine, 6-(5-fluoro-2-methoxyphenyl)-N-[3-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 848639-60-1 CAPLUS

CN Benzeneethanol, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 848639-62-3 CAPLUS

CN 1H-Indazol-6-amine, N-[6-(2-methoxyphenyl)-4-pyrimidinyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 848639-66-7 CAPLUS

CN 1H-Indazol-5-amine, N,1-bis[6-(2-methoxyphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 848639-67-8 CAPLUS

CN 1H-Indol-5-amine, N-[6-(2-methoxyphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 848639-68-9 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[3-(methylsulfinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 848639-69-0 CAPLUS

CN 1H-Indazol-5-amine, N-[6-(2-methoxyphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 848639-74-7 CAPLUS

CN Benzenesulfonamide, 3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 848639-75-8 CAPLUS

CN Benzenesulfonamide, N-ethyl-3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 848639-76-9 CAPLUS

CN Benzenesulfonamide, 3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-N-propyl- (9CI) (CA INDEX NAME)




RN 848639-77-0 CAPLUS

CN 1H-Indol-5-amine, N-[6-(2-methoxyphenyl)-4-pyrimidinyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 848639-78-1 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 848639-79-2 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 848639-83-8 CAPLUS

CN Benzenesulfonamide, 5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 848639-84-9 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 848639-85-0 CAPLUS

CN Benzenesulfonamide, N-(2-hydroxyethyl)-5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 848639-86-1 CAPLUS

CN 1,4-Benzenediamine, N,N-diethyl-N'-[6-(2-methoxyphenyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 848639-87-2 CAPLUS


CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 848639-88-3 CAPLUS

CN Urea, N-cyclohexyl-N'-[5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-


methylphenyl]- (9CI) (CA INDEX NAME)



RN 848639-89-4 CAPLUS


CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[4-(1-pyrrolidinyl)phenyl]- (9CI)
(CA INDEX NAME)

RN 848639-90-7 CAPLUS

CN 1,3-Benzenediamine, 4-chloro-N1-[6-(2-methoxyphenyl)-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)


RN 848639-91-8 CAPLUS

CN Urea, N-[5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 848639-92-9 CAPLUS

CN Urea, N-[5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]-N'-(2-(4-morpholinyl)ethyl)- (9CI) (CA INDEX NAME)




RN 848639-93-0 CAPLUS

CN Urea, N-[2-(dimethylamino)ethyl]-N'-[5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)



RN 848639-94-1 CAPLUS

CN 4-Pyrimidinamine, N-(4-chloro-3-nitrophenyl)-6-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




IT **848640-00-6P**, 4-(1,3-Dioxo-1,3-dihydroisoindol-2-yl)butane-1-sulfonic acid N-[5-[6-(2-methoxyphenyl)pyrimidin-4-ylamino]-2-methylphenyl]amide **848640-01-7P**, [3-[6-[[3-[[4-(1,3-Dioxo-1,3-dihydroisoindol-2-yl)butan-1-ylsulfonyl]amino]-4-methylphenyl]amino]pyrimidin-4-yl]phenyl]carbamic acid 9H-fluoren-9-ylmethyl ester

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of 4,6-disubstituted aminopyrimidines as modulators of protein kinases)


RN 848640-00-6 CAPLUS

CN 2H-Isoindole-2-butanefulfonamide, 1,3-dihydro-N-[5-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-2-methylphenyl]-1,3-dioxo- (9CI) (CA INDEX NAME)



RN 848640-01-7 CAPLUS

CN Carbamic acid, [3-[6-[[3-[[[4-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)butyl]sulfonyl]amino]-4-methylphenyl]amino]-4-pyrimidinyl]phenyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)




IT **848639-98-5**, 4-[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]benzoic acid **848640-02-8**, N-[6-(2-Methoxyphenyl)pyrimidin-4-yl]-4-methylbenzene-1,3-diamine **848640-03-9**, [3-[6-(3-Amino-4-methylphenylamino)pyrimidin-4-yl]phenyl]carbamic acid 9H-fluoren-9-ylmethyl ester

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 4,6-disubstituted aminopyrimidines as modulators of protein kinases)

RN 848639-98-5 CAPLUS


CN Benzoic acid, 4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 848640-02-8 CAPLUS


CN 1,3-Benzenediamine, N1-[6-(2-methoxyphenyl)-4-pyrimidinyl]-4-methyl- (9CI)

(CA INDEX NAME)



RN 848640-03-9 CAPLUS

CN Carbamic acid, [3-[6-[(3-amino-4-methylphenyl)amino]-4-pyrimidinyl]phenyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)




IT 848639-99-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 4,6-disubstituted aminopyrimidines as modulators of protein kinases)

RN 848639-99-6 CAPLUS

CN Carbamic acid, [[4-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 13 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:99484 CAPLUS
 DN 142:198089
 TI Preparation of azinyl aryl amines as vanilloid receptor ligands.
 IN Blum, Charles A.; Briellmann, Harry; Hodgetts, Kevin J.
 PA Neurogen Corporation, USA
 SO PCT Int. Appl., 89 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005009977	A1	20050203	WO 2004-US22820	20040715
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

AU	2004259712	A1	20050203	AU 2004-259712	20040715
CA	2531490	AA	20050203	CA 2004-2531490	20040715
EP	1651619	A1	20060503	EP 2004-778364	20040715

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

PRAI US 2003-487405P P 20030715 ←
 WO 2004-US22820 W 20040715

OS MARPAT 142:198089


AB Title compds. [I; X = CRx, N; Rx = H, halo, NO₂, alkyl, amino, cyano, alkylsulfonyl, (di)alkylsulfonamido, (di)alkylamino; A1 = CH, N; A2-A4 = CH, CRa, N; ≤2 of A1-A4 = N; B1, B5 = CH, N; B2-B4 = CH, CRb; ≥1 of B2-B4 = CRb; Ra, Rb = halo, OH, amino, cyano, CO₂H, alkyl, cycloalkyl, alkoxy, alkoxy, alkanoyl, haloalkyl, haloalkoxy, (di)alkylamino, alkylsulfonyl, etc.; R2 = alkyl, cycloalkyl, haloalkyl, alkylsulfonyl; R3 = cyano, alkyl, LNR5R6, MOR7; L, M = bond, alkylene; R5, R6 = H, alkyl, alkenyl, cycloalkyl, etc.; R7 = H, alkyl, alkenyl, cycloalkyl, alkanoyl, etc.], were prepared Thus, [4-(tert-butyl)phenyl][6-(3-methoxyphenyl)pyrimidin-4-yl]amine was prepared in 2 steps from 4,6-dichloropyrimidine, 3-methoxyphenylboronic acid, and 4-tert-butylaniline. In a capsaicin receptor binding assay, I showed Ki values of <1 μM.

IT 667896-55-1P 837382-71-5P 837382-73-7P
 837382-76-0P 837382-77-1P 837382-78-2P
 837382-79-3P 837382-81-7P 837382-82-8P
 837382-83-9P 837382-84-0P 837382-85-1P
 837382-86-2P 837382-87-3P 837382-88-4P
 837382-89-5P 837382-90-8P 837382-91-9P
 837382-92-0P 837382-93-1P 837382-94-2P
 837382-95-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of azinyl aryl amines as vanilloid receptor ligands)

RN 667896-55-1 CAPLUS

CN 4-Pyrimidinamine, 6-(3,4-dimethoxyphenyl)-N-[4-(1,1-dimethylethyl)phenyl]-
(9CI) (CA INDEX NAME)


RN 837382-71-5 CAPLUS

CN 4-Pyrimidinamine, N-[4-(1,1-dimethylethyl)phenyl]-6-(3-methoxyphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 837382-73-7 CAPLUS

CN 4-Pyrimidinamine, 6-(3-methoxyphenyl)-2,5-dimethyl-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 837382-76-0 CAPLUS

CN Phenol, 2-[[6-(3-methoxyphenyl)-5-nitro-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 837382-77-1 CAPLUS

CN Phenol, 2-[[6-(3-methoxyphenyl)-5-nitro-4-pyrimidinyl]amino]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 837382-78-2 CAPLUS

CN 4-Pyrimidinamine, N-[4-(1,1-dimethylethyl)phenyl]-5-ethyl-6-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 837382-79-3 CAPLUS

CN 4-Pyrimidinamine, N-[4-(1,1-dimethylethyl)phenyl]-6-(3-methoxyphenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 837382-81-7 CAPLUS

CN 4-Pyrimidinamine, 5-ethyl-6-(3-methoxyphenyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 837382-82-8 CAPLUS

CN 4,5-Pyrimidinediamine, 6-(3-methoxyphenyl)-N4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 837382-83-9 CAPLUS

CN 4,5-Pyrimidinediamine, N4-(4-cyclohexylphenyl)-6-(3-methoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 837382-84-0 CAPLUS

CN 4,5-Pyrimidinediamine, N4-[4-(1,1-dimethylethyl)phenyl]-6-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 837382-85-1 CAPLUS

CN 4-Pyrimidinamine, N-[4-(1,1-dimethylethyl)phenyl]-6-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 837382-86-2 CAPLUS

CN 4-Pyrimidinamine, N-[4-(1,1-dimethylethyl)phenyl]-6-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 837382-87-3 CAPLUS

CN 4-Pyrimidinamine, N-[4-(1,1-dimethylethyl)phenyl]-6-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 837382-88-4 CAPLUS

CN 4-Pyrimidinamine, N-[4-(1,1-dimethylethyl)phenyl]-6-(3-ethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 837382-89-5 CAPLUS

CN 4-Pyrimidinamine, N-[4-(1,1-dimethylethyl)phenyl]-6-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 837382-90-8 CAPLUS

CN 4-Pyrimidinamine, N-[4-(1,1-dimethylethyl)phenyl]-6-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 837382-91-9 CAPLUS

CN 4-Pyrimidinamine, N-[4-(1,1-dimethylethyl)phenyl]-6-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 837382-92-0 CAPLUS

CN 4-Pyrimidinamine, 6-(4-chlorophenyl)-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 837382-93-1 CAPLUS

CN 4-Pyrimidinamine, N-[4-(1,1-dimethylethyl)phenyl]-6-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 837382-94-2 CAPLUS

CN 4-Pyrimidinamine, N-[4-(1,1-dimethylethyl)phenyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 837382-95-3 CAPLUS

CN 4-Pyrimidinamine, N-[3-bromo-4-(trifluoromethyl)phenyl]-6-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 26 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:851122 CAPLUS

DN 135:371759

TI Preparation of N-imidazolylphenyl-5,6-dihydrobenzo[h]quinazolin-4-amines and other N-containing heterocyclic amines as 5-hydroxytryptamine antagonists for treatment of CNS disorders

IN Yamada, Akira; Spears, Glen; Hayashida, Hisashi; Tomishima, Masaki; Ito, Kiyotaka; Imanishi, Masashi

PA Fujisawa Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 154 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001087845	A2	20011122	WO 2001-JP4002	20010514
	WO 2001087845	A3	20020829		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 2001056728	A5	20011126	AU 2001-56728	20010514
	US 2003176454	A1	20030918	US 2002-258582	20021101
PRAI	AU 2000-7501	A	20000515		
	AU 2000-1955	A	20001207		
	WO 2001-JP4002	W	20010514		

OS MARPAT 135:371759

AB Title compds. AMQNHZ [I; wherein A = H, (un)substituted, unsatd., N-containing heterocyclic group, or C(NH)NHR; R = (un)substituted aryl or heterocyclic group; M = (CH₂)_n, (CH₂)_nO(CH₂)_m, or (CH₂)_nNH(CH₂)_m; n and m = independently 0-2; Q = (un)substituted cycloalkylene group, arylene, or divalent heterocyclic group; Z = (un)substituted, unsatd., mono-, di-, tri-, or tetra-cyclic, N-containing heterocyclic group which may contain addnl. N, O, and S atoms as the ring member(s), e.g. indeno[1,2,3-de]phthalazinyl or 5,6-dihydrobenzo[h]quinazolinyl; and the prodrugs or pharmaceutically acceptable salts thereof] were prepared. For example, a mixture of 4-chloro-5,6-dihydrobenzo[h]quinazoline, 3-(1,2-dimethyl-1H-imidazol-5-yl)aniline, and 1,3-dimethyl-2-imidazolidinone was heated for an hour at 200°C, cooled, treated with 1N aqueous NaOH and water, and worked up to give II. I are 5-hydroxytryptamine (5-HT) antagonists useful for the prevention and/or treatment of central nervous system (CNS) disorders, such as anxiety, depression, obsessive compulsive disorders, migraine, anorexia, Alzheimer's disease, sleep disorders, bulimia, panic attacks, withdrawal from drug abuse, schizophrenia, and disorders associated with spinal trauma and/or head injury (no data).

IT **374556-01-1P**, [3-(2,3-Dimethyl-3H-imidazol-4-yl)phenyl] (6-phenylpyrimidin-4-yl)amine


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-(imidazolylphenyl)dihydrobenzo[h]quinazolinamines and other N-containing heterocyclic amines as 5-hydroxytryptamine antagonists


for treatment of CNS disorders)

RN 374556-01-1 CAPLUS

CN 4-Pyrimidinamine, N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-6-phenyl-
(9CI) (CA INDEX NAME)



L12 ANSWER 27 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:729784 CAPLUS
DN 132:308303
TI Synthesis and preliminary study of anticonvulsive activity of
4-substituted amino-6-phenylpyrimidines
AU Zhang, Xiaohui; Wang, Donghui; Chen, Naiyong; Tao, Cheng
CS Institute of Applied Pharmacy Science, Beijing Medical Univ., Beijing,
100083, Peop. Rep. China
SO Zhongguo Yaowu Huaxue Zazhi (1999), 9(3), 192-195
CODEN: ZYHZEJ; ISSN: 1005-0108
PB Zhongguo Yaowu Huaxue Zazhi Bianjibu
DT Journal
LA Chinese
AB Seven 4-substituted amino-6-phenylpyrimidines were designed and
synthesized, and their anticonvulsive activities were studied. All the
synthetic compds. showed some anticonvulsive activity,
4-benzylamino-6-phenylpyrimidine showed strong effects, even stronger than
dilatant sodium. Structure-activity relationship was discussed.
IT **266303-85-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); BIOL (Biological
study); PREP (Preparation)
(synthesis and anticonvulsant activity of 4-substituted
amino-6-phenylpyrimidines)
RN 266303-85-9 CAPLUS
CN 4-Pyrimidinamine, N,6-diphenyl- (9CI) (CA INDEX NAME)



L12 ANSWER 30 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1998:197493 CAPLUS
 DN 128:217383
 TI Preparation of pyrimidine compounds as pesticides
 IN Hamamoto, Isami; Ishimitsu, Keiichi; Ihori, Yoichi; Takahashi, Hidemitsu;
 Nakamura, Takehiko; Iwasa, Takao
 PA Nippon Soda Co., Ltd., Japan
 SO PCT Int. Appl., 55 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9812184	A1	19980326	WO 1997-JP3292	19970918
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9742217	A1	19980414	AU 1997-42217	19970918
PRAI	JP 1996-269309	A	19960919		
	JP 1996-356867	A	19961226		
	WO 1997-JP3292	W	19970918		

OS MARPAT 128:217383

AB The title compds. (I; R1-R5, R8-R12 = H, halo, C1-6 alkyl, haloalkyl, alkoxy, alkylthio, or haloalkoxy, etc.; R6, R7 = H, halo, C1-6 alkyl or haloalkyl; R13 = H, optionally substituted C1-6 alkyl, C2-6 alkenyl, or alkynyl, optionally substituted carbamoyl, etc.) are prepared I are useful as pesticides. Thus, 4-chloro-6-(4-fluoro-3-trifluoromethylphenoxy)pyrimidine (preparation given) was reacted with 4-fluoro-3-trifluoromethylaniline in the presence of Et3N to give 67% the title compound (II). II at 125 ppm showed 100% insecticidal effect for Pseudaletia separata after 6 days.


IT 204121-08-4P 204121-09-5P 204121-10-8P
 204121-11-9P 204121-12-0P 204121-13-1P
 204121-14-2P 204121-15-3P 204121-16-4P
 204121-18-6P 204121-19-7P 204121-20-0P
 204121-21-1P 204121-22-2P 204121-24-4P
 204121-25-5P 204121-26-6P 204121-27-7P
 204121-28-8P 204121-29-9P 204121-30-2P
 204121-31-3P 204121-32-4P 204121-33-5P
 204121-34-6P 204121-35-7P 204121-36-8P
 204121-37-9P 204121-38-0P 204121-39-1P
 204121-40-4P 204121-41-5P 204121-42-6P
 204121-43-7P 204121-44-8P 204121-45-9P
 204121-46-0P 204121-47-1P 204121-48-2P
 204121-49-3P 204121-50-6P 204121-52-8P
 204121-53-9P 204121-54-0P 204121-55-1P
 204121-56-2P 204121-57-3P 204121-58-4P
 204121-59-5P 204121-60-8P 204121-61-9P
 204121-62-0P 204121-63-1P 204121-64-2P
 204121-65-3P 204121-66-4P 204121-67-5P
 204121-68-6P 204121-69-7P 204121-70-0P
 204121-71-1P 204121-72-2P 204121-73-3P
 204121-74-4P 204121-75-5P 204121-76-6P

204121-79-9P 204121-80-2P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidine compds. as pesticides)


RN 204121-08-4 CAPLUS

CN 4-Pyrimidinamine, 6-[4-fluoro-3-(trifluoromethyl)phenyl]-N-phenyl- (9CI)
(CA INDEX NAME)




RN 204121-09-5 CAPLUS

CN 4-Pyrimidinamine, 6-[4-fluoro-3-(trifluoromethyl)phenyl]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204121-10-8 CAPLUS

CN 4-Pyrimidinamine, 6-[4-fluoro-3-(trifluoromethyl)phenyl]-N-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 204121-11-9 CAPLUS

CN 4-Pyrimidinamine, 6-[4-fluoro-3-(trifluoromethyl)phenyl]-N-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 204121-12-0 CAPLUS

CN 4-Pyrimidinamine, N-(4-fluorophenyl)-6-[4-fluoro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204121-13-1 CAPLUS

CN 4-Pyrimidinamine, N-[4-(1,1-dimethylethyl)phenyl]-6-[4-fluoro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204121-14-2 CAPLUS

CN 4-Pyrimidinamine, 6-[4-fluoro-3-(trifluoromethyl)phenyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 204121-15-3 CAPLUS

CN 4-Pyrimidinamine, 6-[4-fluoro-3-(trifluoromethyl)phenyl]-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 204121-16-4 CAPLUS


CN 4-Pyrimidinamine, N,6-bis[4-fluoro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 204121-18-6 CAPLUS


CN 4-Pyrimidinamine, N-[4-chloro-3-(trifluoromethyl)phenyl]-6-[4-fluoro-3-

(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204121-19-7 CAPLUS

CN 4-Pyrimidinamine, 6-[4-fluoro-3-(trifluoromethyl)phenyl]-N-methyl-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204121-20-0 CAPLUS

CN 4-Pyrimidinamine, N,6-bis[4-fluoro-3-(trifluoromethyl)phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 204121-21-1 CAPLUS

CN 4-Pyrimidinamine, 6-[4-fluoro-3-(trifluoromethyl)phenyl]-N-methyl-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204121-22-2 CAPLUS

CN 4-Pyrimidinamine, N-[4-chloro-3-(trifluoromethyl)phenyl]-6-[4-fluoro-3-(trifluoromethyl)phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 204121-24-4 CAPLUS

CN Acetamide, N-[4-fluoro-3-(trifluoromethyl)phenyl]-N-[6-[4-fluoro-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 204121-25-5 CAPLUS

CN Methanesulfonamide, N-[4-fluoro-3-(trifluoromethyl)phenyl]-N-[6-[4-fluoro-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)





RN 204121-26-6 CAPLUS

CN Acetamide, N-[6-[4-fluoro-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204121-27-7 CAPLUS

CN 4-Pyrimidinamine, N,6-bis[4-fluoro-3-(trifluoromethyl)phenyl]-N-(methoxymethyl)- (9CI) (CA INDEX NAME)




RN 204121-28-8 CAPLUS

CN 4-Pyrimidinamine, N-(4-chlorophenyl)-6-[4-fluoro-3-(trifluoromethyl)phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 204121-29-9 CAPLUS

CN 4-Pyrimidinamine, N,6-bis[4-fluoro-3-(trifluoromethyl)phenyl]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 204121-30-2 CAPLUS

CN Urea, N-[4-fluoro-3-(trifluoromethyl)phenyl]-N-[6-[4-fluoro-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-N',N'-dimethyl- (9CI) (CA INDEX NAME)




RN 204121-31-3 CAPLUS

CN 4-Pyrimidinamine, N,6-bis[4-fluoro-3-(trifluoromethyl)phenyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)





RN 204121-32-4 CAPLUS

CN Propanamide, N-[4-fluoro-3-(trifluoromethyl)phenyl]-N-[6-[4-fluoro-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 204121-33-5 CAPLUS

CN Propanamide, N-[4-fluoro-3-(trifluoromethyl)phenyl]-N-[6-[4-fluoro-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 204121-34-6 CAPLUS


CN Benzamide, 4-chloro-N-[4-fluoro-3-(trifluoromethyl)phenyl]-N-[6-[4-fluoro-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 204121-35-7 CAPLUS

CN 4-Pyrimidinamine, N-ethyl-N,6-bis[4-fluoro-3-(trifluoromethyl)phenyl]-
(9CI) (CA INDEX NAME)

RN 204121-36-8 CAPLUS


CN 4-Pyrimidinamine, N,6-bis[4-fluoro-3-(trifluoromethyl)phenyl]-N-propyl-
(9CI) (CA INDEX NAME)

RN 204121-37-9 CAPLUS


CN 4-Pyrimidinamine, N,6-bis[4-fluoro-3-(trifluoromethyl)phenyl]-N-hexyl-
(9CI) (CA INDEX NAME)

RN 204121-38-0 CAPLUS


CN 4-Pyrimidinamine, N,6-bis[4-fluoro-3-(trifluoromethyl)phenyl]-N-2-propynyl-
(9CI) (CA INDEX NAME)





RN 204121-39-1 CAPLUS
 CN 4-Pyrimidinamine, N-(4,4-difluoro-2,3-butadienyl)-N,6-bis[4-fluoro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)





RN 204121-40-4 CAPLUS
 CN 4-Pyrimidinamine, N-[(4-chlorophenyl)methyl]-N,6-bis[4-fluoro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)





RN 204121-41-5 CAPLUS
 CN 4-Pyrimidinamine, N-(ethoxymethyl)-N,6-bis[4-fluoro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 204121-42-6 CAPLUS
 CN Acetonitrile, [[4-fluoro-3-(trifluoromethyl)phenyl][6-[4-fluoro-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 204121-43-7 CAPLUS
 CN 4-Pyrimidinamine, N,6-bis[4-fluoro-3-(trifluoromethyl)phenyl]-N-[(trimethylsilyl)methyl]- (9CI) (CA INDEX NAME)




RN 204121-44-8 CAPLUS

CN Glycine, N-[4-fluoro-3-(trifluoromethyl)phenyl]-N-[6-[4-fluoro-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)




RN 204121-45-9 CAPLUS

2-Propanone, 1-[[[4-fluoro-3-(trifluoromethyl)phenyl][6-[4-fluoro-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]-(9CI) (CA INDEX NAME)





RN 204121-46-0 CAPLUS

CN 4-Pyrimidinamine, N,6-bis[4-fluoro-3-(trifluoromethyl)phenyl]-N-
[(tetrahydro-3-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 204121-47-1 CAPLUS

CN Butanamide, N-[4-fluoro-3-(trifluoromethyl)phenyl]-N-[6-[4-fluoro-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 204121-48-2 CAPLUS

CN Cyclopropanecarboxamide, N-[4-fluoro-3-(trifluoromethyl)phenyl]-N-[6-[4-fluoro-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 204121-49-3 CAPLUS

CN 4-Pyrimidinamine, 6-[4-chloro-3-(trifluoromethyl)phenyl]-N-[4-fluoro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204121-50-6 CAPLUS

CN 4-Pyrimidinamine, N-[4-fluoro-3-(trifluoromethyl)phenyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204121-52-8 CAPLUS

CN Acetamide, N-[4-fluoro-3-(trifluoromethyl)phenyl]-N-[6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 204121-53-9 CAPLUS

CN 4-Pyrimidinamine, N-[4-fluoro-3-(trifluoromethyl)phenyl]-N-methyl-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204121-54-0 CAPLUS

CN 4-Pyrimidinamine, N-[4-fluoro-3-(trifluoromethyl)phenyl]-6-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204121-55-1 CAPLUS

CN 4-Pyrimidinamine, 6-[3,5-bis(trifluoromethyl)phenyl]-N-[4-fluoro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204121-56-2 CAPLUS

CN 4-Pyrimidinamine, 6-[3,5-bis(trifluoromethyl)phenyl]-N-[4-fluoro-3-(trifluoromethyl)phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 204121-57-3 CAPLUS

CN Acetamide, N-[6-[3,5-bis(trifluoromethyl)phenyl]-4-pyrimidinyl]-N-[4-fluoro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204121-58-4 CAPLUS

CN 4-Pyrimidinamine, 6-[3-fluoro-5-(trifluoromethyl)phenyl]-N-[4-fluoro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204121-59-5 CAPLUS

CN 4-Pyrimidinamine, 6-(3,4-dichlorophenyl)-N-[4-fluoro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204121-60-8 CAPLUS

CN 4-Pyrimidinamine, 6-(3,5-dichlorophenyl)-N-[4-fluoro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204121-61-9 CAPLUS

CN 4-Pyrimidinamine, 6-(4-chloro-3-methylphenyl)-N-[4-fluoro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204121-62-0 CAPLUS

CN 4-Pyrimidinamine, 6-(4-chloro-3-nitrophenyl)-N-[4-fluoro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204121-63-1 CAPLUS

CN 4-Pyrimidinamine, 6-(4-fluorophenyl)-N-[4-fluoro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204121-64-2 CAPLUS

CN 4-Pyrimidinamine, N-[4-fluoro-3-(trifluoromethyl)phenyl]-6-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 204121-65-3 CAPLUS


CN 4-Pyrimidinamine, N-[4-fluoro-3-(trifluoromethyl)phenyl]-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 204121-66-4 CAPLUS


CN Benzonitrile, 4-[6-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-4-

pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 204121-67-5 CAPLUS

CN Benzonitrile, 3-[6-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 204121-68-6 CAPLUS

CN 4-Pyrimidinamine, N-[4-fluoro-3-(trifluoromethyl)phenyl]-6-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 204121-69-7 CAPLUS

CN 4-Pyrimidinamine, N-[4-fluoro-3-(trifluoromethyl)phenyl]-6-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 204121-70-0 CAPLUS

CN 4-Pyrimidinamine, 6-[3-(1,1-dimethylethyl)phenyl]-N-[4-fluoro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204121-71-1 CAPLUS

CN 4-Pyrimidinamine, 6-[4-(1,1-dimethylethyl)phenyl]-N-[4-fluoro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204121-72-2 CAPLUS

CN 4-Pyrimidinamine, N-[4-fluoro-3-(trifluoromethyl)phenyl]-6-[4-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 204121-73-3 CAPLUS

CN 4-Pyrimidinamine, N-[4-fluoro-3-(trifluoromethyl)phenyl]-6-[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 204121-74-4 CAPLUS

CN 4-Pyrimidinamine, 6-(3-aminophenyl)-N-[4-fluoro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204121-75-5 CAPLUS

CN 4-Pyrimidinamine, 6-[1,1'-biphenyl]-3-yl-N-[4-fluoro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204121-76-6 CAPLUS

CN 4-Pyrimidinamine, N-[4-fluoro-3-(trifluoromethyl)phenyl]-N-methyl-6-[3-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 204121-79-9 CAPLUS

CN 4-Pyrimidinamine, 6-(4-chloro-3-methylphenyl)-N-[4-fluoro-3-(trifluoromethyl)phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 204121-80-2 CAPLUS

CN 3-Cyclohexene-1-carbonitrile, 4-[4-[6-[[4-fluoro-3-(trifluoromethyl)phenyl]methylamino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)



L12 ANSWER 31 OF 48 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1997:772646 CAPLUS

DN 128:34777

TI Preparation of tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders

IN Wilde, Richard Gerald

PA Du Pont Merck Pharmaceutical Company, USA

SO PCT Int. Appl., 97 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9744038	A1	19971127	WO 1997-US8448	19970519
	W: AU, CA, IL, JP, MX, NZ				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	ZA 9703884	A	19981106	ZA 1997-3884	19970506
	US 6083948	A	20000704	US 1997-857349	19970516
	CA 2255650	AA	19971127	CA 1997-2255650	19970519
	AU 9731316	A1	19971209	AU 1997-31316	19970519
	AU 739269	B2	20011011		
	EP 901374	A1	19990317	EP 1997-926590	19970519
	EP 901374	B1	20031210		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
	NZ 332704	A	20000526	NZ 1997-332704	19970519
	JP 2000511183	T2	20000829	JP 1997-542618	19970519
	AT 255896	E	20031215	AT 1997-926590	19970519
	EP 1380298	A2	20040114	EP 2003-78058	19970519
	EP 1380298	A3	20040407		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
	PT 901374	T	20040430	PT 1997-926590	19970519
	ES 2213216	T3	20040816	ES 1997-926590	19970519
	MX 9809730	A	20000531	MX 1998-9730	19981119
	US 6399609	B1	20020604	US 2000-570775	20000511
	US 2003064993	A1	20030403	US 2002-59910	20020129
	US 6869955	B2	20050322		
PRAI	US 1996-18198P	P	19960523		
	US 1997-857349	A3	19970516		
	EP 1997-926590	A3	19970519		
	WO 1997-US8448	W	19970519		
	US 2000-570775	A3	20000511		

OS MARPAT 128:34777

AB The title compds. [I; A = N, CR11 (wherein R11 = H, C1-4 alkyl, halo); X = H, (un)substituted Ph, heteroaryl, etc.; R4 = H, C1-12 alkyl, allyl, etc.; R5-R8 = H, C1-4 alkyl, allyl, etc.; R4R5R6 = along with two interconnecting atoms may form (un)substituted imidazole or tetrazole ring; R5R6 = O, S, NR12 (wherein R12 = H, C1-4 alkyl, Ph); R9 = (un)substituted Ph, pyridyl, pyrimidinyl; R10 = H, C1-4 alkyl, CN], corticotropin releasing factor (CRF) antagonists useful in treating anxiety, depression, and other psychiatric and neurol. disorders, were prepared and formulated. Thus, reaction of 4,6-dichloro-2-methyl-5-nitropyrimidine with EtBuNH followed by reacting the resulting 4-chloro-6-(ethylbutylamino)-2-methyl-5-nitropyrimidine with 2-bromo-4-isopropylaniline, reduction of 6-(2-bromo-4-isopropylphenylamino)-4-(ethylbutylamino)-2-methyl-5-nitropyrimidine with sodium dithionite, treatment of 5-amino-6-(2-bromo-4-isopropylphenylamino)-4-(ethylbutylamino)-2-methylpyrimidine with NaH in DMF, and addition of

BrCH₂CO₂Et afforded I [A = N; X = BuEtN; R₄ = R₇ = R₈ = H; R₅R₆ = O; R₉ = 2-Br-4-iPrC₆H₃; R₁₀ = Me]. Compds. I are effective at 0.002-200 mg/kg/day.


IT **199728-09-1P 199728-10-4P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of tetrahydropteridines and pyridylpiperazines for treatment of neurol. disorders)


RN 199728-09-1 CAPLUS

CN 4-Pyrimidinamine, N-[2-bromo-4-(1-methylethyl)phenyl]-2-methyl-5-nitro-6-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 199728-10-4 CAPLUS

CN 4,5-Pyrimidinediamine, N4-[2-bromo-4-(1-methylethyl)phenyl]-2-methyl-6-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



=> => d his

(FILE 'HOME' ENTERED AT 14:48:32 ON 15 JUN 2006)

FILE 'REGISTRY' ENTERED AT 14:48:39 ON 15 JUN 2006

L1 STRUCTURE UPLOADED
 L2 50 S L1 SSS SAM
 L3 STRUCTURE UPLOADED
 L4 50 S L3 SSS SAM
 L5 STRUCTURE UPLOADED
 L6 50 S L5 SSS SAM
 L7 1679 S L5 SSS FUL
 L8 STRUCTURE UPLOADED
 L9 31 S L8 SSS SAM SUB=L7
 L10 686 S L8 SSS FUL SUB=L7
 L11 993 S L7 NOT L10

FILE 'CAPLUS' ENTERED AT 15:10:46 ON 15 JUN 2006

L12 48 S L11

FILE 'CAOLD' ENTERED AT 15:12:10 ON 15 JUN 2006

=> s l11

L13 0 L11

=> log y

COST IN U.S. DOLLARS

 SINCE FILE
 ENTRY

 TOTAL
 SESSION

FULL ESTIMATED COST

0.44

469.03

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

 SINCE FILE
 ENTRY

 TOTAL
 SESSION

CA SUBSCRIBER PRICE

0.00

-36.00

STN INTERNATIONAL LOGOFF AT 15:12:22 ON 15 JUN 2006